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Abstract
Accuracy of fundus autofluorescence imaging for the
diagnosis and monitoring of retinal conditions:
a systematic review
Geoff K Frampton,1* Neelam Kalita,1 Liz Payne,1 Jill Colquitt2
and Emma Loveman2
1Southampton Health Technology Assessments Centre (SHTAC), University of Southampton,
Southampton, UK
2Effective Evidence LLP, Eastleigh, UK
*Corresponding author G.K.Frampton@soton.ac.uk
Background: Natural fluorescence in the eye may be increased or decreased by diseases that affect the
retina. Imaging methods based on confocal scanning laser ophthalmoscopy (cSLO) can detect this ‘fundus
autofluorescence’ (FAF) by illuminating the retina using a specific light ‘excitation wavelength’. FAF
imaging could assist the diagnosis or monitoring of retinal conditions. However, the accuracy of the
method for diagnosis or monitoring is unclear.
Objective: To conduct a systematic review to determine the accuracy of FAF imaging using cSLO for the
diagnosis or monitoring of retinal conditions, including monitoring of response to therapy.
Data sources: Electronic bibliographic databases; scrutiny of reference lists of included studies and
relevant systematic reviews; and searches of internet pages of relevant organisations, meetings and trial
registries. Databases included MEDLINE, EMBASE, The Cochrane Library, Web of Science and the Medion
database of diagnostic accuracy studies. Searches covered 1990 to November 2014 and were limited to
the English language.
Review methods: References were screened for relevance using prespecified inclusion criteria to capture
a broad range of retinal conditions. Two reviewers assessed titles and abstracts independently. Full-text
versions of relevant records were retrieved and screened by one reviewer and checked by a second. Data
were extracted and critically appraised using the Quality Assessment of Diagnostic Accuracy Studies criteria
(QUADAS) for assessing risk of bias in test accuracy studies by one reviewer and checked by a second.
At all stages any reviewer disagreement was resolved through discussion or arbitration by a third reviewer.
Results: Eight primary research studies have investigated the diagnostic accuracy of FAF imaging in retinal
conditions: choroidal neovascularisation (one study), reticular pseudodrusen (three studies), cystoid macular
oedema (two studies) and diabetic macular oedema (two studies). Sensitivity of FAF imaging using an
excitation wavelength of 488 nm was generally high (range 81–100%), but was lower (55% and 32%) in
two studies using longer excitation wavelengths (514 nm and 790 nm, respectively). Specificity ranged
from 34% to 100%. However, owing to limitations of the data, none of the studies provide conclusive
evidence of the diagnostic accuracy of FAF imaging.
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Limitations: No studies on the accuracy of FAF imaging for monitoring the progression of retinal
conditions or response to therapy were identified. Owing to study heterogeneity, pooling of diagnostic
outcomes in meta-analysis was not conducted. All included studies had high risk of bias. In most studies
the patient spectrum was not reflective of those who would present in clinical practice and no studies
adequately reported how FAF images were interpreted.
Conclusions: Although already in use in clinical practice, it is unclear whether or not FAF imaging is
accurate, and whether or not it is applied and interpreted consistently for the diagnosis and/or monitoring
of retinal conditions. Well-designed prospective primary research studies, which conform to the paradigm
of diagnostic test accuracy assessment, are required to investigate the accuracy of FAF imaging in diagnosis
and monitoring of inherited retinal dystrophies, early age-related macular degeneration, geographic
atrophy and central serous chorioretinopathy.
Study registration: This study is registered as PROSPERO CRD42014014997.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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CMO cystoid macular oedema
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ophthalmoscopy





ICGA indocyanine green angiography
IR infrared reflectance
MPOD macular pigment optical density
NIR-FAF near-infrared fundus
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The retina of the eye (where light is detected) has a natural faint glow called ‘autofluorescence’which can be seen using a specialised camera. Diseases of the retina can affect the intensity of this
autofluorescence. As such, measuring autofluorescence of the retina (called ‘autofluorescence imaging’)
could help in diagnosing retinal diseases, or in monitoring their progression or response to treatment.
However, the accuracy of autofluorescence imaging for these purposes is unknown. We conducted a
rigorous systematic review of research studies to clarify the diagnostic and monitoring accuracy of
autofluorescence imaging. Eight relevant studies were found but they had investigated only the diagnosis,
not the monitoring, of retinal diseases. Four of these studies were diagnosing different aspects of a
condition called age-related macular degeneration and the other four were diagnosing different types of
swelling (oedema) of the retina. All eight studies have limitations in their methods, which means that their
results may not be reliable and are unlikely to be relevant to real-world clinical practice. Therefore, it is
unclear whether or not autofluorescence imaging would be accurate for diagnosing or monitoring retinal
diseases in clinical practice. Based on the available evidence, we provide structured recommendations for
future research. There is a need for studies that are relevant to actual clinical practice, with patients similar
to those who would be tested in real life and that involve comparison tests that are relevant. Studies
would be helpful in diseases where autofluorescence imaging appears most useful for diagnosis and/or
monitoring. These include inherited retinal diseases and ‘geographic atrophy’.
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Retinal conditions are diseases associated with the retina, that is, the part of the eye that collects light
and converts it into electrical signals. They include, among others, age-related macular degeneration
(AMD), central serous chorioretinopathy (CSC), inherited retinal dystrophies, diabetic retinopathy and
cystoid macular oedema. Early identification of retinal conditions and disease stage is essential to allow
prompt diagnosis, enabling timely treatment to prevent visual loss for treatable conditions such as
neovascular AMD. However, for many retinal conditions it may be possible to reduce only the symptoms or
slow disease progression, which can prolong the time during which affected people can continue their
normal activities. Information about diagnosis is also important for patients, particularly regarding the
prognosis and genetic risks of inherited eye disease. Developments in imaging techniques, particularly with
the evolution of scanning laser ophthalmoscopes, have enabled more detailed inspection of the retina and
provided less invasive tools to guide treatment and monitor the efficacy and safety of treatments. At the
same time, advances in treatments for retinal conditions have increased the need for more accurate
information on differential diagnosis and prognosis, so that treatment can be appropriately targeted.
Fundus autofluorescence (FAF) imaging, based on scanning laser ophthalmoscopy, is a relatively new
method that assesses retinal health by detecting changes in the natural fluorescence of the retina.
The presence, absence and intensity of FAF can be affected by diseases of the retina, meaning that FAF
imaging could aid in the diagnosis and/or monitoring of retinal conditions. However, the accuracy of the
method for diagnosing and monitoring different retinal conditions is unclear.
Objectives
The aim of this project was to assess the accuracy of FAF imaging using confocal scanning laser
ophthalmoscopy (cSLO) for the diagnosis and monitoring of retinal conditions. Specific research
objectives were:
l for each retinal condition, to determine the diagnostic and monitoring accuracy of FAF imaging
using cSLO, including monitoring of disease management
l to identify future research needs and develop research recommendations.
Methods
A review of evidence for the diagnostic and monitoring accuracy of FAF imaging for retinal conditions was
undertaken systematically based on pre-specified inclusion criteria. Patients with any retinal condition were
eligible, except malignancy, other ocular disease (e.g. glaucoma), or retinal trauma. Electronic databases
searched included MEDLINE (via Ovid); MEDLINE In-Process & Other Non-Indexed Citations; EMBASE;
The Cochrane Library; Web of Science; Database of Abstracts of Reviews of Effects; Health Technology
Assessment database; and the Medion database of diagnostic accuracy studies. Internet pages of relevant
organisations and meeting and trial registries were also searched, and reference lists of included studies
and relevant systematic reviews were checked. All databases were searched from 1990 (approximately
10 years prior to the likely publication of the earliest relevant evidence) to November 2014 and searches
were limited to the English language. The evidence synthesis and analysis followed good practice
approaches, as recommended by the Centre for Reviews and Dissemination and the Cochrane Handbook
for Systematic Reviews of Diagnostic Test Accuracy. Two reviewers independently screened the titles and
abstracts of all bibliographic records identified against prespecified inclusion criteria. Full-text records were
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obtained for those titles and abstracts that either appeared to meet the inclusion criteria or for which
relevance was unclear, and these were screened against the prespecified eligibility criteria by one reviewer
and checked by a second reviewer. Extraction of data from included studies was undertaken by one
reviewer and checked by a second. Two reviewers independently assessed the risk of bias of the diagnostic
studies using a modified version of the Quality Assessment of Diagnostic Accuracy Studies (QUADAS)
instrument. At all stages of the review, any disagreement between the two reviewers was resolved through
discussion or, if necessary, arbitration by a third reviewer. Synthesis of included studies consisted of a
structured narrative with tabulation of results. An advisory group comprising two independent clinical
experts and a representative of a national charity supporting people with sight problems informed
the review.
Results
Number and quality of studies
Searches identified 2240 bibliographic records, from which 206 full-text papers were obtained for further
inspection; eight full-text papers reporting eight primary research studies were included in the systematic
review. These eight studies all reported diagnostic accuracy of FAF imaging. No studies on the accuracy of
FAF imaging for monitoring retinal conditions (i.e. monitoring progression or response to therapy) met the
inclusion criteria. The diagnostic accuracy of FAF imaging was reported for choroidal neovascularisation in
neovascular AMD in one study; for reticular pseudodrusen in three studies [in early AMD, geographic
atrophy (GA) or neovascular AMD]; for cystoid macular oedema secondary to various conditions in two
studies; and for diabetic macular oedema in two studies. The included studies have a number of limitations
when assessed against the QUADAS criteria. Notably, the studies were considered to be at high (or in one
case unclear) risk of spectrum bias (i.e. the patient population would not be representative of people
presenting for retinal imaging in current NHS practice) and there are uncertainties around the relevance of
the reference standards in most of the studies. Although the reference standards were not necessarily
inappropriate, they were all single imaging tests, whereas in clinical practice diagnosis would more likely
be based on combined information from several tests. In all studies the risk of clinical review bias was
deemed unclear, as the information required to interpret FAF images was not reported.
Diagnostic outcomes
Meta-analysis of sensitivity and specificity of FAF imaging was considered inappropriate owing to the
heterogeneity of the study populations, as well as the limited number of studies available for each retinal
condition. Most included studies used an excitation wavelength of 488 nm and reported high sensitivity of
FAF imaging (range 81–100%). However, sensitivity was lower in two studies that used longer excitation
wavelengths: 32% in a study of reticular pseudodrusen in AMD using 790 nm; and 55% in a study of
diabetic macular oedema using 514 nm. The specificity of FAF imaging across all studies ranged from 34%
to 100% and was not clearly related to the excitation wavelength. However, owing to the relative paucity
of reliable data, and limitations in experimental rigour, these diagnostic outcomes are subject to
considerable uncertainty and may not accurately reflect the diagnostic accuracy of FAF imaging when
applied in clinical practice. As such, none of the eight primary studies provides conclusive quantitative
evidence for the diagnostic accuracy of FAF imaging in any of the four retinal conditions they examined.
More robust studies would be helpful to quantify test accuracy and these should ideally be conducted to
address clinical scenarios relevant to current NHS practice. There is currently no information available on
the diagnostic or monitoring accuracy of FAF imaging for inherited retinal dystrophies (such as retinitis
pigmentosa, Stargardt disease and rod–cone dystrophies), early AMD, AMD-related GA or CSC. These
conditions were identified by the review advisory group as being where FAF imaging might potentially be
most useful for assisting diagnosis or monitoring disease progression in NHS practice.
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Discussion
Strengths of the evidence synthesis
The current review is based on a prespecified, peer-reviewed protocol. It included comprehensive
literature searches in a wide variety of data sources undertaken by an experienced information specialist.
The study selection and data extraction steps were pilot-tested and are based on prespecified worksheets,
which are provided as appendices to this report. The primary evidence was assessed using prespecified
and internationally accepted critical appraisal criteria for test accuracy studies. All studies excluded at
the full-text screening step are listed in an appendix, stating the reasons for exclusion. All steps of the
systematic review were carried out by at least two reviewers, to minimise the risks of errors and bias.
An independent advisory group informed the review.
Limitations of the evidence synthesis
Interpretation of the primary research is hampered by clinical heterogeneity among the included studies
and limitations in their methodological rigour. In some cases where studies included both eyes of patients
in the analysis, intrasubject correlations may have led to underestimation of standard errors for diagnostic
outcomes. This was not assessed quantitatively; however, it would not have markedly affected the
overall conclusions. As prespecified in the protocol, searches were limited to evidence published in the
English language.
Uncertainties
The extent of use of FAF imaging for diagnosing and/or monitoring retinal conditions in the NHS is not
generally known, although the project’s advisory group suggested specialists in the field of inherited retinal
degeneration might already use FAF imaging routinely. The diagnostic accuracy of FAF imaging has been
assessed only in primary research studies on four retinal conditions, and it remains unclear whether or not
the technique would accurately diagnose other conditions, including the inherited retinal dystrophies, early
AMD, GA and CSC. Numerous studies have monitored qualitatively the progression of retinal conditions or
their response to therapy using FAF imaging, but it is unclear whether or not FAF imaging is accurate as a
monitoring tool since no studies have formally assessed this quantitatively. A key limitation of the included
studies is that none reported the clinical information necessary to interpret the FAF images, so it is unclear
whether or not the interpretation in the studies would be consistent with how FAF images are interpreted
in clinical practice.
Conclusions
It is not possible to give a clear indication of the diagnostic or monitoring accuracy of FAF imaging for
retinal conditions based on existing research, even though FAF imaging appears to be already used in
the NHS for diagnosing certain retinal conditions. Although some studies reported relatively high
diagnostic sensitivity, these had various methodological limitations that hinder the interpretation of test
accuracy. There is an indication that standard wavelength FAF imaging (488 nm) may be more sensitive
than longer-wavelength approaches, but this is based on only two studies, involving 790-nm imaging for
detecting reticular pseudodrusen and 514-nm imaging for detecting diabetic macular oedema. Owing to
the relative paucity of reliable data, further studies are required. In particular, prospective studies are
required in inherited retinal dystrophies, dry AMD, GA and CSC, and the studies should be designed
according to the paradigm for the quantitative assessment of test accuracy.
Implications for service provision
Owing to a lack of studies addressing the appropriate populations and employing appropriate imaging
methods it is unclear whether or not FAF imaging is accurate for the diagnosis and monitoring of retinal
conditions in clinical practice.
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Any future research into the accuracy of FAF imaging should consider whether FAF imaging is intended to
supplement or replace existing imaging modalities. Given that FAF imaging is non-invasive, there might be
benefits to patients and the NHS if FAF imaging could replace fluorescein angiography, which is the most
frequently used invasive retinal imaging test, although fluorescein angiography would still be needed to
assess some aspects of eye disease, for example perfusion. None of the studies included in the current
review assessed patients’ perceptions of the test procedures or reported whether or not the angiography
reference standard was associated with any adverse events. Further evidence would therefore be required
to clarify the magnitude of benefits or disadvantages to patients and the NHS of any switch from
fluorescein angiography to FAF imaging.
Quality assessment of FAF imaging would be necessary to ensure consistency of diagnostic interpretation.
The primary studies included in the systematic review provided no clear information on how this might be
achieved. Although intergrader agreement for interpreting FAF images was good in three studies, this is
difficult to extrapolate because of methodological limitations of the studies.
Suggested research priorities
l Prospective studies that conform to the paradigm for test accuracy assessments (i.e. which include a
clearly specified population, index test, reference standard and diagnostic outcomes) would be helpful
to evaluate the diagnostic accuracy of FAF imaging in the inherited retinal dystrophies, early AMD, GA
and CSC.
l Prospective studies that conform to the paradigm for test accuracy assessments would be helpful to
evaluate the accuracy of FAF imaging in monitoring the progression of retinal conditions and their
response to therapy, alongside current best practice, for the inherited retinal dystrophies, early AMD,
GA and CSC.
l Future test accuracy studies for FAF imaging should:
¢ recruit participants who are representative of those likely to present for retinal screening in the NHS
¢ consider carefully whether FAF imaging is appropriate as an ancillary test or as a replacement for
an existing test
¢ employ all relevant components of currently used reference standards
¢ clearly report the clinical information required to interpret FAF images in order to reach diagnostic
and/or therapeutic decisions
¢ report intergrader and intragrader agreement and other aspects of test acceptability (e.g. patient
acceptability, adverse events)
¢ and report clearly the duration of imaging and any resources associated with the acquisition,
processing, quality assurance and interpretation of FAF images.
l A survey or audit of the current use of FAF imaging in NHS practice would be helpful to clarify current
practice and any limitations and research requirements associated with it.
Study registration
This study is registered as PROSPERO CRD42014014997.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Description of the underlying health problem
Retinal conditions are diseases associated with the retina, that is, the part of the eye that collects light and
converts it into electrical signals. Many different conditions can affect the retina, and these vary according to
whether they are inherited or acquired, which parts of the retina they involve, whether they are acute or
chronic, the extent to which they affect a person’s vision, whether they can be treated and at which ages they
occur. Retinal conditions also vary according to whether or not they are limited to the retina or affect other
parts of the body (the latter are referred to as retinal syndromes). Owing to the diversity of retinal conditions,
some of which are very uncommon, it is not possible to describe them all in this report. Since the objective of
this technology assessment is to evaluate the accuracy of fundus autofluorescence (FAF) imaging for
diagnosing and monitoring retinal conditions, we describe those retinal conditions which, according to the
project’s clinical advisors, could be amenable to diagnosis and/or monitoring using FAF imaging, or those
where FAF imaging may already be in use. To help in understanding the terminology relating to retinal
conditions and FAF imaging, we first explain the structures comprising the retina and related parts of the eye.
Overview of the retina and related parts of the eye
The interior surface at the back of the eye, opposite the lens, which can be viewed through the pupil with
an ophthalmoscope, includes the retina, and is referred to as the ocular fundus. As well as the retina, the
fundus includes the optic disc (where axons exit the eye to form the optic nerve), the macula (a yellow
spot which includes the centre of the retina), the fovea (the central part of the macula responsible for
sharp central vision) and the posterior pole (the posterior retina as seen with a slit lamp lens, including the
macula, optic disc and area nasal to the disc). The left and right halves of the retina (i.e. either side of
the fovea) are referred to as ‘temporal’ (the side towards the temple) or ‘nasal’ (the side towards the nose).
Measurements of the retina are often expressed in degrees of visual angle. One degree of visual angle on
the retina is equal to 288 µm, assuming no shrinkage.
When the eye functions well (i.e. without opacity due to cataracts or scars on the cornea, or other visual
loss), light entering the eye is focused by the cornea and lens onto the retina. The retina is a highly
complex structure comprising several layers and diaphanous membranes (Figure 1). Light entering the
retina first passes through a layer of neurons before reaching light-sensitive photoreceptor cells (rods and
cones), which convert the light energy into electrical signals. The electrical signals are then passed to
neurons in the layer above the photoreceptor cells where they are then transferred, via a layer of nerve
fibres near the surface of the retina, to the optic nerve, which connects directly with the brain. The
photoreceptors are supported towards the outside by a layer of cells called the retinal pigment epithelium.
The retinal pigment epithelium reduces light scatter within the eye, provides nourishment and growth
factors for the maintenance and regeneration of the photoreceptors, and limits the passage of fluid and
harmful substances into the retina. Beneath the retina are a vascular layer called the choroid, and the
outside of the eye, known as the sclera. The innermost layer of the choroid is called Bruch’s membrane.
Blood is supplied to the retina by the central retinal artery, which runs alongside the optic nerve and has
four main branches that supply blood vessels in the choroid.
There are two types of photoreceptors, rods and cones. Rods aid vision in low light levels, as well as
providing peripheral vision and movement perception; they are found throughout the retina, but the very
centre of the retina (1-degree diameter) is rod free with a high cone density. Cones in the macula enable
detailed vision of objects directly in front of the viewer and the perception of colour. Cones are also
located throughout the retina but their highest density is at the fovea.
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Given the complexity of the retina, and the fact that any component of the retina and its surrounding
structures can malfunction or become damaged, a diverse range of retinal conditions can occur.
Retinal conditions included in this review
In this report the term ‘retinal condition’ (or retinopathy) refers to any acquired or genetically determined
disease of the retina. The protocol for the present research focused on the retinal conditions agreed by
the project advisory group as being those for which the technology under review, FAF imaging, may be
most useful. These are early and late age-related macular degeneration (AMD), geographic atrophy (GA),
inherited retinal dystrophies and central serous chorioretinopathy (CSC). However, as explained in
Chapter 3, Inclusion and exclusion criteria, the scope of the review was subsequently widened to include
any retinal conditions (other than those caused by malignancy, major primary ocular conditions or trauma)
in which the accuracy of FAF imaging as a diagnostic or monitoring test has been assessed. Where
possible, descriptions of retinal conditions in the current report are based on the classification of Lois and
Forrester.1 Below we describe some common retinal conditions and those with significant impacts on
patients; due to the wide variety of retinal conditions that exists, this list is not exhaustive.
Prevalence, natural history, symptoms and risk factors of
retinal diseases
The estimated UK prevalence of different retinal diseases is summarised below, although this is difficult to
compare accurately across the retinal conditions owing to the scarcity of epidemiological data on incidence
and prevalence of visual impairment in the UK,2 and because of differences in how prevalence data have
been calculated. As indicated in the sections on specific retinal conditions below, in some cases prevalence
rates have been reported without clearly specifying the time periods they refer to. Overall, according to the
Royal National Institute of Blind People (RNIB) Eye Health Data Summary 20143 (which does not include
the less prevalent retinal conditions), based on data for 2010, early AMD is the most prevalent retinal
condition in the UK (1,494,000 cases), followed by early diabetic retinopathy (748,000 cases) and late
AMD (609,000 cases). Other retinal conditions affect fewer people but, in the case of the inherited retinal
dystrophies, symptoms may appear and become debilitating in childhood or young adulthood, unlike in
the more prevalent conditions. Where data are available for incidence and prevalence of retinal conditions
these are reported in the sections on specific retinal conditions below. For some conditions only incidence
or prevalence data are available, not both.
Light
Internal limiting membrane






Photoreceptors (rods and cones)
Neurons (including horizontal, bipolar, 
amacrine and ganglion cells)
Retina
FIGURE 1 Simplified schematic overview of retinal structure (not to scale).
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Age-related macular degeneration
Age-related macular degeneration is categorised as either early AMD or late AMD. In early AMD the vision
is initially unaffected, but there are risk features for late AMD. Late AMD is classified into two types: wet
AMD, which is also known as exudative or neovascular AMD (the term neovascular is used in this report);
and dry AMD, which, in advanced cases, is also known as GA. AMD is the commonest cause of visual
impairment, and results in progressive, irreversible damage to the macula, the retinal pigment epithelium
and retinal photoreceptors.4 Clinical and phenotypic variations have been identified, and increasing age
and smoking are risk factors for the condition.5 Although AMD usually affects both eyes, it rarely results in
complete blindness, as the peripheral vision is not usually affected.
Early age-related macular degeneration
In the early stages of AMD, lipid and basal laminar waste products are deposited under the retinal pigment
epithelium6 and in Bruch’s membrane,7 due to retinal pigment epithelium cells becoming less efficient as
people age.8 These deposits, called ‘drusen’, are thought to result from incomplete metabolism by retinal
pigment epithelial cells.6 Drusen gradually increase in number and size, although vision is not affected
at first. However, central vision becomes less sharp as drusen become larger. Different types of drusen
include hard discrete yellow drusen smaller than 50 µm in diameter; tiny whitish basal laminar drusen; soft
yellowish drusen with poorly defined margins that often coalesce, and are usually larger than 50 µm; and
discrete, calcific crystalline drusen, which look like yellow spots on the retina.9 Drusen can spontaneously
disappear in patients with AMD, often leaving atrophic lesions.10 With advances in retinal imaging, reticular
pseudodrusen have been identified which, unlike ‘conventional’ drusen, are located within the retinal
pigment epithelium.11,12 The retinal pigment epithelium also undergoes progressive changes in early AMD
that appear as patches of hyperpigmentation and hypopigmentation.7 As noted above, the prevalence of
early AMD in the UK has been estimated (based on data from 2010) as 1,494,000 cases.3
The sight of people with early AMD may deteriorate gradually over years, and, in some cases, the disease
progresses to the more severe GA or neovascular AMD (see Late, neovascular AMD), with genetic and
environmental risk factors playing a part.13 About 250,000 older adults in the UK suffer from blindness due
to late AMD,14 and the two main late AMD phenotypes, GA and neovascular AMD, account for two-thirds
of registrations for visual impairment or blindness in the UK.7
Late, dry age-related macular degeneration (geographic atrophy)
Advanced dry AMD involving atrophy of the retinal pigment epithelium as a result of cell death, is known as
GA.15 GA progresses slowly from early AMD; the evolution from high-risk large drusen to hypopigmentation
to death of retinal pigment epithelial cells to legal blindness (Snellen visual acuity < 3/60) can take between
5 and 10 years,8 and varies considerably between patients.16 Patients can experience loss of central vision
and have difficulty reading small sizes of print, although this may not be noticeable if GA affects only one
eye.7 GA accounts for 12–20% of legal blindness in AMD, but some people retain visual acuity because the
atrophy is away from the part of the retina where images are focused, as in foveal-sparing GA.6 Increasing
age, genetic factors and smoking have been reported as the most consistent factors leading to GA.15 The UK
annual incidence rate of GA is 2.4 per 1000 in women and 1.7 per 1000 in men.17 In the UK, prevalence of
dry AMD (based on data from 2010), has been estimated as 194,000 cases.3 Prevalence rates of GA (based
on data for 2007–9) have been reported as 1.3%, 2.6% and 6.7% in people aged over 50 years, over
65 years, and over 80 years, respectively.17
Late, neovascular age-related macular degeneration
Neovascular AMD may result in rapid deterioration in vision.18 Neovascular AMD is characterised by
choroidal neovascularisation, which is the development of new blood vessels in the choroid.7 With the
development of new blood vessels, fluid accumulates leading to symptoms of visual distortion. If there is
leakage of blood the vision will deteriorate significantly so treatment is needed before permanent damage
occurs. As photoreceptors are displaced by fluid, vision becomes distorted and blurred and, without
intervention, cell loss, fibrosis and eventual scarring are likely.7 Patients may suddenly become unable to
read, drive and see fine detail, such as facial expressions and features, because of haemorrhaging, fibrosis
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or scarring.7 There are about 26,000 new cases of neovascular AMD per million each year in the UK,7
and women have slightly higher age-specific prevalence rates than men, although the greater number of
older women in the UK results in sex differences in the number of prevalent and incident cases.17 The UK
prevalence of neovascular AMD (based on data from 2010) has been estimated at 415,000 cases.3
Prevalence rates based on data for Wales from 2005–9 were reported as 1.2% among people aged over
50 years, 2.5% in those aged over 65 years and 6.3% in those aged over 80 years.17
Diabetic retinopathy
Diabetic retinopathy is the leading cause of vision loss in people aged under 50 years in the developed
world. Its prevalence is increasing,19 and it is the commonest cause of blindness certification in working
age adults.2 Diabetic retinopathy is a term that describes any pathological features that occur at the
retina due to diabetes. This can range from minimal non-sight-threatening vascular features such as
microaneurysms, to proliferative retinopathy, which is the growth of delicate new blood vessels that can
bleed easily and may result in intraocular haemorrhage with sudden loss of vision.20,21 Proliferative
retinopathy may be transient if the haemorrhage clears, but may have features of advanced disease with
an associated retinal detachment. Other types of diabetic retinopathy include fluid collecting at the macula
(diabetic macular oedema) or loss of blood vessels at the macula, known as macular ischaemia, which can
be associated with severe central visual loss depending on the extent of the loss of vascular perfusion.22
The most common symptom of diabetic macular oedema is blurred vision. Other symptoms include
metamorphopsia (distortion of the visual image); floaters (moving spots seen in the field of view); loss of
contrast sensitivity; photosensitivity (intolerance to light); changes in colour vision; scotomas (where part
of the visual field is missing); vision becoming blurred, hazy or fluctuating, or with the appearance of black
lines or dots; periods of temporary ‘blackness’ caused by retinal haemorrhage; poor peripheral vision; and
poor depth perception.23 People with diabetic macular oedema may also be affected by a difference in
sight between their two eyes.22 Laser treatment of macular disease or proliferative retinopathy can also
lead to visual symptoms including field loss and photosensitivity.
Estimates of UK prevalence of diabetic retinopathy vary owing to the range of different sources of data.
Based on data from 2010, there is an estimated prevalence of 748,000 cases of early diabetic retinopathy in
the UK, 85,000 cases of more advanced retinopathy and 188,000 cases of diabetic maculopathy.3 In a study
of people with diabetes in England (which also estimated prevalence data for 2010), 7.12% had diabetic
macular oedema in one or both eyes, of which 39% had clinically significant diabetic macular oedema.24
Central serous chorioretinopathy
Central serous chorioretinopathy is the fourth most common retinopathy after AMD, diabetic retinopathy
and retinal vein occlusion.25 It is characterised by fluid accumulating as a result of dysfunction of retinal
pigment epithelial cells and/or the choroid. Usually, if the patient experiences symptoms, the fluid will have
accumulated under the central macula.26 Spontaneous visual recovery can occur within 2 or 3 months in
the acute type,25 but chronic CSC, which is more common in older people, can lead to persistent or
episodic blurred vision. In some cases of chronic CSC, disease progression is more severe, leading to retinal
pigment epithelial atrophy,27 which may result in permanent visual loss.25 There is some evidence that risk
factors for CSC include smoking, hypertension or sympathetic responses (nervous system activation in
response to stressors),27 steroid medications28 or genetic susceptibility. Symptoms of the condition include
image size disparity between the eyes, blurred central vision, altered colour vision and, in chronic disease
with atrophic change, a loss of visual acuity.25
Men are more often affected by CSC than women, in a ratio of up to 8 : 1.26 Although predominantly an
adult disease, some cases of CSC have been reported in children.26 People aged over 50 years are more
likely to have the condition in both eyes, may develop choroidal neovascularisation25 and may have
coincidental polypoidal choroidopathy. CSC recurs in about one-third of patients within around 1 year.25
The peak incidence is around 40–45 years in men, but later in women, at about 51 years.26 Reliable
incidence and prevalence data are not available for the UK. According to a study in the USA (based on data
for 1980–2002), the incidence of CSC is about 9.9 per 100,000 in men and 1.7 per 100,000 in women.25
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Inherited retinal dystrophies
Inherited retinal dystrophies are a broad group of genetically determined disorders that affect the retina
and lead to progressive visual loss. These disorders can be generally classified according to whether they
affect primarily the centre of the vision, the periphery or both. Further classification depends on whether
rods or cones are primarily affected, whether or not both central and peripheral systems are involved and
which is more affected (referred to as rod–cone or cone–rod).29 Macular dystrophies may only involve
central vision without affecting the visual fields, and the rods and cones may not be affected. However,
progression may occur so that, for example, a disorder that was classified as macular dystrophy may,
in time, develop cone and rod dysfunction. Terms used to describe these conditions depend on the
appearance of the retina, which cells are involved, and (more recently) if the gene mutation(s) is/are
known. Retinal dystrophies include, among others, retinitis pigmentosa, macular dystrophy, Stargardt
disease (which primarily develops in childhood and adolescence) and Best disease.
The age of onset of retinal dystrophies varies, with early and late onset forms having different inheritance
patterns, and mutations in over 200 different genes are known to be involved in different types, including
syndromic retinal dystrophies.30 Symptoms and disease progression also vary within each named condition.
Symptoms may be apparent from birth or may appear at any age, depending on the type and the specific
genetic variant inherited. The degree of central visual loss, peripheral field loss and difficulty with seeing in
the dark depends on how well each group of photoreceptor cells is working, and the speed of sight loss
varies with different genetic forms and between individuals.31 In cases of severe rod–cone dystrophy with
early onset, macular involvement may lead to early decline of visual acuity, and these cases may be more
challenging to diagnose.29
Although some inherited retinal dystrophies affect few people, overall, these disorders are stated as being
a cause in 15.8% of certified blindness registrations and 10% of partial sight registrations in England and
Wales, and are considered to be a significant burden in the working age population.2 The annual incidence
of hereditary retinal disorders in the UK has been estimated at around 1500 cases, and about 100 children
and 480 adults of working age in the UK are registered as blind or partially sighted as a result of these
conditions.2 A study published in 201232 estimated that (based on data from 2006 to 2008) the annual UK
incidence of childhood-onset retinal dystrophies, is 1.4 in 100,000 children (aged 0–15 years) and the
cumulative incidence by age 16 years is 22.3 in 100,000 children.
Cystoid macular oedema
Macular oedema is the accumulation of fluid within the retina at the macular area, secondary to various
retinal conditions. Depending on its cause, acute oedema may resolve spontaneously.33 Cystoid macular
oedema is the result of chronic oedema that persists for ≥ 4 months, leading to the formation of cystic
honeycomb-like spaces in the retina,34 and can occur as a consequence of retinal dystrophies,35 inflammatory
diseases (uveitis, scleritis, birdshot chorioretinopathy, toxoplasmosis),36 retinal vascular disease (retinal vein
occlusions, idiopathic retinal telangiectasia, radiation retinopathy),34 diabetic retinopathy,34 cataract or other
eye surgery, injury to the eye, choroidal tumours, or may be drug induced, for example with prostaglandins
such as latanoprost.37 As with other macular conditions, the main symptoms of cystoid macular oedema are
blurred or decreased central vision, but peripheral vision is unaffected. Estimates of the incidence and
prevalence of cystoid macular oedema vary considerably depending on the cause of the oedema. For
example, the incidence of clinically significant cystoid macular oedema caused by uncomplicated cataract
surgery has been estimated across studies as 0.6–2.6%,38 whereas the prevalence of cystoid macular oedema
in patients with retinitis pigmentosa may be as high as 32–49% (unilateral) or 18–44% (bilateral).39,40
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Impact of retinal conditions
Significant distress results from developing visual loss,41 particularly when the loss is marked and/or of rapid
onset. Depending on the condition, patients can experience a wide range of symptoms, as described
above. Such symptoms can have a profound impact, for example, the loss of central vision associated with
AMD affects patients’ ability to perform normal daily activities such as reading, writing and recognising
faces.18 People with diabetic retinopathy may experience a visual difference between their two eyes.22
Visual loss adversely affects people’s ability to drive, which has a serious negative impact on work, social
life, relationships, responsibilities and independence.22,42 Visual loss also adversely affects self-care,
increases the risk of falls, hip fractures and early admission to residential care, and adversely affects quality
of life.18 The psychological impact of changes caused by vision loss include alterations to the self-concept,
life goals and social functioning.43 Having to adapt to vision loss may result in emotional distress, which
can lead to depression, anxiety and sleep problems.18,43
Diagnosis and monitoring of retinal conditions may involve invasive procedures such as fluorescein or
indocyanine green angiography (ICGA), which involve intravenous injections of dye. People with retinal
conditions may require frequent treatments and regular monitoring of their response to treatment and
disease progression, which may be uncomfortable and can cause anxiety and apprehension.18 With the
ageing population and recent treatment advances, demand for early identification of people who are at
greatest risk of progressive disease is also increasing.44 More accurate and less-invasive diagnostic
procedures may therefore be helpful if they can improve the efficiency of diagnosis and/or monitoring of
retinal conditions.
Measurement of disease: diagnostic features
Imaging techniques capture morphological patterns (appearance of structural features) at the back of the
eye, as well as dynamic features such as transit of dye in blood vessels. These features are seen more or
less clearly with different imaging modalities, for example, pooling, leakage or staining can be seen with
fluorescein angiography. Grading systems have been proposed to classify different conditions, using
different imaging modalities, although there is not always universal consensus about the most appropriate
classification for each condition. For example, the Wisconsin age-related Maculopathy system consists
of three sections: drusen, other lesions and other abnormalities, each of which includes subgroups
of characteristics.6
A classification by the International Fundus Autofluorescence Classification group describes patterns
of fluorescence in early AMD and GA using FAF imaging.45,46 With advances in imaging, reticular
pseudodrusen have been identified, which unlike conventional drusen are located within the retinal
pigment epithelium,11 and these are characteristic of AMD.47 Determining the type and number of drusen
present allows clinicians to better inform patients of their risk of developing AMD.
Geographic atrophy is defined as any sharply delineated round or oval area of hypopigmentation
(paleness), or apparent absence of the retinal pigment epithelium and overlying photoreceptors, in which
choroidal vessels are more visible than in surrounding areas, and the oval area is > 175 µm in diameter.15
Diabetic macular oedema is characterised by macular thickening (focal, multifocal or diffuse) or hard
exudates within 500 µm of the centre of the macula. Cystoid macular oedema is also characterised by
retinal thickening and the development of honeycomb-like spaces in the retina on optical coherence
tomography evaluation.34
In inherited retinal dystrophies, clinical signs may indicate the type of dystrophy. For example, in retinitis
pigmentosa, pigment changes (known as bone spicules because they look like bone under the
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microscope), pallor of the optic disc and narrowing of retinal blood vessels may be seen. Stargardt disease
is characterised by white/yellow flecks at the back of the eye between the optic disc and the macula, seen
by fundoscopy, colour imaging or autofluorescence, and can extend to cover a larger area of the retina.48
In most patients some of the flecks will atrophy, leaving lesions with a beaten metal appearance on an
electroretinogram.48 Patients with cone–rod disorders may have pigment deposits in the retina, mainly
in the macular region,29 or little or no pigment change but a ‘bull’s-eye maculopathy’ on fundus
examination.49 As diagnostic features of inherited retinal dystrophies overlap, for example Stargardt
disease can be mistaken for pattern dystrophy and vice versa, genetic testing plays a helpful and necessary
part in clarifying which disease is present.
Description of the technology under assessment
Fundus autofluorescence in relation to retinal health
The fundus of the human eye has a ‘natural’ or ‘background’ level of fluorescence, which is referred to as
autofluorescence. This is caused by the presence of molecules with fluorescent properties (i.e. molecules
that, when exposed to light of an appropriate wavelength, absorb the incident electromagnetic energy and
re-emit this as light at wavelengths longer than those of the initial source). The fluorescent molecules,
known as fluorophores, are potentially of clinical value in detecting age- or disease-related processes,
since their density and distribution alters with ageing of the eye and with certain pathological conditions.
Notably, lipofuscin is a fluorescent pigment that accumulates in the retinal pigment epithelium as a
by-product of cell metabolism and can lead to the development of drusen. Lipofuscin deposition normally
increases with age but its accumulation may also reflect cell dysfunction or metabolic abnormalities in the
retinal pigment epithelium. Excessive lipofuscin deposition in the retinal pigment epithelium is considered
pathologic and is associated with visual loss.50 FAF imaging techniques have potential value as diagnostic
tools, since the presence and distribution of fluorophores may correlate with disease activity and may
provide an early indication of future disease development, progression or response to treatment.
FAF imaging is also potentially valuable in detecting areas of reduced or absent autofluorescence
(hypoautofluorescence), which can arise either through atrophy of retinal structures or blocking of FAF
reflectance (e.g. by blood vessels).
Fundus autofluorescence imaging techniques
The intensity of light emitted during FAF is relatively weak (about two orders of magnitude lower than
the background of a fluorescein angiogram at peak dye transit) and so specialist imaging techniques are
required to enable FAF to be detected and mapped. FAF has been an area of interest in ophthalmic
research for more than 40 years but it has only recently become clinically relevant, as a result of
technological advances.50 As outlined below, there are three main methods for assessing FAF: using a
fundus camera, fundus spectrophotometry or confocal scanning laser ophthalmoscopy (cSLO).
The fundus camera uses a single flash to image the entire retinal area instantaneously. The acquired
autofluorescence image is derived from all tissues in the light beam with fluorescent properties; light
scattered anterior and posterior to the plane of interest can greatly influence the detected signal.
Fundus spectrophotometry was developed to measure FAF from small retinal areas (2 degrees of visual
angular diameter). It incorporates an image intensifier diode array as a detector and beam separation in
the pupil to minimise the contribution of autofluorescence from the crystalline lens.51
In cSLO a focused low-power laser beam is swept across the fundus in a raster pattern (horizontal and
vertical scanning across a grid) to provide the excitatory light source for fluorophores.52 Different excitation
wavelengths can be generated, depending on the type of laser used, including 488 nm (blue light) with a
solid-state laser and 514 nm (green light) with an argon-ion laser. For near-infrared fundus autofluorescence
(NIR-FAF), the excitation wavelength is 790 nm. The confocal nature of the optics reduces the detection of
autofluorescence from structures anterior to the retina, such as the lens and cornea. Unlike fundus
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spectrophotometry, cSLO allows imaging of FAF over larger retinal areas [e.g. 55 degrees in Heidelberg
Retina Angiograph-based systems (Heidelberg Engineering, Heidelberg, Germany)]. To reduce background
noise and enhance image contrast, the mean image of several FAF images is obtained (usually based on up
to 20 frames, after adjustments to correct for eye movement). In order to block the reflected light
but permit autofluorescence light to pass, cSLO have barrier filters of 500 nm, 525 nm and 800 nm for
excitation wavelengths of 488 nm, 514 nm and 790 nm, respectively. As well as the excitation and barrier
filter wavelengths, image contrast and brightness settings also differ among cSLO devices and these
differences must be taken into account when comparing the results of FAF imaging obtained from different
cSLO devices.16
Confocal scanning laser ophthalmoscopy is the most sensitive imaging approach for identifying
autofluorescence that arises specifically from the fundus (i.e. minimising the detection of autofluorescence
arising from other parts of the eye such as the lens).16 According to clinical experts advising the review,
cSLO is the current standard method employed for obtaining FAF images of retinal conditions, and is
therefore the only type of scanning laser ophthalmoscopy permitted as an index test for assessing FAF in
the current review.
Fundus autofluorescence for diagnosis and monitoring of disease
The quantitative accuracy of FAF imaging for the diagnosis and/or monitoring of retinal conditions
(i.e. its sensitivity and specificity) is unclear. However, FAF imaging is considered helpful in a number of
conditions to help establish a diagnosis and monitor treatment without the need for angiography,1 is
relatively easy to accomplish and requires little time.53 Studies have suggested the potential diagnostic
value of FAF imaging as a more sensitive marker of retinal pathology than existing examinations alone,
for example, in GA,54 choroidal neovascularisation development in AMD,55 retinal pigment epithelium
alterations,56 Best disease,57 cystoid macular oedema58 and CSC.59 Clinical advisors to the current review
also suggested that FAF is useful for diagnosing any type of inherited retinal dystrophy, and has the
potential to show pathologic features earlier than on fundoscopy. FAF imaging also appears promising for
monitoring changes in a number of retinal conditions, either natural progression or responses to therapy.
FAF imaging has been used, for example, for monitoring changes in GA;60–66 retinal pigment epithelium
tear or loss;67–69 retinitis pigmentosa;70,71 Stargardt disease,72 CSC,73 diabetic macular oedema74 and retinal
vasculitis.75 Increasingly, FAF has been specified as an end point in clinical research studies of therapies
for retinal conditions, for example, with antivascular endothelial growth factor drugs,68,76–78 sirolimus,65
lampalizumab,66 finasteride,73 photodynamic therapy79 and vitrectomy.80
Reference standards
‘Reference standard’ refers to the current gold standard or best available method for accurately identifying
a given retinal condition. A reference standard may consist of more than one retinal imaging test since
different imaging modalities can provide different types of information which, when interpreted together,
improve diagnosis. According to the paradigm for assessing test accuracy, the reference standard (against
which any new tests will be compared) should have high (ideally 100%) sensitivity and high (ideally 100%)
specificity for identifying the retinal condition, that is, the method should minimise false-positive and
false-negative results.81 The extent to which existing methods used in diagnosing retinal conditions fulfil
these strict requirements is not always clear and there is not always agreement among clinicians on which
method is the ‘best’. In early AMD, optical coherence tomography and fluorescein angiography are needed
to distinguish between wet and dry AMD,82 but ICGA may be also used, for example if there is doubt
about the presence of choroidal polyps or chorioretinal anastomoses.
Clinical advisors to the current review suggested that spectral-domain optical coherence tomography
would be a standard approach for identification of reticular pseudodrusen in AMD, possibly also with
fluorescein angiography and/or colour fundus photography. GA diagnosis is confirmed by clinical
examination using a high-definition fundus lens for stereo biomicroscopy, as well as being noted on
BACKGROUND
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fluorescein angiography.7 As noted above, FAF imaging and spectral-domain optical coherence
tomography have made it easier to diagnose GA, particularly early signs of GA, as these imaging
modalities can reveal areas of GA that may not be clinically visible on biomicroscopy.7 The gold standard
for diagnosing cystoid macular oedema has been specified as fluorescein angiography,38,83 although in
practice optical coherence tomography is also important34,38 as diagnosis involves assessment of macular
thickness as well as assessment of perfusion of the retinal vascular epithelium. Colour fundus photography,
and more recently optical coherence tomography, are the reference standards for assessing diabetic
macular oedema.84 Fluorescein angiography may be used to identify leaking microaneurysms or capillaries
and areas of macular ischaemia, as well as checking the rest of the retina for ischaemia or
neovascularisation. Indocyanine green angiography is a standard approach for detecting choroidal
abnormalities in CSC, and enhanced depth optical coherence tomography can provide three-dimensional
information.85 Diagnosis of retinitis pigmentosa involves visual field testing, electroretinography to measure
the functional status of photoreceptors and stereo fundus biomicroscopy. Diagnosis of Stargardt disease
may be based on visual acuity, fundus examination, electroretinography and fluorescein angiography,
although optical coherence tomography and microperimetry may also be useful.86
Current service provision
Although FAF imaging may be used on an ad-hoc basis in the NHS to support the diagnosis and
monitoring of a range of retinal conditions, the extent to which it is used in practice is unclear. Clinical
experts advising the current review suggested that the use of FAF imaging depends on the eye unit, its
field of expertise and specialism. Although the role of FAF imaging is still evolving, the method is already
widely used within the NHS for the assessment of inherited retinal dystrophies, such as retinitis pigmentosa
and Stargardt disease, as high-resolution imaging of the distribution and levels of FAF correlate with
pathogenesis in these conditions (e.g. indicating areas where the retina is dying). This is, however, in
centres where there is provision of an inherited retinal dystrophy service and often a strong associated
research unit. The extent to which FAF imaging is used for diagnosing and/or monitoring GA and CSC is
unclear, but clinical experts have suggested that FAF imaging would mainly be used in specialised retinal
clinics such as those seen in teaching hospitals. FAF imaging is unlikely to be used in isolation and would
commonly be conducted together with other tests such as (depending on the retinal condition) optical
coherence tomography, fundus photography, fluorescein angiography or indocyanine green angiography.
FAF imaging would complement these tests rather than replace them, since the imaging modalities provide
different information to help clinicians reach a diagnostic or therapeutic decision. An exception could be
for the inherited retinal dystrophies where FAF imaging has potential to replace fluorescein angiography,
for example, as the main test for diagnosing Stargardt disease (FAF could be an alternative indicator of
disease by demonstrating flecks and atrophy, where previously fluorescein angiography was performed
with the aim of confirming Stargardt disease if a dark choroid was identified). The clinical experts
suggested that, for the diagnosis or monitoring of neovascular AMD, choroidal neovascularisation and
macular oedemas (cystoid and diabetic), FAF imaging would provide little or no added value over optical
coherence tomography and fluorescein angiography. This is because the accumulation and/or leakage of
fluid in these conditions could mask the FAF signal, which might make the assessment of the distribution
and intensity of autofluorescence unreliable, and also because dye leakage, as assessed using angiography,
is necessary for confirming choroidal neovascularisation and macular oedema.
According to the Royal College of Ophthalmologists’ guidelines,7 FAF imaging along with spectral domain
optical coherence tomography has made it easier to diagnose GA in AMD, but its role in diabetic
retinopathy has yet to be fully elucidated.20 Despite the potential value and existing use of FAF imaging in
the inherited retinal dystrophies, no guidelines are currently available concerning the use of FAF imaging
in diagnosing these retinal conditions.
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Chapter 2 Definition of the decision problem
Decision problem
Fundus autofluorescence imaging appears to be a promising procedure for the diagnosis and/or
monitoring of certain diseases of the retina.50 Although FAF imaging is already employed (to an unclear
extent) in the NHS, its accuracy for the diagnosis and monitoring of the different retinal conditions is
uncertain. A systematic evaluation of both the quantity and the quality of the available evidence on the
diagnostic and monitoring accuracy of FAF imaging is needed to inform best practice for retinal imaging in
the NHS and to inform future research.
Population
The relevant population is patients of any age who are suspected to have, or have previously been
diagnosed with, any retinal conditions, excluding those resulting from malignancy, other ocular diseases
(such as glaucoma) or trauma. Note: this population is wider than that specified in the review protocol,
as it is not limited to specific retinal conditions (see Chapter 3, Inclusion and exclusion criteria).
Index test
The relevant index tests are any FAF imaging approaches performed to assist diagnosis and/or monitoring
of retinal conditions, using cSLO. As noted above, in some retinal conditions such as GA and Stargardt
disease, FAF imaging may already contribute information to making the diagnosis. The use of FAF imaging
as an index test has to be considered carefully because interpretation of its diagnostic or monitoring
accuracy may be influenced by whether or not it is already part of the reference standard and by whether
results of FAF imaging would normally be interpreted in isolation or in conjunction with other clinical
information (e.g. results of other imaging tests). These issues are an important part of the critical
appraisal of the available evidence and are considered in detail in this review when interpreting results
(see Chapter 4).
Reference standard
To account for the wide range of retinal conditions eligible for inclusion in the review and differences in
how reference standards have been defined and employed in various studies, fundus imaging performed
using any clinically relevant method (e.g. fundus photography, fundus fluorescein angiography, indocyanine
green angiography, optical coherence tomography or any combination of relevant tests) is eligible for
inclusion in the current review.
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Outcomes
The key outcome measures include: sensitivity and specificity; positive and negative likelihood ratios;
positive and negative predictive values; and diagnostic odds ratios. The working definitions of each of
these outcomes are:87
l Sensitivity: true identification of the people with the condition of interest. It is also known as the
true-positive rate. A high sensitivity implies that a negative result rules out a condition.
l Specificity: also known as the true-negative rate, it indicates the true identification of people without
the condition. A test with high specificity implies that a positive result confirms the condition.
l Likelihood ratios: a positive likelihood ratio is the ratio of the true-positive rate to the false-positive rate,
which is expressed as: sensitivity/(100 – specificity) whereas a negative likelihood ratio is the ratio of the
false-negative rate to the true-negative rate, expressed as: (100 – sensitivity)/specificity. The positive
likelihood ratio describes how many times more likely positive index test results are in the group with
the retinal condition compared with those without the condition, and should be > 1 for the test to be
informative. The negative likelihood ratio describes how many times more likely negative index test
results are in the group with the retinal condition compared with those without the condition, and
should be < 1 for the test to be informative.
l Positive and negative predictive values: positive predictive value is the probability of the condition of
interest among people with a positive test result. Negative predictive value is the probability of not
having the condition among people with a negative test result.
l Diagnostic odds ratio: this summarises the diagnostic accuracy of the index test in a single number that
describes how many times higher the odds are of obtaining a positive test result in a patient with the
retinal condition than in one without the condition.
Overall aims and objectives of the assessment
The aim of this project was to assess the accuracy of FAF imaging using cSLO for the diagnosis and
monitoring of retinal conditions. Specific research objectives were:
l for each retinal condition, to determine the diagnostic and monitoring accuracy of FAF imaging using
cSLO, including monitoring of disease management
l to identify future research needs and develop research recommendations.
DEFINITION OF THE DECISION PROBLEM
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Chapter 3 Methods for reviewing test
performance
A review of the evidence for test accuracy was undertaken systematically and is reported systematicallyfollowing the general principles outlined in the Centre for Reviews and Dissemination guidance,88 the
Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy87,89 and the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) statement,90 taking into consideration specific
aspects of methodology that are relevant to the synthesis of evidence of test accuracy.
The project was informed by an advisory group of three independent clinical experts (see Acknowledgements).
Two of the experts were experienced ophthalmologists and the third represented RNIB, which is a national
charity supporting people with sight problems.
Identification of studies
A comprehensive search strategy (see Appendix 1) was developed, tested and refined by an experienced
information scientist. The search strategy aimed to identify studies on the diagnosis and/or monitoring of
relevant retinal conditions based on the prespecified inclusion and exclusion criteria (see Inclusion and
exclusion criteria). The search strategy comprised the following main elements:
l searching electronic databases
l searching internet pages of relevant organisations, meetings and trial registries
l scrutiny of bibliographies of retrieved papers and relevant systematic reviews.
The following electronic databases were searched: MEDLINE (via Ovid); MEDLINE In-Process & Other
Non-Indexed Citations; EMBASE; The Cochrane Library; Web of Science; Database of Abstracts of Reviews
of Effectiveness (via the Centre for Reviews and Dissemination); Health Technology Assessment database;
Medion database of diagnostic accuracy studies.
Internet pages of the following organisations were searched: American Academy of Ophthalmology,
Association for Research in Vision and Ophthalmology; Cochrane Eyes and Vision Group; European
Association for Vision and Eye Research; and Royal College of Ophthalmologists.
Searches for grey literature and research in progress included: the UK Clinical Research Network Portfolio
Database; World Health Organization International Clinical Trials Registry Platform; Current Controlled
Trials; Clinical Trials.gov; and the National Institute for Health Research Clinical Research Network Portfolio.
All databases were searched from 1990 (approximately 10 years prior to the likely publication of the
earliest relevant evidence) to November 2014 and searches were limited to the English language.
Inclusion and exclusion criteria
The eligibility criteria for the systematic review are as specified in the review protocol,91 with two
exceptions. First, the population has been widened to include patients with any retinal condition, but
excluding those resulting from malignancy, major ocular conditions (e.g. glaucoma) or trauma. This change
was made because the pilot screening process identified potentially relevant studies in which FAF imaging
had been conducted on retinal conditions not specified in the protocol but did not appear to identify many
studies on the prespecified conditions. Widening of the population inclusion criterion was considered
acceptable on the basis that it was deemed unlikely to affect resource requirements for the review.
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To avoid any inconsistency and bias, the updated population eligibility criterion was applied to all of the
bibliographic records screened. Second, the protocol specified that, if appropriate, prospective studies
would be prioritised and retrospective studies would be included only if no prospective studies were
available for a given retinal condition. However, this criterion was amended so that both prospective and
retrospective studies would be included, owing to the limited number of available relevant studies.
The eligibility criteria employed were therefore as follows:
l Population: patients of any age who were suspected to have, or have previously been diagnosed with,
any retinal conditions, excluding those resulting from malignancy, other ocular diseases (such as
glaucoma) or trauma.
l Index test: FAF imaging performed using cSLO.
l Reference standard: fundus imaging performed using any clinically relevant method (e.g. fundus
photography, fundus fluorescein angiography, indocyanine green angiography, optical coherence
tomography, or any combination of relevant tests).
l Primary outcomes: sensitivity and/or specificity (including any data from which these could be
calculated) for the diagnosis or monitoring of retinal conditions.
l Secondary outcomes (applicable only if primary outcomes were also reported): inter- and intraobserver
agreement, adverse events, test acceptability to patients and clinicians, and test interpretability.
l Study designs: any prospective or retrospective study design, provided that the index test(s) and
reference standard were compared in the same patient group.
l Studies were excluded if they had small sample sizes, that is, fewer than 10 study eyes. Based on
published tables of sample sizes required to achieve a given level of diagnostic outcome precision,92
we considered a minimum sample size of 10 eyes per study appropriate to exclude highly
imprecise evidence.
Study selection
Studies were selected for inclusion through a two-stage process using predefined and explicit criteria
(as specified in Inclusion and exclusion criteria). First, two reviewers independently screened all titles and
abstracts identified in the searches to identify bibliographic records that met the inclusion criteria, using a
standard pilot-tested study selection worksheet (see Appendix 2). Second, full-text articles were retrieved
for those bibliographic records judged to be relevant or unclear at the title and abstract screening step.
If a study was reported in more than one article, all articles relating to the study were grouped together
for assessment. One reviewer assessed eligibility of each study using the study selection worksheet and a
second reviewer checked the decision. At each step of the selection process, any disagreements were
resolved by discussion between the two reviewers or, if necessary, by involving a third reviewer.
Data extraction
Data extraction was undertaken by one reviewer and checked by a second reviewer using a predesigned
and piloted data extraction form to minimise errors. Any disagreements between reviewers were
resolved by consensus or, if necessary, arbitration by a third reviewer. Where sensitivity and specificity
were reported in the primary studies with confidence intervals these were extracted and checked and,
if necessary and possible, missing values were calculated. Positive and negative likelihood ratios, positive
and negative predictive values and the diagnostic odds ratio were also checked and, if necessary,
calculated where possible.
METHODS FOR REVIEWING TEST PERFORMANCE
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Critical appraisal
The methodological rigour of studies reporting diagnostic accuracy was assessed using the Cochrane
adaptation81 of the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool93 (which focuses on
methodological rigour rather than quality of reporting) (see Appendix 3). For each of the included studies,
judgements on study rigour were made by one reviewer using the QUADAS criteria and were checked by
a second reviewer. Any disagreements between reviewers were resolved by consensus or, if necessary,
arbitration by a third reviewer. The QUADAS tool93 asks 11 questions about the characteristics of the
primary studies. These questions aim to identify potential threats to the validity of the study findings, and
(in our classification) reflect 10 different types of bias that can be present in studies of test accuracy.
The way these are interpreted in the current report is summarised in Table 1.
The QUADAS question on ‘patient spectrum’ takes into consideration two elements: whether or not the
population characteristics are likely to be representative of those found in actual clinical practice; and
whether the primary study design is retrospective or prospective. In this sense the question combines
elements of bias and applicability. The reason is that empirical evidence suggests that retrospectively
conducted studies are at high risk of bias and as such this limits interpretation of the population relevance.94
In addition to the modified QUADAS criteria, if necessary, a distinction was made between studies that
included one or both eyes per individual so as to avoid any unit-of-analysis issues (e.g. using a subgroup
analysis approach).95
TABLE 1 Types of bias possible in studies of the accuracy of FAF imaging
QUADAS
question Type of bias Explanation
1 Spectrum bias The study population is not representative of those who will receive the
index test (FAF imaging) in clinical practice
2 Verification bias The reference standard does not accurately diagnose the target
retinal condition
3 Disease progression bias The time interval between index (FAF imaging) and reference standard tests
is long enough that the two tests may not have measured the same retinal
disease state
4, 5 Differential verification bias Diagnosis is inaccurate because not all patients receive the same reference
standard test
6 Incorporation bias The index test (FAF imaging) is not independent of the reference standard
(e.g. may be one of several tests used as the reference standard)
7 Diagnostic review bias The index (FAF imaging) test result influences interpretation of the reference
standard result
8 Test review bias The reference standard result influences interpretation of the reference index
test (FAF imaging) result
9 Clinical review bias The information used when interpreting the index test (FAF imaging) does
not reflect that likely to be available in clinical practice
10 Image classification bias Incorrect inclusion or exclusion from the analysis of index test (FAF imaging)
images classified as intermediate or of unclear quality may systematically
influence sensitivity or specificity
11 Attrition bias Exclusion of patients or eyes from analysis may systematically influence
sensitivity or specificity if the reason for exclusion is linked to test
performance, or if criteria for permitting exclusions differ between imaging
tests, especially if the magnitude of attrition is unbalanced across the
test methods
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Method of data synthesis
Studies were synthesised through a structured narrative review with tabulation of results of included
studies. Heterogeneity among studies and analyses of relevant subgroups was explored and presented
using paired sensitivity and specificity forest plots. Paired forest plots differ from standard forest plots,
which provide a measure of effect on the x-axis; one of the paired plots provides a measure of sensitivity
on its x-axis and the other plot a measure of specificity on its x-axis. As such, visualising both plots
together can illustrate how both sensitivity and specificity vary among a group of displayed studies.
The x-axis in both cases ranges from 0 to 1, and in the ideal test both sensitivity and specificity would be 1.
The analysis and synthesis followed good practice approaches as recommended by the Centre for Reviews
and Dissemination (chapter 2: systematic reviews of clinical tests)88 and the Cochrane Handbook for
Systematic Reviews of Diagnostic Test Accuracy.87,89
We planned (subject to the availability and suitability of the primary data) to conduct one or more
meta-analyses of data on test sensitivity and specificity, in order to improve the precision of any estimates
of the accuracy of FAF imaging for diagnosing or monitoring retinal conditions. The appropriateness of
meta-analysis was determined by critical appraisal of the primary studies during the quality assessment step
(see Critical appraisal). To account for correlation between sensitivity and specificity, and their dependence
on the prevalence of retinal conditions, the planned pooling of sensitivity and specificity outcomes was
based on appropriate hierarchical random-effects models [using statistical software such as Winbugs (MRC
Biostatistics Unit, Cambridge, UK) or SAS (SAS Institute Inc., Cary, NC, USA)].
METHODS FOR REVIEWING TEST PERFORMANCE
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Chapter 4 Assessment of diagnostic and
monitoring studies
This chapter presents the quantity of research available, including the number of studies, their designs,participant characteristics and the characteristics of the index tests and reference standards that they
compared (see Quantity of research available). Critical appraisal of the included studies is then reported,
including their risks of bias (see Quality of research available) before the assessment of diagnostic accuracy
is presented (see Assessment of test accuracy), which takes into consideration the available evidence on
diagnostic outcomes as well as any threats to validity highlighted in the preceding sections.
Quantity of research available
The selection of evidence for the systematic review is summarised in Figure 2. Searches yielded 2240
unique bibliographic records, the majority of which were excluded on inspection of the title and/or abstract
because the record did not meet one or more of the specified criteria listed in the study selection worksheet
(see Appendix 2). Full-text versions were obtained for 206 bibliographic records for further scrutiny where
the title and abstract appeared to meet the inclusion criteria, or insufficient information was available to
make a judgement on eligibility. Scrutiny of these 206 full-text articles revealed that the majority (198) were
not relevant, primarily because they did not report (or provide sufficient data to enable us to calculate)
sensitivity and specificity of FAF imaging. Reasons for excluding each of these 198 full-text articles are listed
in Appendix 4. The remaining eight full-text articles (all peer-reviewed journal papers) met all of the specified
eligibility criteria and are included in the current systematic review.
References identified
after deduplication
(n =  2240)
Full-text articles retrieved
(includes 6 meeting abstracts)
(n =  206)
Full-text papers reporting
eight individual studies
(n =  8)
References excluded on
screening titles and abstracts
(n =  2034)
References excluded on checking 
full text (listed with reasons for 
exclusion in Appendix 4)
(n =  198)
• Sensitivity and specificity not 
   reported and not calculable, n =  163
• No appropriate reference 
   standard, n =  19
• Inadequate sample size (< 10 eyes), n =  9
• No appropriate index test, n =  3
• Not a retinal condition, n =  2
• Not primary research, n =  1
• Non-English language, n =  1
FIGURE 2 Flow chart for the identification of studies.
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Number and type of studies included
The eight included research papers describe eight unique primary studies.83,84,96–101 Full details of these studies,
including our assessment of their methodological rigour, are given in the data extraction forms (see Appendix 5).
Characteristics of the included studies
Key characteristics of the included studies are summarised in Table 2.
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CFP, colour fundus photography.
a Informed consent was sought from all participants, suggesting the study was probably prospective.
ASSESSMENT OF DIAGNOSTIC AND MONITORING STUDIES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
18
Although FAF imaging may be used to detect autofluorescence in a wide range of retinal diseases
(see Chapter 1), the eight included studies83,84,96–101 cover only three broad retinal conditions. These are AMD
(four studies96,97,99,101) cystoid macular oedema (two studies83,100) and diabetic macular oedema (two studies84,98).
Of four studies on AMD, three studies specifically investigated FAF imaging in the detection of reticular
pseudodrusen96,97,101 and one study investigated FAF imaging in the diagnosis of choroidal neovascularisation.99
The eight studies included in the systematic review provide information on diagnostic accuracy only (see
Table 2). No studies of the use of FAF imaging for monitoring the natural progression of retinal conditions,
or for monitoring the response of retinal conditions to therapy, met the inclusion criteria.
Four of the studies involved the analysis of retrospective data,84,97,100,101 two involved prospective
recruitment of patients,96,99 one appeared to prospectively recruit patients, although this was not explicitly
reported,83 and it is unclear whether the remaining study was retrospective or prospective98 (see Table 2).
Four of the studies selected patients consecutively (i.e. in the chronological order in which they first
presented to clinicians)84,97,98,100 and the remaining studies did not report whether selection was
consecutive.83,96,99,101 Retrospective studies, and those lacking consecutive patient recruitment, may be at
greater risk of selection bias, and this is considered further below in relation to the overall assessment of
the quality of evidence (see Quality of research available).
Most of the studies were conducted in Europe. The study by McBain and colleagues100 was exclusively in the
UK and the study by Waldstein and colleagues84 also appears to have been conducted in the UK, although this
was not explicitly reported. Two studies were conducted in multiple countries, which included the UK. Hogg
and colleagues96 conducted studies in Italy, Portugal and the UK, and Smith and colleagues101 in the USA and
UK. The remaining studies were conducted in Italy,98 Portugal,99 Turkey83 and Japan.97 The studies were
published between 2006 and 2014. The earliest reported participant recruitment was in 2004100 and the latest
in November 201084,97 but dates of recruitment were not reported in three studies.96,99,101
Both men and women were included in the studies. Where reported (in seven studies83,84,96–100),
the proportion of men ranged from 50% to 69%. Age was not reported in one study on AMD,101
but in the remaining studies participants were older in the AMD studies (mean age 74–76 years)96,97,99 than
in the studies on cystoid macular oedema (mean age 59–62 years)83,100 and diabetic macular oedema
(mean age 49–67 years)84,98 (see Table 3).
As indicated in Table 3, three of the four studies on AMD excluded participants with ocular comorbidities,96,97,99
but this was not reported in the fourth study.101 One study on cystoid macular oedema excluded participants
with ocular comorbidities,83 while the other did not report exclusion criteria.100 For diabetic macular oedema,
one study excluded patients with significant media opacities98 while the other excluded patients with any
macular comorbidity.84
In all studies the unit of analysis was the eye, and the number of eyes included ranged from 34 to 263
(see Table 3). As shown in Table 4, the studies differed according to whether they included one eye per
patient,96,99,100 both eyes,97 or a mixture of single eyes and both eyes.83,84,98,101 In the study on AMD by
Smith and colleagues,101 the results of two case series are reported (obtained from two databases – one in
the USA and one in the UK) each with different inclusion criteria, one of which included both eyes,
while the other included single eyes. However, the data on test accuracy from the study by Smith and
colleagues101 relevant to the current review are only available for the pooled population.
Descriptions of the retinal conditions varied considerably in detail and the studies were generally
heterogeneous in terms of the conditions they included (see Table 4). The three studies on reticular
pseudodrusen in AMD96,97,101 differed according to the stage of AMD and whether it affected one or both
eyes. The two studies on cystoid macular oedema83,100 differed in the primary conditions from which the
cystoid macular oedema developed. The studies on diabetic macular oedema84,98 differed on whether they
included ocular comorbidities.
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Cachulo et al.99 Portugal 52a 52 76 (56–92) 50 No
AMD: reticular
pseudodrusen
Hogg et al.96 Italy,
Portugal, UK
105 105 76 (52–93) 50 No





Japan 114 220 74 (52–92) 69 No
Cystoid macular
oedema
McBain et al.100 UK 34 34 59 (17–89) 59 Yes







Italy 137 263 T1D: 49 (28–64);b
T2D: 67 (41–85)b







71 125 63 (not reported) 65 No
T1D, type 1 diabetes mellitus; T2D, type 2 diabetes mellitus.
a There were 62 eyes in total but only 52 were included in analyses.
b Not reported for all participants.
TABLE 4 Distribution and definition of the retinal conditions
Retinal
condition Study Eye(s) studied (one or both) and definition of the condition
AMD: choroidal
neovascularisation
Cachulo et al.99 Fellow eyes (defined as having early age-related maculopathy) of patients who had
neovascular AMD in the non-study eye. Study eyes had: ≥ 5 intermediate (> 63 µm) or
one large soft druse (> 125 µm), and/or confluent drusen within 3.0 µm of the foveal
centre, with or without pigmentary changes
AMD: reticular
pseudodrusen
Hogg et al.96 Fellow eyes of patients who had advanced unilateral neovascular AMD in the non-study
eye. Study eyes specifically had early AMD with no features of GA or neovascular AMD
Smith et al.101 Mixture of 83 pairs of eyes which had bilateral large, soft drusen (with or without GA)
but had no evidence of choroidal neovascularisation, and 55 single eyes which were
the fellow eyes of patients who had unilateral choroidal neovascularisation
Ueda-Arakawa
et al.97
Both eyes of patients newly diagnosed with early AMD, neovascular AMD or GA in at least
one eye. Early AMD was defined as the presence of soft drusen (≥63µm) or areas of
hyper- or hypopigmentation in the retinal pigment epithelium, and GA was defined using
colour fundus photography as a sharply delineated area (≥175µm) of hypopigmentation,
depigmentation or apparent absence of the retinal pigment epithelium in which choroidal
vessels were clearly visible. Neovascular AMD was defined as neovascularisation detected
using fluorescein or indocyanine green angiography
Cystoid macular
oedema
McBain et al.100 Single eyes of patients with clinically suspected cystoid macular oedema secondary to
cataract extraction, inherited retinopathies, inflammatory eye disease or idiopathic
cases. In bilateral cases the left eye was arbitrarily chosen
Dinc et al.83 Single eyes of 43 patients and both eyes of 12 patients whose cystoid macular
oedema was secondary to diabetic retinopathy, retinal vein occlusions, uveitis, cataract





Both eyes of 126 patients and single eyes of 11 patients with diabetes mellitus
(type 1 or 2) who had any stage of treated or untreated diabetic retinopathy
Waldstein
et al.84
Both eyes of 54 patients and single eyes of 17 patients with diabetic retinopathy with
or without diabetic macular oedema
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In keeping with the inclusion criteria for the current review, all FAF imaging tests were conducted using
confocal scanning ophthalmoscopy (Table 5). The studies (except one that did not specify the image
acquisition equipment101) used variants of the Heidelberg Retina Angiograph (Heidelberg Engineering,
Heidelberg, Germany). Where reported (six studies83,84,97–100), the excitation wavelength was 488 nm (blue)
and, where reported (five studies83,97–100), the detection wavelength was > 500 nm. Two of the studies
included an additional FAF imaging test with a higher excitation wavelength; these were at 514 nm
(green) in a study of diabetic macular oedema84 and at 790 nm (near infrared) in a study of reticular
pseudodrusen.97 The field of view, which was specified in five studies,83,84,96,99,100 was 30 degrees and the
number of frames from which the final (mean) FAF image was calculated (specified in all studies except
one101) ranged from 9 to 20.
TABLE 5 Test characteristics and diagnostic criteria
Retinal
condition Study Index test
Index test diagnostic
criteria (full details in
Appendix 5) Reference standard
AMD: choroidal
neovascularisation
Cachulo et al.99 FAF: excitation 488 nm;
detection > 500 nm
(used HRA 2 cSLO)
Five types of FAF patterns.
Images classified according
to the International Fundus
Autofluorescence
Classification Group.45,46
No other details provided
FA – stated as being





















a background of mildly
increased autofluorescence
occurring in a regular and
well-defined array
Positive diagnosis on
one or more of five
imaging modalities











stated only that definition
excluded atrophic drusen
patterns that were more
central, darker and
more scattered than the
lower-contrast reticular
autofluorescence that
filled a whole region
homogeneously
CFP (diagnostic criteria
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The reference standards reported in the primary studies were: fluorescein angiography for diagnosing
choroidal neovascularistion99 and cystoid macular oedema;83,100 colour fundus photography101 or multiple
imaging modalities96,97 for diagnosing reticular pseudodrusen; and either retromode scanning laser
ophthalmology98 or spectral-domain optical coherence tomography84 for diagnosing diabetic macular
oedema (see Table 5). In the two studies that employed multiple imaging modalities,96,97 the reference
standard is somewhat unusual since diagnosis required a positive result on a specified minimum number of
modalities. The clinical relevance of the reference standards is discussed further in our assessment
of study quality (see Quality of research available).
Six of the studies reported that patients underwent an ophthalmic examination, which included assessments
of visual acuity, intraocular pressure and/or slit lamp biomicroscopy83,84,96–99 but they did not specify whether
or not information obtained from these examinations was necessary to assist any of the diagnostic decisions
made using the index test or reference standard. Three studies employed further retinal imaging tests in
addition to their index test and reference standard83,98,99 (these are listed as ‘comparators’ in Appendix 5).
Two of these, by Cachulo and colleagues99 on choroidal neovascularisation (where the additional tests were
colour fundus photography, indocyanine green angiography, optical coherence tomography and a retinal
leakage analysis) and by Dinc and colleagues83 on cystoid macular oedema (where the additional test was
TABLE 5 Test characteristics and diagnostic criteria (continued )
Retinal
condition Study Index test
Index test diagnostic
criteria (full details in
Appendix 5) Reference standard
Cystoid macular
oedema
McBain et al.100 FAF: excitation 488 nm;
detection > 500 nm
(used HRA cSLO)
Round or oval areas of FAF
at the fovea, with an
autofluorescence signal
similar to background
levels (normal eyes would
have hypoautofluorescence
at this location due to
luteal pigment blocking)
FA – stated used as the
reference test as it has
been used routinely for
diagnosis of CMO;
diagnosed if late-phase
FA gave a petaloid dye
leakage pattern
around the fovea
Dinc et al.83 FAF: excitation 488 nm;
detection > 500 nm
(used HRA cSLO)
Not reported explicitly but
mentioned post hoc (in
results section) as being
round and oval hyperFAF
at the fovea
FA – diagnosis of CMO
made if late-phase FA
showed pathognomonic
leakage of fluorescein at





Vujosevic et al.98 FAF: excitation 488 nm;
detection > 500 nm
(used HRA 2 cSLO)
Single or multiple spot














the current report –
see Appendix 5)
Not reported explicitly but
mentioned post hoc (in
results section) that DMO
typically stands out as
relatively bright, single or
multiple, round or oval
areas, mostly bordered by
darker rims












CBR, confocal blue reflectance; CFP, colour fundus photography; CMO, cystoid macular oedema; DMO, diabetic macular
oedema; FA, fluorescein angiography; HRA, Heidelberg Retina Angiograph; ICGA, indocyanine green angiography;
IRP, infrared photography; IRR, infrared reflectance; MPOD, macular pigment optical density; OCT, optical coherence
tomography; RFP, red fundus photography; RM-SLO, retromode scanning laser ophthalmoscopy; SD-OCT, spectral-domain
optical coherence tomography.
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optical coherence tomography), did not explain whether or not any information from the additional tests
was taken into account when making diagnostic decisions using FAF imaging or the reference standard
(fluorescein angiography). The third study, by Vujosevic and colleagues98 on diabetic macular oedema
(where the additional tests were time-domain optical coherence tomography and fluorescein angiography),
mentioned that images were graded in a masked fashion, suggesting that the additional tests would not have
influenced any diagnostic decisions made using FAF imaging or the reference standard (retromode scanning
laser ophthalmoscopy). One of the studies on diabetic macular oedema which employed both 488 nm and
514 nm wavelengths of FAF imaging used the results of both tests to calculate macular pigment optical
density maps.84 This approach was reported to have lower sensitivity and specificity for detecting diabetic
macular oedema than either of the individual FAF imaging tests on which it was based (see Appendix 5) and
as such is not considered as a separate index test in the current report.
The diagnostic criteria on FAF imaging for each of the retinal conditions were qualitative (i.e. descriptive)
in all studies (see Table 5), and only one of the studies reported an objective (quantitative) approach for
determining how abnormal (hypo or hyper) autofluorescence was defined.101 The three studies on reticular
pseudodrusen all specified that the diagnostic criterion was a reticular pattern of hypoautofluorescence,
although there were slight differences in how this was described in each study.96,97,101 The two studies on
cystoid macular oedema83,100 both appeared to diagnose the condition as round or oval patterns of
autofluorescence at the fovea, although this was not stated explicitly in one study.83 The two studies on
diabetic macular oedema84,98 only mentioned the diagnostic criteria briefly and differed in how these were
described. Despite the subjective nature of the diagnostic criteria, only three of the eight studies investigated
intergrader agreement in the classification of retinal images (see Table 2).84,97,98 Limited information was
provided about the expertise of the image graders, who were described as two independent ophthalmologists,97
two retinal specialists trained in image grading98 and two independent graders.84
Quality of research available
This section presents an overview of study rigour as assessed using the Cochrane adaptation81 of the
QUADAS tool.93 Table 6 summarises the critical appraisal judgements for each of the eight included
studies.83,84,96–101 Supporting explanations for the judgements are given in the full versions of the data
extraction forms (see Appendix 5). As explained above (see Table 1) each of the QUADAS questions relates
to a different aspect of bias or applicability that could limit the validity of the study results. An overview of
these risks of bias is provided at the end of the section.
Quality assessment of diagnostic accuracy studies question 1: applicability of
the patient spectrum
The populations included in the primary studies were considered unlikely to be representative of those
who would present in NHS clinical practice (the patient spectrum was considered ‘probably not
representative’ in seven studies83,84,96,97,99,100,101 and unclear in one study98) (see Table 6). In the studies by
Cachulo and colleagues,99 Hogg and colleagues96 and Smith and colleagues101 the case mix was considered
atypical and unlikely to represent patients in the NHS as the retinal condition was required to differ
between the two eyes. In the studies by McBain and colleagues,100 Dinc and colleagues,83 Ueda-Arakawa
and colleagues97 and Waldstein and colleagues84 the case mix also appears to have limited relevance to
current NHS practice, as McBain and colleagues100 and Dinc and colleagues83 required cystoid macular
oedema to be specific to certain causal conditions, while Ueda-Arakawa and colleagues97 and Waldstein
and colleagues84 excluded patients with ocular comorbidities. In addition, the studies by McBain and
colleagues,100 Ueda-Arakawa and colleagues97 and Waldstein and colleagues84 selected patients
retrospectively, which may further limit their applicability to current practice (as the case mix is potentially
selective).102 The study by Vusojevic and colleagues98 included patients with any stage of treated or untreated
diabetic retinopathy and permitted ocular comorbidities and, as such, appears potentially relevant to the NHS;
however, the study was conducted in Italy and it is unclear whether patients were selected prospectively
or retrospectively.
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Quality assessment of diagnostic accuracy studies question 2:
applicability of reference standards
In five of the studies83,84,99–101 the reference standards employed for diagnosing the target retinal condition
were judged to be appropriate in principle as they are accepted standard methods: fluorescein
angiography was used for diagnosing choroidal neovascularisation99 and cystoid macular oedema;83,100
colour fundus photography was used for diagnosing reticular pseudodrusen;101 and spectral-domain optical
coherence tomography was used for diagnosing diabetic macular oedema.84 However, there are caveats
around this interpretation because clinical experts advised that it is unlikely that individual imaging tests
would be used in isolation, as appeared to be the case in these primary studies. For instance, fluorescein
angiography would typically be employed in conjunction with optical coherence tomography when
diagnosing cystoid macular oedema and diabetic macular oedema.34,38 For the detection of reticular
pseudodrusen, although colour fundus photography has been commonly used and is often considered a
standard approach, this may not capture all the reticular pseudodrusen that could be identifiable using
other imaging methods.11,103 As noted in Table 6, for three studies we judged the ability of the reference
standard to diagnose the target retinal condition as unclear.96–98 This was either because the studies
employed a suite of imaging modalities and required a positive result on a specified minimum number
of these96,97 (i.e. a non-standard diagnostic approach) or because the reference standard employed in the
primary study (retromode scanning laser ophthalmology) has not been previously explored as a diagnostic
tool for the specified condition (diabetic macular oedema).98 As such, these three studies would not be
reflective of standard imaging approaches employed in the NHS.
Quality assessment of diagnostic accuracy studies question 3: test interval
The time period between the index and reference tests (QUADAS question 3) was unclear (not reported)
in five of the studies83,96,97,99,101 and hence the risk of disease progression bias in these studies is unclear.
In one study on cystoid macular oedema100 and both studies on diabetic macular oedema84,98 the time
interval was considered short enough that both tests would have been assessing the same disease state
and so these studies would be considered at low risk of disease progression bias.
Quality assessment of diagnostic accuracy studies question 4: population receiving
the reference standard
In all studies except one96 all the patients included in each study received the reference standard. In the
study by Hogg and colleagues96 on reticular pseudodrusen, multiple imaging methods were used, but it is
unclear, according to the reported sample sizes, whether all participants received all tests and some data
were then excluded, or whether some participants did not receive all tests.
Quality assessment of diagnostic accuracy studies question 5: same reference
standard for all patients
In six studies all the patients included in each study received the same reference standard.83,84,98–101 In the
two studies where this was not the case, conducted by Hogg and colleagues96 and Ueda-Arakawa and
colleagues,97 the combination of imaging modalities that contributed to a diagnosis (at least one of five
tests96 or at least two of seven tests97) could have differed between the patients.
Quality assessment of diagnostic accuracy studies question 6: independence of
index test and reference standard
In six studies the index text was independent of the reference standard.83,84,98–101 In the two studies where
this was not the case, conducted by Hogg and colleagues96 and Ueda-Arakawa and colleagues,97 the index
tests were among five tests96 or seven tests97 that made up the reference standard.
False positives are not possible where FAF imaging is also part of the reference standard and, as would
be expected, no false positives were reported for FAF imaging by Hogg and colleagues.96 However,
Ueda-Arakawa and colleagues did report false positives (9/217 for FAF imaging and 5/136 for near-infrared
FAF imaging). These false positives appear to be an artefact of the diagnostic criterion for reticular
pseudodrusen, which required a positive result on two or more of seven imaging modalities. The ‘false
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positives’ in this case indicate that, in nine and five eyes, FAF imaging and near-infrared FAF imaging,
respectively, were the only tests out of seven in the reference standard that detected reticular pseudodrusen.
Quality assessment of diagnostic accuracy studies question 7: interpretation of
reference standard independent of index test results
In all studies except one98 it was unclear (not reported) whether or not investigators interpreting the results
of the reference standard test might have been aware of the results of the index test. In the study by
Vusojevic and colleagues98 the order of tests was not reported but it was stated that images were
independently graded in a masked fashion.
Quality assessment of diagnostic accuracy studies question 8: interpretation of
index test independent of reference standard results
In six studies it was unclear (not reported) whether or not investigators interpreting the results of the index
test might have been aware of the results of the reference standard.84,96,97,99–101 In the study by Dinc and
colleagues83 interpretation of the index test was independent of the reference standard as the index test
was conducted first. In the study by Vusojevic and colleagues,98 the order of tests was not reported but it
was stated that images were independently graded in a masked fashion.
Quality assessment of diagnostic accuracy studies question 9: clinical information
available for test interpretation
None of the studies explicitly stated whether or not their index tests or reference standards were
interpreted in conjunction with other clinical information (i.e. the results from standard ophthalmic
examinations or other imaging tests) and this casts considerable doubt over whether or not any of the
reference standard tests as employed in the primary studies would properly represent how the tests would
be employed in clinical practice.
Quality assessment of diagnostic accuracy studies question 10: reporting of
uninterpretable or intermediate test results
Five of the studies (two on reticular pseudodrusen,96,101 two on diabetic macular oedema84,98 and one on
cystoid macular oedema83) did not report whether uninterpretable or intermediate test results were
considered either in the calculation of diagnostic accuracy or as exclusion criteria, so it is unclear whether
or not image quality might have limited the utility of any of the imaging tests in these studies. Three
studies reported poor quality or uninterpretable images.97,99,100 Cachulo and colleagues99 mentioned that
the pattern of autofluorescence could not be determined for two eyes (4%) because of poor-quality
images, but it is unclear whether or not these were included in the diagnostic accuracy calculation.
Ueda-Arakawa and colleagues97 reported that 84 eyes (38%) were excluded from analysis because of
poor image quality. McBain and colleagues100 stated that nine eyes (9%) were excluded because of poor
FAF images.
Quality assessment of diagnostic accuracy studies question 11: study
withdrawals explained
In four studies there were no withdrawals and so this question was answered as ‘not applicable’.83,84,98,101
In three studies the authors provided explanations for the withdrawals.97,99,100 Cachulo and colleagues99
reported these as death, withdrawal of informed consent, hospitalisation and loss to follow-up. McBain
and colleagues100 reported these as no FAF, more than 2 weeks between tests, FAF imaging < 4 days after
the reference standard (no explanation provided), poor FAF images related to media opacities and cystoid
macular oedema related to other diseases (e.g. previous branch vein occlusion, diabetic retinopathy or
AMD). Ueda-Arakawa and colleagues97 reported these as due to phthisis bulbi or poor image quality in
three or more imaging modalities. One study, by Hogg and colleagues,96 explained that images were
excluded from analysis because of poor image quality but did not provide this information specifically for
the index test.
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Summary of quality assessment in relation to risks of bias
Seven of the eight included studies appear to be at high risk of spectrum bias (QUADAS
question 1)83,84,96,97,99–101 since their patient populations appeared not to be representative of those likely to
be encountered in clinical practice, and in the remaining study98 the risk of spectrum bias is unclear.
Although most (five) of the studies appear to have employed reference standards that are commonly used
and therefore might be considered acceptable (QUADAS question 2),83,84,99–101 these studies appeared to
employ single imaging tests as the reference standard whereas diagnostic decisions in clinical practice
would more likely employ a combination of imaging tests. For this reason the risk of verification bias was
considered as being unclear for these five studies and high for the remaining three studies96–98 where the
reference standard was unlikely to have accurately diagnosed the target retinal condition. The risk of
disease progression bias (assessed in QUADAS question 3) is largely unclear, except for one study on cystoid
macular oedema100 and both studies on diabetic macular oedema,84,98 which were judged to be at low risk.
The risk of differential verification bias, that is, bias arising as a result of participants not all receiving the
same reference standard (assessed in QUADAS questions 4 and 5), was considered to be low for most
(six)83,84,98–101 of the studies but high for two studies96,97 on reticular pseudodrusen owing an unorthodox
design of reference standard (where diagnosis required a positive result on a specified minimum number of
imaging modalities). These same two studies on reticular pseudodrusen were considered at high risk of
incorporation bias (assessed in QUADAS question 6) since the index test was not independent of the
reference standard; the remaining six studies were judged to have low risk of this bias.83,84,98–101 The risk of
diagnostic review bias, that is, the index test result influencing interpretation of the reference standard
result (assessed in QUADAS question 7) was unclear for most (seven) studies but judged to be low for one
study on diabetic macular oedema.98 The risk of test review bias, that is, where results of the reference
standard influence interpretation of the index test result (assessed in QUADAS question 8) was unclear in
most (six) studies84,96,97,99–101 but judged to be low for one study on cystoid macular oedema83 and for one
study on diabetic macular oedema.98 The risk of clinical review bias (assessed in QUADAS question 9) is
unclear since none of the included studies reported whether their index tests were interpreted together
with other clinical information, such as the results of routine ophthalmic examinations or results of other
imaging modalities they employed. The risk of bias from uninterpretable or intermediate test results
(QUADAS question 10) is generally unclear. Risk of attrition bias (QUADAS question 11) was judged to be
low in five studies since either there were no exclusions,83,84,98,101 or the exclusions were clearly explained
and appeared unlikely to influence the analysis.97 Two studies explained their withdrawals but presented
discrepancies in the numbers they analysed99,100 (see Appendix 5), while one study did not explain
withdrawals;96 these three studies were judged to have an unclear risk of attrition bias. Overall, taking into
consideration the different risks of bias mentioned above, it is not possible to identify individual studies, or
specific retinal conditions, for which the quality of the clinical evidence would be regarded as being
adequately robust to directly inform clinical practice.
An aspect of study quality not captured by the QUADAS criteria is that studies that included both eyes of a
patient did not take into account adjustment for the correlation between the patient’s eyes, and this might
lead to underestimation of standard errors for sensitivity and specificity.95 This applies to two studies of
reticular pseudodrusen in AMD by Ueda-Arakawa and colleagues97 and Smith and colleagues,101 and to
both studies of diabetic macular oedema, by Vusojevic and colleagues98 and Waldstein and colleagues.84
Assessment of test accuracy
This section presents the best evidence available on the diagnostic accuracy of FAF imaging. Given the
heterogeneity of study characteristics with respect to the retinal conditions included, whether they were
assessed in one or both eyes and differences between studies in the reference standards employed
(see Quantity of research available), it would be inappropriate to quantitatively pool diagnostic accuracy
outcomes (i.e. sensitivity and specificity) across individual studies within each of the retinal conditions.
Instead a narrative synthesis was undertaken, which provides sensitivity and specificity estimates for each
retinal condition together with their confidence intervals, as well as likelihood ratios to illustrate the overall
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diagnostic results from each study and their uncertainty. Paired sensitivity and specificity forest plots are
presented for illustrative purposes, without pooling the sensitivity or specificity measures across the studies.
For brevity, likelihood ratios are discussed below only in cases where they suggest that the results of a
given study might not be diagnostically informative (based on the criteria given in Chapter 2). Diagnostic
odds ratios and positive and negative predictive values are also available for all studies (see Appendix 5).
However, these statistics have to be interpreted with caution.89 Given that there are concerns about the
quality of the evidence in all studies (see Quality of research available), and in the absence of a quantitative
meta-analysis, the predictive values and diagnostic odds ratio would not provide additional interpretational
value in the assessment of diagnostic accuracy and as such they are not referred to below.
Choroidal neovascularisation in neovascular age-related
macular degeneration
One study, by Cachulo and colleagues,99 assessed the diagnostic accuracy of FAF imaging (488 nm) against
fluorescein angiography in detecting choroidal neovascularisation in AMD. The study authors reported
sensitivity of 93% and specificity of 37%. However, using the data available from Cachulo and colleagues,99
we calculated sensitivity of 88% and specificity of 34% (Table 7) (for calculations see Appendix 5). This
discrepancy might result from differences in categorising two (out of 52) eyes for which the pattern of FAF
could not be determined because of poor-quality images. Confidence intervals for the estimates of sensitivity
and specificity suggest moderate uncertainty around these values (Figure 3), but were not reported for the
estimates calculated by the study authors.
Cachulo and colleagues99 did not report any information on interobserver or intraobserver agreement in
image grading, test acceptability to patients or clinicians, or adverse events that might influence the
interpretation of diagnostic outcomes.
As noted above (see Quality of research available), the single available study on diagnosis of choroidal
neovascularisation in AMD99 was judged to be at high risk of spectrum bias (owing to an unrepresentative
case mix); in addition the risks of several types of bias that could arise in relation to the sequence and
timing of the index and reference tests, as well as the risk of bias in the interpretation of these tests, were
unclear. Taking these considerations into account, it is not possible to draw a rigorous clinically relevant
conclusion about the diagnostic accuracy of FAF 488 nm imaging as compared against fluorescein
angiography in this retinal condition.
TABLE 7 Diagnostic accuracy of FAF imaging for choroidal neovascularisation in neovascular AMD
Study Sensitivity, % (95% CI) Specificity, % (95% CI)
Positive likelihood
ratio, % (95% CI)
Negative likelihood
ratio, % (95% CI)
Cachulo et al.,
201199
93 (not reported) 37 (not reported) Not reported Not reported
Calculated by
reviewer
88.24 (63.52 to 98.20) 34.29 (19.15 to 52.21) 1.34 (1.00 to 1.80) 0.34 (0.09 to 1.36)
CI, confidence interval.
Study TP FP FN TN
Cachulo99 (FAF 488 nm vs.
fluorescein angiography)
15 23 2 12
Sensitivity (95% CI) Specificity (95% CI)
0.0 0.2 0.4 0.6 0.8 1.0 0.0 0.2 0.4 0.6 0.8 1.0
FIGURE 3 Diagnostic accuracy of FAF imaging for choroidal neovascularisation in neovascular AMD. CI, confidence
interval; FN, false negative; FP, false positive; TN, true negative; TP, true positive.
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Reticular pseudodrusen in age-related macular degeneration
(different stages)
Three studies, by Hogg and colleagues,96 Smith and colleagues101 and Ueda-Arakawa and colleagues,97
assessed the accuracy of FAF imaging for detecting reticular pseudodrusen in AMD.
Two of the studies did not report the FAF imaging excitation wavelength,96,101 while Ueda Arakawa
and colleagues97 used FAF 488 nm and infrared FAF 790 nm (NIR-FAF) as index tests. The studies used
various reference standards. Smith and colleagues101 used colour fundus photography, Hogg and
colleagues96 required a positive result on one or more of five imaging modalities, and Ueda-Arakawa
and colleagues97 required a positive result on two or more of seven imaging modalities. Each study aimed
to detect reticular pseudodrusen in a different stage of AMD (see Table 4). Hogg and colleagues96 studied
fellow eyes of patients with neovascular AMD in the non-study eye, Ueda-Arakawa and colleagues97
studied both eyes of patients newly diagnosed with early AMD, neovascular AMD or GA, and Smith and
colleagues101 included a mixture of both eyes of patients without any evidence of choroidal neovascularisation
and fellow eyes of patients with unilateral choroidal neovascularisation in the non-study eye.
By taking together the appropriate reference standards for diagnosing reticular pseudodrusen (i.e. colour
fundus photography and optical coherence tomography) and the other reference standards nominated in
the primary studies, data are available for six diagnostic accuracy comparisons for FAF imaging (Table 8).
Although the reference standard reported by Hogg and colleagues96 involves a positive result on one or
more tests, individual comparisons of FAF imaging against colour fundus photography and FAF imaging
against optical coherence tomography were also reported.













































































CBR, confocal blue reflectance; CFP, colour fundus photography; CI, confidence interval; ICGA, indocyanine green
angiography; IRP, infrared photography; IRR, infrared reflectance; OCT, optical coherence tomography; RFP, red fundus
photography; SD-OCT, spectral domain optical coherence tomography.
a Excitation wavelength not stated.
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FAF imaging based on a 488 nm excitation wavelength had relatively high (86–100%) sensitivity for
detecting reticular pseudodrusen when compared against the various reference standards (Figure 4).
However, near-infrared FAF imaging had low (32%) sensitivity (see Figure 4). In contrast, both FAF and
NIR-FAF imaging had high (84–100%) specificity compared against the various reference standards, except
for a lower specificity (67%) when FAF imaging was compared against colour fundus photography in the
study by Hogg and colleagues.96 A major limitation of the results for near-infrared FAF imaging reported by
Ueda-Arakawa and colleagues97 is that 38% of the eyes were excluded owing to poor image quality.
For most of the studies the 95% confidence intervals around the specificity estimates are relatively narrow.
However, confidence intervals for specificity reported by Hogg and colleagues,96 and those reported for
sensitivity by all studies are wider, meaning that these estimates may be less reliable (see Figure 4).
However, it is possible that the width of the confidence intervals reported by Smith and colleagues101 and
Ueda-Arakawa and colleagues97 might have been underestimated, as the analyses did not account for any
intrapatient correlations in cases where both eyes of the same patient were analysed.
Two of the studies, by Hogg and colleagues96 and Ueda-Arakawa and colleagues,97 provided information
on intergrader agreement in diagnosing reticular pseudodrusen using FAF imaging. Kappa values indicate
actual agreement compared with that which would occur by chance. A value of 1 indicates perfect
agreement and a value of 0 indicates agreement equivalent to chance. Kappa values were 0.563 (n= 35,
p< 0.001) (84.2% agreement)97 and 0.94 (sample size, p-value and percentage agreement not reported).96
These kappa values could be interpreted as ‘moderate’ and ‘almost perfect’ agreement, respectively.104
Although intergrader agreement was almost perfect in Hogg and colleagues’ study,96 it was reported for
only one of their three study centres and so it is unclear whether or not the ‘best’ agreement was
selectively presented or whether or not the reported agreement is reflective of that across all the study
centres. None of the studies on reticular pseudodrusen provided any information on intragrader variation
in diagnosis, the acceptability of the imaging modalities to patients or clinicians, or on whether any
adverse events of any tests were observed.
In summary, the diagnostic outcomes suggest that FAF imaging with an excitation wavelength of 488 nm
could potentially contribute to the diagnosis of reticular pseudodrusen but near-infrared FAF imaging
(790 nm) does not appear adequately sensitive to be of diagnostic value. However, there is considerable
uncertainty around these findings, owing to the limited number of studies and comparisons available and
shortcomings in the study designs. As noted above (see Quality of research available), the three available
studies on diagnosis of reticular pseudodrusen in AMD96,97,101 were judged to be at high risk of spectrum
Study TP FP FN TN
Hogg96 (FAF vs. Spectralis OCT)
Hogg96 (FAF vs. CFP)
Hogg96 (FAF vs. > 1 imaging 
modality)
Smith101 (FAF vs. CFP)
Ueda-Arakawa97 (FAF 488 nm)a

























Sensitivity (95% CI) Specificity (95% CI)
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FIGURE 4 Diagnostic accuracy of FAF imaging for reticular pseudodrusen in AMD. CFP, colour fundus photography;
CI, confidence interval; FN, false negative; FP, false positive; OCT, optical coherence tomography; TN, true negative;
TP, true positive. a, Versus two or more imaging modalities.
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bias (owing to an unrepresentative case mix), while the risks of several types of bias that could arise in
relation to the sequence and timing of the FAF imaging tests in relation to those of the reference
standards, and in the interpretation of these tests, were unclear. In addition, in the studies by Hogg
and colleagues96 and Ueda-Arakawa and colleagues,97 the FAF imaging index tests also formed part of the
reference standard, which complicates interpretation of any diagnostic outcomes. Furthermore, Ueda-Arakawa
and colleagues97 had to exclude over one-third of the eyes from their analysis of near-infrared FAF imaging
because good image quality could not be obtained with this method. Taking these considerations into
account, it is not possible to draw a rigorous clinically relevant conclusion about the diagnostic accuracy of FAF
imaging for diagnosing reticular pseudodrusen in AMD.
Cystoid macular oedema secondary to various conditions
Two studies, by Dinc and colleagues83 and McBain and colleagues,100 reported the diagnostic accuracy of
488 nm FAF imaging for identifying cystoid macular oedema secondary to various conditions. Both studies
employed fluorescein angiography as the reference standard, which would partly reflect current clinical
practice (optical coherence tomography and possibly also colour fundus imaging would be used in addition
to fluorescein angiography to reach a diagnosis in clinical practice). The study by Dinc and colleagues83
indicated high (98%) sensitivity with a narrow confidence interval suggesting good precision of the
estimate, while that of McBain and colleagues100 indicated moderate sensitivity (81%) but with high
uncertainty (Table 9 and Figure 5). However, the former study had 0% specificity (reflecting a lack of
true negatives in the data) and hence, as the likelihood ratios suggest, the study is not diagnostically
informative. The latter study, by McBain and colleagues,100 is limited by the uncertainty around its
sensitivity and specificity estimates which, according to the lower confidence limits, could have been as low
as 58% and 39%, respectively.
Neither of the two studies on cystoid macular oedema83,100 reported any information on interobserver or
intraobserver agreement in image grading, test acceptability to patients or clinicians, or adverse events of
any tests that might influence the interpretation of diagnostic outcomes.





























CI, confidence interval; CMO, cystoid macular oedema; FA, fluorescein angiography.
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Dinc83 (FAF 488 nm vs. FA)









Sensitivity (95% CI) Specificity (95% CI)
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FIGURE 5 Diagnostic accuracy of FAF imaging for cystoid macular oedema. CI, confidence interval; FA, fluorescein
angiography; FN, false negative; FP, false positive; TN true negative; TP, true positive.
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As noted above (see Quality of research available), both studies on diagnosis of cystoid macular
oedema83,100 were judged to be at high risk of spectrum bias, owing to an unrepresentative case mix.
Although Dinc and colleagues83 interpreted results of the index test (FAF imaging) without knowledge of
the results of the reference standard (fluorescein angiography), indicating a low risk of test review bias, the
risks of diagnostic review bias and clinical review bias were unclear in both studies. Taking these
considerations into account, noting that one study appears to be diagnostically uninformative83 while the
other has high uncertainty of its diagnostic outcomes,100 it is not possible to draw a rigorous clinically
relevant conclusion about the accuracy of FAF imaging for diagnosing cystoid macular oedema.
Diabetic macular oedema
Two studies, by Vujosevic and colleagues98 and Waldstein and colleagues,84 reported the diagnostic
accuracy of FAF imaging for diabetic macular oedema. Vujosevic and colleagues98 compared 488 nm FAF
imaging against a reference standard of retromode scanning laser ophthalmoscopy. Waldstein and
colleagues84 compared 488 nm and 514 nm FAF imaging against a reference standard of spectral-domain
optical coherence tomography. For diabetic macular oedema, optical coherence tomography would be a
clinically relevant reference standard (as acknowledged by Vusojevic and colleagues98), although, according
to clinical experts consulted during the present review, it would likely be combined in clinical practice with
colour fundus imaging and, if macular ischaemia is suspected, also with fluorescein angiography.
Diagnostic outcomes are shown in Table 10 and Figure 6. Sensitivity of FAF imaging (488 nm) for diagnosing
diabetic macular oedema was highest (92%) when compared against retromode scanning laser
ophthalmoscopy, although this is unlikely to be used routinely in clinical practice. Sensitivity of FAF imaging
when compared against spectral-domain optical coherence tomography was moderate (81%) for the
shorter-wavelength imaging (488 nm) but relatively low (55%) for the longer-wavelength method (514 nm).






































CI, confidence interval; RM-SLO, retromode scanning laser ophthalmoscopy; SD-OCT, spectral domain optical
coherence tomography.
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Sensitivity (95% CI) Specificity (95% CI)
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FIGURE 6 Diagnostic accuracy of FAF imaging for diabetic macular oedema. CI, confidence interval; FN, false
negative; FP, false positive; RM-SLO, retromode scanning laser opthalmoscopy; SD-OCT, spectral domain optical
coherence tomography; TN, true negative; TP, true positive.
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In contrast, specificity was relatively high for both wavelengths of FAF imaging when compared against
spectral-domain optical coherence tomography (90% to 95%) but lower when 488 nm FAF imaging was
compared against retromode scanning laser ophthalmoscopy (85%). The estimates of sensitivity and
specificity have relatively narrow confidence intervals, suggesting they are reasonably precise, although it is
possible that the width of the confidence intervals for both studies might have been underestimated, since the
analyses did not account for any intrapatient correlations where both eyes of the same patient were analysed.
Vusojevic and colleagues98 did not report intergrader agreement on interpreting FAF images. Waldstein
and colleagues84 reported kappa values (but not sample size, p-value or percentage reviewer agreement)
for intergrader agreement in interpretation of the FAF images, which were 0.84 for 488 nm FAF imaging
and 0.63 for 514 nm FAF imaging. These could be interpreted as ‘almost perfect agreement’ and
‘substantial agreement’, respectively.104 Neither study reported intraobserver agreement for image grading,
test acceptability to patients or clinicians, or adverse events of any tests that might influence the
interpretation of diagnostic outcomes.
As noted above (see Quality of research available), the study by Waldstein and colleagues84 was judged to
be at high risk of spectrum bias (owing to an unrepresentative and retrospectively selected case mix) while
the risks of various types of bias associated with the timing of the index test and reference standard, and
interpretation of these tests, were judged to be unclear. The study by Vujosevic and colleagues98 was
considered to be at unclear risk of spectrum bias because although the case mix appears potentially
reflective of patients likely to receive retinal imaging in clinical practice (diabetic retinopathy patients with
comorbidities permitted) it is unclear whether the patients were selected prospectively or retrospectively.
This study98 was the only one of the eight included in the systematic review that was deemed to be at low
risk of both test review bias and diagnostic review bias. However, as noted above, the reference standard
employed by Vusojevic and colleagues98 is unlikely to reflect clinical practice. Taking these considerations
into account, it is not possible to draw a rigorous clinically relevant conclusion about the accuracy of FAF
imaging for diagnosing diabetic macular oedema, although results from the study by Waldstein and
colleagues84 suggest that the longer-wavelength FAF imaging method (514 nm) was less sensitive for
diagnosing diabetic macular oedema than the standard wavelength approach (488 nm).
Summary of diagnostic accuracy assessment
The eight studies83,84,96–101 included in the systematic review suggest qualitatively that FAF imaging may
have a potential role in supporting the diagnosis of choroidal neovascularisation in AMD, reticular
pseudodrusen in AMD, cystoid macular oedema or diabetic macular oedema. However, after taking into
account a number of quality issues concerning the study designs, none of the studies were found to
provide convincing quantitative information about the diagnostic accuracy of FAF imaging of relevance to
current clinical practice. In two cases where long and short excitation wavelengths of FAF imaging could
be compared, the longer wavelength appeared less diagnostically sensitive: 719 nm was less sensitive than
488 nm for detecting reticular pseudodrusen97 while 514 nm was less sensitive than 488 nm for detecting
diabetic macular oedema.84 However, these differences are based on only two studies that had
methodological limitations and, as such, are illustrative only.
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Statement of principal findings
l There is considerable primary research interest in FAF imaging of retinal conditions (of 206 full-text
papers retrieved for inspection, 199 papers reported on primary studies that had employed FAF
imaging to investigate retinal conditions). However, most studies have been descriptive, providing
reports of how FAF patterns reflect the pathology of retinal conditions (e.g.105–107), rather than
quantitatively assessing diagnostic or monitoring accuracy.
l Eight primary research studies met the inclusion criteria for the current review.83,84,96–101 These
investigated the accuracy of FAF imaging in diagnosing choroidal neovascularisation (one study99),
reticular pseudodrusen in various stages of AMD (three studies96,97,101), cystoid macular oedema
(two studies83,100) and diabetic macular oedema (two studies84,98).
l No studies have assessed the accuracy of FAF imaging for monitoring the progression of retinal
conditions or their response to therapy.
l Most of the studies included in the current review provided very limited information on the diagnostic
criteria they used and these were qualitative (descriptive); most studies did not check for intergrader
agreement in reading FAF images, despite the potential subjectivity of the descriptive diagnostic criteria; and
none of the studies reported the clinical information used by researchers when interpreting FAF images.
l In most of the included studies that used an excitation wavelength of 488 nm, the sensitivity of FAF
imaging was high (range 81–100%), although it was lower in two studies that used longer excitation
wavelengths (32% in one study of reticular pseudodrusen in AMD which used an excitation wavelength
of 790 nm,97 and 55% in one study of diabetic macular oedema, which used an excitation wavelength
of 514 nm84). The specificity of FAF imaging across all studies ranged from 34% to 100% and was not
clearly related to the excitation wavelength. However, owing to the relative paucity of reliable data, and
limitations in experimental rigour, it is unclear whether FAF imaging would be accurate in diagnosing
retinal conditions or in monitoring their progression or response to therapy in clinical practice.
The current review has identified several evidence gaps, including:
l Robust data on the monitoring accuracy of FAF imaging for assessing the progression of retinal
conditions or their response to therapy do not currently exist.
l Limited data are available on the diagnostic accuracy of FAF imaging but these are for four retinal
conditions and suffer from methodological limitations. As such, they are effectively qualitative rather
than reliably quantitative.
l No diagnostic or monitoring accuracy studies of FAF imaging were found for the inherited retinal
dystrophies, early AMD, GA or CSC. According to the review advisory group, these are conditions
where FAF imaging might be most useful and is already being used (to an unclear extent) in the NHS.
Methodological challenges
A challenge in the current review was to identify studies of the diagnostic accuracy of FAF imaging based
on screening titles and abstracts. It was difficult to determine, based on titles and abstracts alone, whether
or not studies reported sensitivity and specificity, or data from which these could be calculated. As a result
it was necessary to retrieve and check 206 full-text records. Nevertheless, only eight studies finally met the
inclusion criteria.83,84,96–101 A difficulty is that most of these eight studies that provided relevant diagnostic
outcomes were not primarily diagnostic studies and as such they were rated relatively poorly against the
QUADAS criteria for risks of bias. Ideally, future studies that wish to explore the diagnostic accuracy of FAF
imaging should be based on appropriate designs and methods compatible with the paradigm of diagnostic
accuracy assessment,108,109 and should include a clear statement in the abstract as to the availability of
quantitative diagnostic outcomes.110
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Patient and public involvement
This review did not formally involve patients or the general public. However, the draft protocol and report
were provided to the advisory group, which included the RNIB, for comment. The RNIB did not identify any
major issues of equitability in the use of FAF imaging from the perspective of patients and the general
public. However, it should be noted that the technology is relatively new and the extent to which patients
have access to the technology is currently unclear.
Strengths and limitations of the assessment
Strengths
l The review was based on a prespecified peer-reviewed protocol.
l A comprehensive literature search was conducted based on a wide range of prespecified
evidence sources.
l All steps of the systematic review process were conducted by at least two reviewers, minimising the
risks of errors and bias.
l The primary evidence was assessed critically using accepted criteria for the critical appraisal of test
accuracy studies.
l All steps of the evidence synthesis are reported transparently; worksheets for study selection and data
extraction were pilot tested and are presented with this report; all studies excluded at full-text
screening are listed in Appendix 4, stating reasons for exclusion.
l An independent advisory group informed the review.
Limitations
l Interpretation of the primary research is hampered by clinical heterogeneity among the studies and
limitations in methodological rigour, which in all studies led to judgements of high risk of bias. Owing
to the small number of studies available it was not possible to assess the impact of methodological
rigour on observed diagnostic outcomes.
l The primary research studies had an inappropriate (or in one study unclear98) patient spectrum
(i.e. a case mix unlikely to be reflective of that presenting for retinal imaging in current NHS practice).
l Some studies included both eyes of patients in analyses, which (because of intrasubject correlations)
may have led to underestimation of standard errors for sensitivity and specificity (and hence also
underestimation of the width of the confidence intervals).95 As there is no formally agreed approach
for analysing such data in evidence syntheses,95 the current review does not investigate their impact
on the precision of diagnostic outcomes. However, such cases are clearly identified in the review
and any inaccuracy of confidence intervals in these cases would not have markedly altered the
review conclusions.
l The systematic review was limited to English-language studies.
DISCUSSION
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Uncertainties
l The current use of FAF imaging for diagnosing and/or monitoring retinal conditions in clinical practice
is unclear.
l The relevance of FAF imaging for monitoring retinal conditions is uncertain. Numerous studies suggest
FAF imaging appears to have potential value as a monitoring tool (e.g. detecting the progression of the
GA area in dry AMD, or the presence and distribution of autofluorescence and development of atrophy
in different inherited retinal dystrophies), but so far all studies that have assessed FAF imaging as a
monitoring tool have lacked a reference standard.
l The information required to adequately interpret FAF images in primary studies is unclear, as it was not
reported in any study whether FAF images were interpreted in isolation or in conjunction with other
clinical information. All studies were therefore judged to be at unclear risk of clinical review bias. This is
important as diagnostic tests should ideally be interpreted using the same information that would be
available in clinical practice.
l It is uncertain how variability between methods (different models of cSLO with different software and
image acquisition protocols) may have affected diagnostic outcomes as this level of detail was not
consistently reported in the included studies.
l It is uncertain whether or not diagnostic criteria used for FAF imaging are reliable (interobserver
reliability of diagnostic criteria was assessed in only three out of eight studies and only in limited
detail84,96,97). The recently updated classification of early AMD and GA using FAF, by the International
Fundus Autofluorescence Classification group,45,46 was used in one of the included studies.99 However,
the classification consists of descriptions of patterns seen on retinal imaging rather than quantifiable
characteristics, and, as such, is open to subjective interpretation. There appears to be a lack of
internationally identified and agreed classifications for other conditions, although these may be needed
to allow meaningful interpretation in future diagnostic accuracy studies of FAF imaging.
l Although it was not an objective of the current review to assess costs or cost-effectiveness of FAF
imaging, it was noted during the inspection of full-text articles that none of the studies that have
assessed the diagnostic accuracy of FAF imaging provided any information on costs or resources, such
as the time taken to acquire images or any resources used for image processing and quality control.
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I t is not possible to give a clear indication of the diagnostic or monitoring accuracy of FAF imaging forretinal conditions based on existing research. Although some studies reported relatively high sensitivity,
these had various methodological limitations, which hinder the interpretation of test accuracy. There is an
indication that standard wavelength FAF imaging (488 nm) may be more sensitive than longer-wavelength
approaches but this is based on only two studies, involving 790-nm imaging for detecting reticular
pseudodrusen97 and 514-nm imaging for detecting diabetic macular oedema.84 Owing to the relative
paucity of reliable data, further studies are required. In particular, prospective studies would be helpful in
inherited retinal dystrophies, early AMD, GA and CSC, and the studies should be designed according to
the paradigm for the quantitative assessment of test accuracy.
Implications for service provision
Owing to a lack of studies addressing the appropriate populations and employing appropriate imaging
methods there remains uncertainty whether or not FAF imaging is accurate for the diagnosis and
monitoring of retinal conditions in clinical practice. As noted in the specific recommendations below,
research is needed to address these knowledge gaps.
The current extent of use of FAF imaging for different retinal conditions in the NHS is unclear. An audit or
survey of current practice would be helpful to clarify how the method is used and whether or not its usage
is appropriate, so as to inform future guidance for NHS practice. The review advisory group suggested that
although the role of FAF imaging in clinical practice is still developing it may already be used by specialists
in the NHS to assist with diagnosis and monitoring of inherited retinal dystrophies such as Stargardt
disease, and may also have a role in the diagnosis and/or monitoring of early AMD and GA.
There seems to be lack of consensus on whether or not FAF imaging may have a role in diagnosing wet
AMD or macular oedemas. Clinical experts advising the current review suggested that the oedema and
fluid leakage in these conditions would obscure the FAF signal, meaning that both fluorescein angiography
and optical coherence tomography would be more appropriate imaging modalities for making a diagnosis
(since blood perfusion and leakage, and macular thickness are key diagnostic aspects of these conditions).
However, some researchers have suggested that FAF imaging could have a role for diagnosing cystoid
macular oedema107 and retinal pigment epithelium loss in wet AMD,67 while the studies on choroidal
neovascularisation,99 cystoid macular oedema83,100 and diabetic macular oedema84,98 that were included in
the current review highlight that there is research interest in the use of FAF imaging in detecting and
diagnosing, or monitoring these conditions.
Given that FAF imaging is non-invasive, there might be benefits to both patients and the NHS if FAF
imaging could, in some cases, replace fluorescein angiography, which is the most frequently used invasive
retinal imaging test. Fluorescein angiography carries a risk of complications (adverse reaction to dye), side
effects (ranging from mild nausea or hives to anaphylaxis and death) and may impact on patients’ quality
of life (e.g. fear of needles), as well as requiring specialist clinical facilities (including a sterile clinical
environment and staff qualified in venous access). Where complications occur or patients experience
diminished quality of life this may require additional therapy, which would impact on health resources.
None of the studies included in the current review assessed patients’ perceptions of the test procedures or
reported whether or not the angiography reference standard was associated with any adverse events.
Further evidence would therefore be helpful to clarify the magnitude of benefits or disadvantages to
patients and the NHS of any switch from fluorescein angiography to FAF imaging.
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Any future research into the accuracy of FAF imaging (see Suggested research priorities) will need to
consider whether FAF imaging is intended to supplement or replace existing imaging modalities.111
According to clinical experts (see Chapter 1, Current service provision), FAF could potentially replace
fluorescein angiography for diagnosing inherited retinal dystrophies, such as retinitis pigmentosa and
Stargardt disease. FAF imaging has also been proposed as a replacement for fluorescein angiography in
certain monitoring applications, for example, in monitoring the progression of Best’s disease,57 verifying the
results of laser therapy in retinal oedema,112 or monitoring outcomes of macular hole surgery,113 but
evidence of whether FAF imaging can completely replace angiography in these roles is currently lacking.
In the majority of retinal conditions FAF imaging is likely to be applied as an additional test, and would
probably accompany optical coherence tomography and other tests, such as angiography or fundus
photography, as needed.
Review of the primary evidence suggests that guidance on how to standardise FAF imaging is limited and
this would need to be considered before formal recommendation of the use of FAF imaging could be
made. It is unclear which guidance, if any, is being currently followed in NHS practice for classifying and
interpreting FAF images. Potentially relevant methods that might serve as a starting point for further
development and evaluation include those of the International Fundus Autofluorescence Classification
group,45,46 although the classification of FAF patterns is currently descriptive. Development of quantitative
diagnostic criteria based on FAF patterns may help to reduce subjectivity of interpretation.114
Suggested research priorities
l Prospective studies that conform to the paradigm for test accuracy assessments (i.e. those that include
a clearly specified population, index test, reference standard and diagnostic outcomes) would be
helpful to evaluate the diagnostic accuracy of FAF imaging in the inherited retinal dystrophies, early
AMD, GA and CSC.
l Prospective studies that conform to the paradigm for test accuracy assessments would be helpful to
evaluate the accuracy of FAF imaging in monitoring the progression of retinal conditions and their
response to therapy, alongside current best practice, in the inherited retinal dystrophies, early AMD,
GA and CSC.
l Future test accuracy studies for FAF imaging should:
¢ recruit participants who are representative of those likely to present for retinal screening in the NHS
¢ employ all relevant components of currently used reference standards
¢ clearly report the clinical information required to interpret FAF images in order to reach diagnostic
and/or therapeutic decisions
¢ consider carefully whether FAF imaging is appropriate as an ancillary test or as a replacement for
an existing test
¢ assess intergrader and intragrader agreement
¢ assess other aspects of test acceptability (e.g. patient acceptability, adverse events).
l Future test accuracy studies for FAF imaging should also report clearly the duration of imaging and any
resources associated with the acquisition, processing, quality assurance and interpretation of FAF
images. This would assist any evaluations of the cost-effectiveness of FAF imaging that are conducted
for the NHS.
l A survey or audit of the current use of FAF imaging in NHS practice would be helpful to clarify current
practice and any limitations and research requirements associated with it. In particular, a survey or audit
of the extent to which FAF imaging is currently used for different retinal conditions and which
standards are currently employed for ensuring consistency of test results would assist prioritisation of
areas where NHS resources may be needed to support the future development of FAF imaging.
l Research would be helpful to clarify which guidance, if any, is currently being followed in NHS practice
for classifying and interpreting FAF images.
CONCLUSIONS
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Appendix 1 Search strategy
Database, host, years
searched, date of search Literature search strategy Results
MEDLINE(R), via Ovid, 1990 to
November week 1 2014,
searched 13 November 2014
1 (autofluorescen* and (fundus or fundi
or fundal)).tw. (892)
2 FAF.tw. (569)
3 1 or 2 (1180)
4 topcon.tw. (407)






11 ‘heidelberg retina angiograph’.tw. (92)
12 ‘heidelberg engineering’.tw. (365)
13 ‘AO SLO’.tw. (22)
14 ‘spectral domain OCT’.tw. (447)
15 optovue.tw. (77)
16 ‘carl zeiss meditec’.tw. (653)
17 or/4-16 (2552)
18 (fluorescen* or autofluorescen*).tw. (316,708)
19 Fluorescence/ (32,554)
20 or/18-19 (325,649)
21 17 and 20 (287)
22 3 or 21 (1287)
23 (image* or imaging).tw. (668,379)
24 (camera* or photograph* or laser* or infrared or
ophthalmoscop* or instrument*).tw. (418,062)
25 Tomography, Optical Coherence/ (15,722)
26 Fluorescein Angiography/ (18,783)
27 Optical Imaging/ (1622)
28 Electroretinography/ (14,273)
29 Microscopy, Confocal/ (44,481)
30 (diagnos* or electrodiagnos*).tw. (1,620,715)
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Database, host, years
searched, date of search Literature search strategy Results
31 Diagnosis, Computer-Assisted/ (20,766)
32 Lasers/du, is [Diagnostic Use, Instrumentation] (4259)
33 Image Processing, Computer-Assisted/ (100,139)
34 (automat* adj5 (detect* or captur* or quantif*)).tw.
(10,352)
35 or/23-34 (2,559,128)
36 22 and 35 (992)
37 exp Retinal Diseases/ (102,626)
38 (retina* or retinitis or retinopath* or epiretina* or
subretina* or preretina* or posterioretina* or intraretina*
or chorioretinopath* or vitreoretinopath*).tw. (167,490)
39 (macula* or maculopath* or ‘wet AMD’ or ‘dry AMD’
or ‘exud* AMD’).tw. (38,891)
40 ((fundus or fundi or fundal) adj5 (change* or impair*
or disease* or disorder* or detect* or diagnos*)).tw. (2365)
41 (geographical adj atroph*).tw. (11)
42 hyperfluorescen*.tw. (822)
43 (RVO or CRVO or BRVO).tw. (1256)
44 (cone*1 adj2 dystroph*).tw. (850)
45 or/37-44 (212,953)
46 36 and 45 (929)
47 (comment or editorial or letter).pt. (1,326,748)
48 46 not 47 (922)
49 limit 48 to english language (855)
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Database, host, years
searched, date of search Literature search strategy Results
MEDLINE(R) In-Process & Other
Non-Indexed Citations, via Ovid,
searched from 1990 to
12 November 2014, searched
on 13 November 2014
As per MEDLINE 112
EMBASE, via Ovid, searched from
1990 to 12 November 2014,
searched 13 November 2014
1 (autofluorescen* and (fundus or fundi or fundal)).tw.
(1043)
2 FAF.tw. (673)
3 1 or 2 (1384)
4 topcon.tw. (486)






11 ‘heidelberg retina angiograph’.tw. (104)
12 ‘heidelberg engineering’.tw. (424)
13 ‘AO SLO’.tw. (29)
14 ‘spectral domain OCT’.tw. (603)
15 optovue.tw. (93)
16 ‘carl zeiss meditec’.tw. (695)
17 or/4-16 (3004)
18 (fluorescen* or autofluorescen*).tw. (379,356)
19 Fluorescence/ (89,241)
20 or/18-19 (393,399)
21 17 and 20 (344)
22 3 or 21 (1517)
23 (image* or imaging).tw. (906,976)
24 (camera* or photograph* or laser* or infrared
or ophthalmoscop* or instrument*).tw. (556,941)
25 optical coherence tomography/ (20,952)
26 Fluorescein Angiography/ (14,527)
27 fluorescence imaging/ (6870)
28 Electroretinography/ (11,726)
29 confocal microscopy/ (40,822)
1152
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Database, host, years
searched, date of search Literature search strategy Results
30 (diagnos* or electrodiagnos*).tw. (2,271,388)
31 computer assisted diagnosis/ (31,733)
32 Laser/ and Diagnosis/ (1798)
33 image processing/ (49,197)
34 (automat* adj5 (detect* or captur*
or quantif*)).tw. (13,596)
35 or/23-34 (3,455,191)
36 22 and 35 (1154)
37 autofluorescence imaging/ (1207)
38 36 or 37 (2000)
39 exp Retinal Disease/ (184,028)
40 chorioretinopathy/ (1483)
41 retina* vein occlusion/ (3370)
42 retina macula degeneration/ or retina macula age
related degeneration/ or retina maculopathy/ or retina
degeneration/ or subretinal neovascularization/ (32,777)
43 diabetic retinopathy/ (28,376)
44 (retina* or retinitis or retinopath* or epiretina*
or subretina* or preretina* or posterioretina* or
intraretina* or chorioretinopath* or vitreoretinopath*).tw.
(193,702)
45 (macula* or maculopath* or ‘wet AMD’ or
‘dry AMD’ or ‘exud* AMD’).tw. (47,694)
46 ((fundus or fundi or fundal) adj5 (change*
or impair* or disease* or disorder* or detect*
or diagnos*)).tw. (3129)
47 (geographical adj atroph*).tw. (11)
48 hyperfluorescen*.tw. (1120)
49 (RVO or CRVO or BRVO).tw. (1782)
50 (cone*1 adj2 dystroph*).tw. (951)
51 or/39-50 (296,820)
52 38 and 51 (1294)
53 (autofluorescence and fund* and imag*).tw. (765)
54 (FAF and imag*).tw. (275)
55 53 or 54 (776)
56 52 or 55 (1359)
57 limit 56 to (human and yr=‘1990 -Current’) (1248)
58 limit 57 to english language (1152)
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Database, host, years
searched, date of search Literature search strategy Results




# 1 (TS=(FAF and imag*)) AND LANGUAGE:
(English) (233)
# 2 (TS=((autofluorescen* and imag*) and
(fundus or fundi or fundal))) (732)
# 3 (TS=(‘confocal scanning laser ophthalmoscop*’))
(592)
# 4 (TS=(Topcon or optos or spectralis or bluepeak or
‘Heidelberg retina angiograph’ or ‘AO SLO’ or ‘spectral
domain OCT’ or optovue)) (1404)
# 5 (TS=(image* or imaging or electroretinography))
AND LANGUAGE: (English) (1,325,626)
# 6 #5 AND #4 (860)
# 7 (TS=(autofluorescenc* and (‘fundus camera*’ or
‘fundus spectrophotometry’ or ‘confocal scan*’ or ‘laser
ophthalmoscop*’ or CsLO))) (311)
# 8 (TS=(retina* or retinitis or retinopath* or
epiretina* or subretina* or preretina* or posterioretina*
or intraretina* or chorioretinopath* or
vitreoretinopath*)) (150,838)
# 9 (TS=(macula* or maculopath* or ‘wet AMD’ or
‘dry AMD’ or ‘exud* AMD’)) (45,128)
# 10 (TS=((fundus or fundi or fundal) NEAR (change*
or impair* or disease* or disorder* or detect* or
diagnos*))) (3652)
# 11 (TS=(geographical adj atroph*)) (80)
# 12 (TS=(hyperfluorescen*)) (548)
# 13 (TS=(RVO or CRVO or BRVO)) (1097)
# 14 (TS=(cone* NEAR dystroph*)) (1301)
# 15 #7 OR #6 OR #3 OR #2 OR #1 (2053)
# 16 #14 OR #13 OR #12 OR #11 OR #10 OR #9
OR #8 (175,649)
# 17 #16 AND #15 (1669)
# 18 (TI=(‘fundus autofluorescence imaging’)) (38)
#19 #18 OR #17 (1661)
1661
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Database, host, years
searched, date of search Literature search strategy Results
The Cochrane Library, all years,
searched 13 November 2014.
Results found only in CDSR.
Issue 11 of 12, November 2014
and CENTRAL Issue 10 of 12,
October 2014 (nothing in HTA,
NHS Economic Evaluation
Database, DARE Issue 4 October
2014)
(Also nothing unique in Cochrane
Eyes and Vision group)
#1 (autofluorescen* and (fundus or fundi or fundal))
(25)
#2 FAF (31)
#3 #1 or #2 (44)
#4 topcon (74)






#11 ‘Heidelberg retina* angiograph*’ (12)
#12 ‘Heidelberg Engineering’ (46)
#13 ‘AO SLO’ (0)
#14 ‘spectral domain OCT’ (16)
#15 optovue (6)
#16 ‘carl zeiss meditec’ (73)
#17 #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11
or #12 or #13 or #14 or #15 or #16 (240)
#18 (fluorescen* or autofluorescen*) (2613)
#19 MeSH descriptor: [Fluorescence] this term only
(185)
#20 #18 or #19 (2613)
#21 #17 and #20 (19)
#22 #3 or #21 (53)
#23 (image* or imaging) (27,896)
#24 (camera* or photograph* or laser* or infrared
or ophthalmoscop* or instrument*) (43,198)
#25 MeSH descriptor: [Tomography, Optical
Coherence] this term only (527)
#26 MeSH descriptor: [Fluorescein Angiography]
this term only (545)
#27 MeSH descriptor: [Optical Imaging] explode
all trees (593)
#28 MeSH descriptor: [Electroretinography] explode all
trees (140)
37 (4 CDSR, 33 CENTRAL)
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Database, host, years
searched, date of search Literature search strategy Results
#29 MeSH descriptor: [Microscopy, Confocal] explode
all trees (164)
#30 (diagnos* or electrodiagnos*) (101,633)
#31 MeSH descriptor: [Diagnosis, Computer-Assisted]
explode all trees (1610)
#32 MeSH descriptor: [Lasers] explode all trees and
with qualifier(s): [Diagnostic use - DU] (150)
#33 MeSH descriptor: [Image Processing,
Computer-Assisted] explode all trees (2935)
#34 (automat* N/5 (detect* or captur* or quantif*)) (124)
#35 #23 or #24 or #25 or #26 or #27 or #28 or #29
or #30 or #31 or #32 or #33 or #34 (148,379)
#36 #22 and #35 (37)
CRD databases: DARE,
HTA, NHS EED. Searched from
1990 to 12 November 2014,
searched on 13 November 2014
1 ((autofluorescen* and (fundus or fundi or fundal)) )
FROM 1990 TO 2014 (0)
2 (FAF) FROM 1990 TO 2014 (0)
3 (#1 or #2) FROM 1990 TO 2014 (0)
4 (topcon) FROM 1990 TO 2014 (2)
5 ((‘confocal scanning laser ophthalmoscop*’))
FROM 1990 TO 2014 (2)
6 (cslo) FROM 1990 TO 2014 (1)
7 (optos) FROM 1990 TO 2014 (0)
8 (spectralis) FROM 1990 TO 2014 (0)
9 (imagenet) FROM 1990 TO 2014 (0)
10 (bluepeak) FROM 1990 TO 2014 (0)
11 ((heidelberg retina* angiograph*)) FROM 1990
TO 2014 (0)
12 (heidelberg engineering) FROM 1990 TO 2014 (0)
13 (‘AO SLO’) FROM 1990 TO 2014 (0)
14 (‘spectral domain’) AND (OCT) FROM 1990 TO 2014 (1)
15 (optovue) FROM 1990 TO 2014 (0)
16 (carl zeiss meditec) FROM 1990 TO 2014 (1)
17 (#4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12
or #13 or #14 or #15 or #16) FROM 1990 TO 2014 (5)
18 ((fluorescen* or autofluorescen*)) FROM 1990
TO 2014 (141)
Two NHS EED (three
results from HTA were all
glaucoma – agreed not to
download these ones;
zero from DARE)
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Database, host, years
searched, date of search Literature search strategy Results
19 MeSH DESCRIPTOR Fluorescence EXPLODE
ALL TREES (16)
20 (#18 or #19) FROM 1990 TO 2014 (141)
21 (#17 and #20) FROM 1990 TO 2014 (0)
22 ((image* or imaging)) FROM 1990 TO 2014 (2889)
23 ((camera* or photograph* or laser* or infrared
or ophthalmoscop* or instrument*)) FROM 1990
TO 2014 (4177)
24 MeSH DESCRIPTOR Tomography, Optical Coherence
EXPLODE ALL TREES (20)
25 MeSH DESCRIPTOR Tomography, Optical EXPLODE
ALL TREES (21)
26 MeSH DESCRIPTOR Fluorescein Angiography
EXPLODE ALL TREES (11)
27 MeSH DESCRIPTOR Optical Imaging EXPLODE
ALL TREES (29)
28 MeSH DESCRIPTOR Electroretinography EXPLODE
ALL TREES (3)
29 MeSH DESCRIPTOR Microscopy, Confocal EXPLODE
ALL TREES (9)
30 ((diagnos* or electrodiagnos*)) FROM 1990 TO 2014
14978
31 MeSH DESCRIPTOR Diagnosis, Computer-Assisted
EXPLODE ALL TREES (114)
32 MeSH DESCRIPTOR lasers EXPLODE ALL TREES WITH
QUALIFIER DU (5)
33 MeSH DESCRIPTOR Image Processing, Computer-
Assisted EXPLODE ALL TREES (168)
34 ((automat* NEAR (detect* or captur* or quantif*)))
FROM 1990 TO 2014 (11)
35 (#22 or #23 or #24 or #25 or #26 or #27 or #28 or
#29 or #30 or #31 or #32 or #33 or #34) FROM 1990
TO 2014 (18,561)
36 (#4 or #5 or #6 or #14 or #16) FROM 1990 TO 2014 (5)
37 (#35 and #36) FROM 1990 TO 2014 (5)
CDSR, Cochrane Database of Systematic Reviews; CENTRAL, Cochrane Central Register of Controlled Trials; CRD, Centre
for Reviews and Dissemination; SCI-E, Science Citation Index Expanded; DARE, Database of Abstracts of Reviews of Effects;
HTA, Health Technology Assessment; NHS EED, NHS Economic Evaluation Database.
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Appendix 2 Study selection worksheet
aMay not be specifically referred to as a reference standard or gold standard.   
Study selection worksheet for full 
records 
Reviewer 1: Reviewer 2: 
Lead author name and Ref ID Number: 
Research type: Does the study report 
results of primary research with an 











Index test: Does the study report using 
FAF imaging for a retinal condition?  
Exclude tumours or secondary retinal 
conditions (e.g. caused by drug toxicity or 










Reference standard:a Does the study 
report the use of one or more of: fundus 
fluorescein angiography, indocyanine green 
angiography, optical coherence 
tomography, fundus photography or other 
standard imaging test(s) for diagnosis or 










Diagnostic data: Does the study report 
sensitivity and/or specificity data for FAF 
imaging or data that could be used to 










Final Decision INCLUDE UNCLEAR (Discuss) EXCLUDE 
Additional questions for level of evidence   
Is the study prospective, retrospective or 
unclear?  
Does the study report both sensitivity AND 
specificity data for FAF imaging? 
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Appendix 3 Critical appraisal worksheet
Critical appraisal criteria (based on Reitsma and colleagues81




1 Was the spectrum of patients representative of the patients who
will receive the test in practice?
2 Is the reference standard likely to classify the target
condition correctly?
3 Is the time period between reference standard and index test
short enough to be reasonably sure that the target condition did
not change between the two tests?
4 Did the whole sample or a random selection of the sample
receive verification using the intended reference standard?
5 Did patients receive the same reference standard irrespective of
the index test result?
6 Was the reference standard independent of the index test
(i.e. the index test did not form part of the reference standard)?
7 Were the reference standard results interpreted without
knowledge of the results of the index test?
8 Were the index test results interpreted without knowledge of
the results of the reference standard?
9 Were the same clinical data available when test results were
interpreted as would be available when the test is used
in practice?
10 Were uninterpretable/ intermediate test results reported?
11 Were withdrawals from the study explained?
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Appendix 4 Table of excluded studies
with rationale
Note that some studies may have been excluded for more than one reason; the primary reasonreported here is the first reason agreed by reviewers when following the study selection worksheet
(see Appendix 2).
Study Primary reason for exclusion
Ahn SJ, Ahn J, Park KH, Woo SJ. Multimodal imaging of occult macular dystrophy.
JAMA Ophthalmol 2013;131:880–90
Sensitivity of FAF imaging not
reported, not calculable
Aizawa S, Mitamura Y, Hagiwara A, Sugawara T, Yamamoto S. Changes of fundus
autofluorescence, photoreceptor inner and outer segment junction line, and visual
function in patients with retinitis pigmentosa. Clin Exp Optom 2010;38:597–604
Sensitivity of FAF imaging not
reported, not calculable
Alten F, Heiduschka P, Clemens CR, Eter N. Multifocal electroretinography in eyes with
reticular pseudodrusen. Invest Ophthalmol Vis Sci 2012;53:6263–70
Sensitivity of FAF imaging not
reported, not calculable
Alten F, Clemens CR, Heiduschka P, Eter N. Characterisation of reticular pseudodrusen
and their central target aspect in multi-spectral, confocal scanning laser ophthalmoscopy.
Graefes Arch Clin Exp Ophthalmol 2014;252:715–21
Sensitivity of FAF imaging not
reported, not calculable
Asao K, Gomi F, Sawa M, Nishida K. Additional anti-vascular endothelial growth factor
therapy for eyes with a retinal pigment epithelial tear after the initial therapy. Retina
2014;34:512–18
Sensitivity of FAF imaging not
reported, not calculable
Ayata A, Tatlipinar S, Kar T, Unal M, Ersanli D, Bilge AH. Near-infrared and
short-wavelength autofluorescence imaging in central serous chorioretinopathy.
Br J Ophthalmol 2009;93:79–82
Sensitivity of FAF imaging not
reported, not calculable
Batioglu F, Demirel S, Ozmert E, Oguz YG, Ozyol P. Autofluorescence patterns as a
predictive factor for neovascularization. Optom Vis Sci 2014;91:950–5
Sensitivity of FAF imaging not
reported, not calculable
Bessho K, Gomi F, Harino S, Sawa M, Sayanagi K, Tsujikawa M, et al. Macular
autofluorescence in eyes with cystoid macula edema, detected with 488 nm-excitation
but not with 580 nm-excitation. Graefes Arch Clin Exp Ophthalmol 2009;247:729–34
Sensitivity of FAF imaging not
reported, not calculable
Bessho K, Rodanant N, Bartsch DU, Cheng L, Koh HJ, Freeman WR. Effect of
subthreshold infrared laser treatment for drusen regression on macular autofluorescence
in patients with age-related macular degeneration. Retina 2005;25:981–8
No appropriate reference
standard
Bonnet C, Querques G, Zerbib J, Oubraham H, Garavito RB, Puche N, et al.
Hyperreflective pyramidal structures on optical coherence tomography in geographic
atrophy areas. Retina 2014;34:1524–30
Sensitivity of FAF imaging not
reported, not calculable
Boon CJF. SD-OCT and fundus autofluorescence imaging for differential diagnosis of
macular and retinal dystrophies. Ophthalmologica 2013;230:15–16 (meeting abstract)
Sensitivity of FAF imaging not
reported, not calculable
Bottoni F, Carmassi L, Cigada M, Moschini S, Bergamini F. Diagnosis of macular
pseudoholes and lamellar macular holes: is optical coherence tomography the ‘gold
standard’? Br J Ophthalmol 2008;92:635–9
Sensitivity of FAF imaging not
reported, not calculable
Bottoni F, Eandi CM, Pedenovi S, Staurenghi G. Integrated clinical evaluation of type 2A
idiopathic juxtafoveolar retinal telangiectasis. Retina 2010;30:317–26
Sensitivity of FAF imaging not
reported, not calculable
Brar M, Kozak I, Cheng L, Bartsch DU, Yuson R, Nigam N, et al. Correlation between
spectral-domain optical coherence tomography and fundus autofluorescence at the
margins of geographic atrophy. Am J Ophthalmol 2009;148:439–44
Sensitivity of FAF imaging not
reported, not calculable
Carreno E, Portero A, Herreras JM, Lopez MI. Assesment of fundus autofluorescence
in serpiginous and serpiginous-like choroidopathy. Eye 2012;26:1232–6
Sensitivity of FAF imaging not
reported, not calculable
Chen Z, Song Y. Functional and structural changes after pattern scanning laser
photocoagulation in diabetic retinopathy. Doc Ophthalmol 2013;127:37
(meeting abstract)
Sensitivity of FAF imaging not
reported, not calculable
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Study Primary reason for exclusion
Chen FK, Patel PJ, Coffey PJ, Tufail A, Da Cruz CL. Increased fundus autofluorescence
associated with outer segment shortening in macular translocation model of neovascular
age-related macular degeneration. Invest Ophthalmol Vis Sci 2010;51:4207–12
Sensitivity of FAF imaging not
reported, not calculable
Chhablani JK, Narayanan R. Fundus autofluorescence patterns in type 2A idiopathic
juxtafoveolar retinal telangiectasis. Eur J Ophthalmol 2012;22:398–403
Sensitivity of FAF imaging not
reported, not calculable
Chia A, Tan A, Boon KL, Cheung G. Autofluorescence imaging in children with retinal




Chung H, Park B, Shin HJ, Kim HC. Correlation of fundus autofluorescence with
spectral-domain optical coherence tomography and vision in diabetic macular edema.
Ophthalmology 2012;119:1056–65
Sensitivity of FAF imaging not
reported, not calculable
Clemens CR, Alten F, Baumgart C, Heiduschka P, Eter N. Quantification of retinal




Cuba J, Gomez-Ulla F. Fundus autofluorescence: applications and perspectives.
Arch Soc Esp Oftalmol 2013;88:50–5
Sensitivity of FAF imaging not
reported, not calculable
De Bats F, Wolff B, Mauget-Faysse M, Meunier I, Denis P, Kodjikian L. Association
of reticular pseudodrusen and early onset drusen. ISRN Ophthalmol 2013;2013
Sensitivity of FAF imaging not
reported, not calculable
de Laat P, Smeitink JA, Janssen MC, Keunen JE, Boon CJ. Mitochondrial retinal dystrophy
associated with the m.3243A>G mutation. Ophthalmology 2013;120:2684–96
Sensitivity of FAF imaging not
reported, not calculable
Deli A, Moetteli L, Ambresin A, Mantel I. Comparison of fundus autofluorescence
images acquired by the confocal scanning laser ophthalmoscope (488 nm excitation)
and the modified Topcon fundus camera (580 nm excitation). Int Ophthalmol
2013;33:635–43
Sensitivity of FAF imaging not
reported, not calculable
Dinc UA, Tatlipinar S, Yenerel M, Gorgun E, Ciftci F. Fundus autofluorescence in acute
and chronic central serous chorioretinopathy. Clin Exp Optom 2011;94:452–7
Sensitivity of FAF imaging not
reported, not calculable
Dinc UA, Tatlipinar S, Gorgun E, Yenerel M. Fundus autofluorescence in optic disc
drusen: comparison of confocal scanning laser ophthalmoscope and standard fundus
camera. Neuroophthalmology 2009;33:318–21
Sensitivity of FAF imaging not
reported, not calculable
Duncker T, Tabacaru MR, Lee W, Tsang SH, Sparrow JR, Greenstein VC. Comparison
of near-infrared and short-wavelength autofluorescence in retinitis pigmentosa. Invest
Ophthalmol Vis Sci 2013;54:585–91
Sensitivity of FAF imaging not
reported, not calculable
Duncker T, Greenberg JP, Ramachandran R, Hood DC, Smith RT, Hirose T, et al.
Quantitative fundus autofluorescence and optical coherence tomography in Best
vitelliform macular dystrophy. Invest Ophthalmol Vis Sci 2014;55:1471–82
Sensitivity of FAF imaging not
reported, not calculable
Einbock W, Moessner A, Schnurrbusch UE, Holz FG, Wolf S, FAM study group. Changes
in fundus autofluorescence in patients with age-related maculopathy. Correlation
to visual function: a prospective study. Graefes Arch Clin Exp Ophthalmol
2005;243:300–5
Sensitivity of FAF imaging not
reported, not calculable
Ergun E, Hermann B, Wirtitsch M, Unterhuber A, Ko TH, Sattmann H, et al.
Assessment of central visual function in Stargardt’s disease/fundus flavimaculatus with
ultrahigh-resolution optical coherence tomography. Invest Ophthalmol Vis Sci
2005;46:310–16
Sensitivity of FAF imaging not
reported, not calculable
Erol MK, Ozdemir O, Coban DT, Ceran BB, Bulut M. Ranibizumab treatment for
choroidal neovascularization secondary to causes other than age-related macular
degeneration with good baseline visual acuity. Semin Ophthalmol 2014;29:108–13
Sensitivity of FAF imaging not
reported, not calculable
Finger RP, Charbel IP, Schmitz-Valckenberg S, Holz FG, Scholl HN. Long-term
effectiveness of intravitreal bevacizumab for choroidal neovascularization secondary
to angioid streaks in pseudoxanthoma elasticum. Retina 2011;31:1268–78
Sensitivity of FAF imaging not
reported, not calculable
Finger RP, Charbel IP, Ladewig M, Gotting C, Holz FG, Scholl HP. Fundus
autofluorescence in Pseudoxanthoma elasticum. Retina 2009;29:1496–505
Sensitivity of FAF imaging not
reported, not calculable
Finger RP, Charbel IP, Ladewig M, Holz FG, Scholl HP. Intravitreal bevacizumab
for choroidal neovascularisation associated with pseudoxanthoma elasticum.
Br J Ophthalmol 2008;92:483–7
Sensitivity of FAF imaging not
reported, not calculable
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Study Primary reason for exclusion
Forte R, Querques G, Querques L, Leveziel N, Benhamou N, Souied EH. Multimodal
evaluation of foveal sparing in patients with geographic atrophy due to age-related
macular degeneration. Retina 2013;33:482–9
Sensitivity of FAF imaging not
reported, not calculable
Forte R, Querques G, Querques L, Massamba N, Le Tien V, Souied EH. Multimodal
imaging of dry age-related macular degeneration. Acta Opthalmol 2012;90:e281–7
Sensitivity of FAF imaging not
reported, not calculable
Framme C, Brinkmann R, Birngruber R, Roider J. Autofluorescence imaging after
selective RPE laser treatment in macular diseases and clinical outcome: a pilot study.
Br J Ophthalmol 2002;86:1099–106
Sensitivity of FAF imaging not
reported, not calculable
Framme C, Walter A, Gabler B, Roider J, Sachs HG, Gabel VP. Fundus autofluorescence
in acute and chronic-recurrent central serous chorioretinopathy. Acta Ophthalmol
Scand 2005;83:161–7
Sensitivity of FAF imaging not
reported, not calculable
Framme C, Bunse A, Sofroni R, Thalhammer T, Walter A, Sachs HG, et al. Fundus
autofluorescence before and after photodynamic therapy for choroidal
neovascularization secondary to age-related macular degeneration. Ophthalmic Surg
Lasers Imaging 2006;37:406–14
Sensitivity of FAF imaging not
reported, not calculable
Fujiwara T, Imamura Y, Giovinazzo VJ, Spaide RF. Fundus autofluorescence and
optical coherence tomographic findings in acute zonal occult outer retinopathy.
Retina 2010;30:1206–16
Sensitivity of FAF imaging not
reported, not calculable
Furino C, Boscia F, Cardascia N, Sborgia L, Sborgia C. Fundus autofluorescence, optical
coherence tomography and visual acuity in adult-onset foveomacular dystrophy.
Ophthalmologica 2008;222:240–4
Sensitivity of FAF imaging not
reported, not calculable
Gajdzik-Gajdecka U, Dorecka M, Nita E, Michalska A, Miniewicz-Kurowska J, Romaniuk
W. Indocyanine green angiography in chronic central serous chorioretinopathy. Med Sci
Monit 2012;18:CR51–7
Sensitivity of FAF imaging not
reported, not calculable
Garcia CR, Rivero ME, Bartsch DU, Ishiko S, Takamiya A, Fukui K, et al. Oral fluorescein
angiography with the confocal scanning laser ophthalmoscope. Ophthalmology
1999;106:1114–18
No appropriate index test
Gendy MG, Fawzi AA, Wendel RT, Pieramici DJ, Miller JA, Jampol LM. Multimodal
imaging in persistent placoid maculopathy. JAMA Ophthalmol 2014;132:38–49
Sensitivity of FAF imaging not
reported, not calculable
Giani A, Pellegrini M, Carini E, Peroglio DA, Bottoni F, Staurenghi G. The dark atrophy
with indocyanine green angiography in Stargardt disease. Invest Ophthalmol Vis Sci
2012;53:3999–4004
Sensitivity of FAF imaging not
reported, not calculable
Gili P, Flores-Rodriguez P, Yanguela J, Herreros Fernàndez ML. Using autofluorescence
to detect optic nerve head drusen in children. J AAPOS 2013;17:568–71
No appropriate index test
Gillies MC, Zhu M, Chew E, Barthelmes D, Hughes E, Ali H, et al. Familial asymptomatic
macular telangiectasia type 2. Ophthalmology 2009;116:2422–9
Sensitivity of FAF imaging not
reported, not calculable
Giuliari G, Hinkle DM, Foster CS. The spectrum of fundus autofluorescence findings in
birdshot chorioretinopathy. J Ophthalmol 2009;2009
Sensitivity of FAF imaging not
reported, not calculable




Gomes NL, Greenstein VC, Carlson JN, Tsang SH, Smith RT, Carr RE, et al. A comparison
of fundus autofluorescence and retinal structure in patients with Stargardt disease.
Invest Ophthalmol Vis Sci 2009;50:3953–9
Sensitivity of FAF imaging not
reported, not calculable
Gomes NL, Corcostegui I, Fine HF, Chang S. Subfoveal pigment changes in patients
with longstanding epiretinal membranes. Am J Ophthalmol 2009;147:865–8
Sensitivity of FAF imaging not
reported, not calculable
Greenberg JP, Sherman J, Zweifel SA, Chen RW, Duncker T, Kohl S, et al.
Spectral-domain optical coherence tomography staging and autofluorescence imaging
in achromatopsia. JAMA Ophthalmol 2014;132:437–45
Sensitivity of FAF imaging not
reported, not calculable
Greenstein VC, Santos RA, Tsang SH, Smith RT, Barile GR, Seiple W. Preferred
retinal locus in macular disease: characteristics and clinical implications. Retina
2008;28:1234–40
Sensitivity of FAF imaging not
reported, not calculable
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Study Primary reason for exclusion
Greenstein VC, Duncker T, Holopigian K, Carr RE, Greenberg JP, Tsang SH, et al.
Structural and functional changes associated with normal and abnormal fundus
autofluorescence in patients with retinitis pigmentosa. Retina 2012;32:349–57
Sensitivity of FAF imaging not
reported, not calculable
Haas P, Esmaeelpour M, Ansari-Shahrezaei S, Drexler W, Binder S. Choroidal thickness in
patients with reticular pseudodrusen using 3D 1060-nm OCT maps. Invest Ophthalmol
Vis Sci 2014;55:2674–81
Sensitivity of FAF imaging not
reported, not calculable
Heimes B, Lommatzsch A, Zeimer M, Gutfleisch M, Spital G, Bird AC, et al. Foveal RPE
autofluorescence as a prognostic factor for anti-VEGF therapy in exudative AMD.
Graefes Arch Clin Exp Ophthalmol 2008;246:1229–34
No appropriate reference
standard
Helb HM, Charbel IP, van der Veen RL, Berendschot TT, Scholl HP, Holz FG.
Abnormal macular pigment distribution in type 2 idiopathic macular telangiectasia.
Retina 2008;28:808–16
Sensitivity of FAF imaging not
reported, not calculable
Helb HM, Charbel IP, Fleckenstein M, Schmitz-Valckenberg S, Scholl HP, Meyer CH, et al.
Clinical evaluation of simultaneous confocal scanning laser ophthalmoscopy imaging
combined with high-resolution, spectral-domain optical coherence tomography.
Acta Opthalmol 2010;88:842–9
Sensitivity of FAF imaging not
reported, not calculable
Henderson RH, Mackay DS, Li Z, Moradi P, Sergouniotis P, Russell-Eggitt I, et al.
Phenotypic variability in patients with retinal dystrophies due to mutations in CRB1.
Br J Ophthalmol 2011;95:811–17
Sensitivity of FAF imaging not
reported, not calculable
Heussen FM, Tan CS, Sadda SR. Prevalence of peripheral abnormalities on ultra-widefield
greenlight (532 nm) autofluorescence imaging at a tertiary care center. Invest
Ophthalmol Vis Sci 2012;53:6526–31
Sensitivity of FAF imaging not
reported, not calculable
Heussen FMA, Fawzy NF, Joeres S, Lux A, Maaijwee K, Meurs JC, et al. Autologous
translocation of the choroid and RPE in age-related macular degeneration: 1-year follow-up
in 30 patients and recommendations for patient selection. Eye 2008;22:799-807
Sensitivity of FAF imaging not
reported, not calculable
Holz FG, Bindewald-Wittich A, Fleckenstein M, Dreyhaupt J, Scholl HP,
Schmitz-Valckenberg S, et al. Progression of geographic atrophy and impact of fundus




Hu Z, Medioni GG, Hernandez M, Hariri A, Wu X, Sadda SR. Segmentation of the
geographic atrophy in spectral-domain optical coherence tomography and fundus
autofluorescence images. Invest Ophthalmol Vis Sci 2013;54:837–83
Sensitivity of FAF imaging not
reported, not calculable
Imamura Y, Fujiwara T, Spaide RF. Fundus autofluorescence and visual acuity in central
serous chorioretinopathy. Ophthalmology 2011;118:700–5
No appropriate reference
standard
Iriyama A, Yanagi Y. Fundus autofluorescence and retinal structure as determined by
spectral domain optical coherence tomography, and retinal function in retinitis
pigmentosa. Graefes Arch Clin Exp Ophthalmol 2012;250:333–9
Sensitivity of FAF imaging not
reported, not calculable
Issa PC, Finger RP, Holz FG, Scholl HPN. Multimodal imaging including spectral domain
OCT and confocal near infrared reflectance for characterization of outer retinal
pathology in pseudoxanthoma elasticum. Invest Ophthalmol Vis Sci 2009;50:5913–18
Sensitivity of FAF imaging not
reported, not calculable
Jarc-Vidmar M, Kraut A, Hawlina M. Fundus autofluorescence imaging in Best’s
vitelliform dystrophy. Klin Monatsbl Augenheilkd 2003;220:861–7
Sensitivity of FAF imaging not
reported, not calculable
Jeong YJ, Hong IH, Chung JK, Kim KL, Kim HK, Park SP. Predictors for the progression
of geographic atrophy in patients with age-related macular degeneration: fundus
autofluorescence study with modified fundus camera. Eye 2014;28:209–18
Sensitivity of FAF imaging not
reported, not calculable
Jung JJ, Khan S, Mrejen S, Gallego-Pinazo R, Cunningham ET Jr, Freund KB, et al.
Idiopathic multifocal choroiditis with outer retinal or chorioretinal atrophy.
Retina 2014;34:1439–50
Sensitivity of FAF imaging not
reported, not calculable
Kaya M, Yaman A, Oner FH, Saatci AO. Autofluorescence imaging in eyes with various
types of retinal artery occlusion: case report. Turk Klin J Med Sci 2011;31:1283–7
Inadequate sample size
(< 10 eyes)
Kellner U, Weinitz S, Kellner S. Visualizing the onset of retinitis pigmentosa.
Doc Ophthalmol 2010;121:17–18 (meeting abstract)
Sensitivity of FAF imaging not
reported, not calculable
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Study Primary reason for exclusion
Kellner S, Neuhann TM, Abicht A, Wissinger B, Renner AB, Weinitz S, et al. Combined
confocal near-infrared reflectance (815 nm) and macular spectral domain OCT identify
optic atrophy in patients with bilateral unexplained visual loss. Doc Ophthalmol
2013;127:28 (meeting abstract)
Not a retinal condition
Khanifar AA, Lederer DE, Ghodasra JH, Stinnett SS, Lee JJ, Cousins SW, et al.
Comparison of color fundus photographs and fundus autofluorescence images in
measuring geographic atrophy area. Retina 2012;32:1884–91
Sensitivity of FAF imaging not
reported, not calculable
Kim SK, Kim SW, Oh J, Huh K. Near-infrared and short-wavelength autofluorescence in
resolved central serous chorioretinopathy: association with outer retinal layer
abnormalities. Am J Ophthalmol 2013;156:157–64
Sensitivity of FAF imaging not
reported, not calculable
Kim SW, Oh J, Huh K. Correlations among various functional and morphological tests
in resolved central serous chorioretinopathy. Br J Ophthalmol 2012;96:350–5
Sensitivity of FAF imaging not
reported, not calculable
Koizumi H, Pozzoni MC, Spaide RF. Fundus autofluorescence in birdshot
chorioretinopathy. Ophthalmology 2008;115:e15–20
Sensitivity of FAF imaging not
reported, not calculable
Kojima H, Otani A, Ogino K, Nakagawa S, Makiyama Y, Kurimoto M, et al. Outer retinal
circular structures in patients with Bietti crystalline retinopathy. Br J Ophthalmol
2012;96:390–3
Sensitivity of FAF imaging not
reported, not calculable
Kolomeyer AM, Baumrind BR, Szirth BC, Shahid K, Khouri AS. Fundus autofluorescence
and colour fundus imaging compared during telemedicine screening in patients with
diabetes. J Telemed Telecare 2013;19:209–12
Sensitivity of FAF imaging not
reported, not calculable
Kolomeyer AM, Nayak NV, Szirth BC, Khouri AS. Fundus autofluorescence imaging in an
ocular screening program. Int J Telemed Appl 2012;2012
Inadequate sample size
(< 10 eyes)
Kramer M, Priel E. Fundus autofluorescence imaging in multifocal choroiditis: beyond the
spots. Ocul Immunol Inflamm 2014;22:349–55
Inadequate sample size
(< 10 eyes)
Kumar N, Mrejen S, Fung AT, Marsiglia M, Loh BK, Spaide RF. Retinal pigment epithelial
cell loss assessed by fundus autofluorescence imaging in neovascular age-related
macular degeneration. Ophthalmology 2013;120:334–41
Sensitivity of FAF imaging not
reported, not calculable
Kurz-Levin MM, Halfyard AS, Bunce C, Bird AC, Holder GE. Clinical variations in
assessment of bull’s-eye maculopathy. Arch Ophthalmol 2002;120:567–75
Inadequate sample size
(< 10 eyes)
Lai WW, Leung GY, Chan CW, Yeung IY, Wong D. Simultaneous spectral domain
OCT and fundus autofluorescence imaging of the macula and microperimetric
correspondence after successful repair of rhegmatogenous retinal detachment.
Br J Ophthalmol 2010;94:311–18
Sensitivity of FAF imaging not
reported, not calculable
Landa G, Rosen RB, Pilavas J, Garcia PM. Drusen characteristics revealed by spectral-domain
optical coherence tomography and their corresponding fundus autofluorescence
appearance in dry age-related macular degeneration. Ophthalmic Res 2012;47:81–6
Sensitivity of FAF imaging not
reported, not calculable
Lee CS, Lee AY, Forooghian F, Bergstrom CS, Yan J, Yeh S. Fundus autofluorescence
features in the inflammatory maculopathies. Clin Ophthalmol 2014;8:2001–12
No appropriate reference
standard
Lee JE, Lim DW, Bae HY, Park HJ. Photoreceptor layer map using spectral-domain optical
coherence tomography. Optom Vis Sci 2009;86:E1320–27
Sensitivity of FAF imaging not
reported, not calculable
Lee JY, Lee DH, Lee JY, Yoon YH. Correlation between subfoveal choroidal thickness
and the severity or progression of nonexudative age-related macular degeneration.
Invest Ophthalmol Vis Sci 2013;54:7812–18
Sensitivity of FAF imaging not
reported, not calculable
Lee M, Yoon J, Ham DI. Clinical features of reticular pseudodrusen according to the
fundus distribution. Br J Ophthalmol 2012;96:1222–6
Sensitivity of FAF imaging not
reported, not calculable
Lee MY, Yoon J, Ham DI. Clinical characteristics of reticular pseudodrusen in Korean
patients. Am J Ophthalmol 2012;153:530–5
Sensitivity of FAF imaging not
reported, not calculable
Lee MY, Ham DI. Subretinal drusenoid deposits with increased autofluorescence in eyes
with reticular pseudodrusen. Retina 2014;34:69–76
Sensitivity of FAF imaging not
reported, not calculable
Lee TJ, Hwang JC, Chen RW, Lima LH. The role of fundus autofluorescence in late-onset
retinitis pigmentosa (LORP) diagnosis. Ophthalmic Genet 2014;35:170–9
No appropriate reference
standard
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Study Primary reason for exclusion
Lenassi E, Troeger E, Wilke R, Hawlina M. Correlation between macular morphology
and sensitivity in patients with retinitis pigmentosa and hyperautofluorescent ring.
Invest Ophthalmol Vis Sci 2012;53:47–52
Sensitivity of FAF imaging not
reported, not calculable
Lenassi E, Troeger E, Wilke R, Tufail A, Hawlina M, Jeffery G, et al. Laser clearance of
drusen deposit in patients with autosomal dominant drusen (p.Arg345Trp in EFEMP1).
Am J Ophthalmol 2013;155:190–8
Sensitivity of FAF imaging not
reported, not calculable
Leon PE, Saviano S, Zanei A, Pastore MR, Guaglione E, Mangogna A, et al. Spontaneous
or secondary to intravitreal injections of anti-angiogenic agents retinal pigment epithelial
tears in age-related macular degeneration. Int J Ophthalmol 2014;7:681–5
Sensitivity of FAF imaging not
reported, not calculable
Levinson RD, Monnet D. Imaging in birdshot chorioretinopathy. Int Ophthalmol
Clin 2012;52:191–8
Not primary research
Lima LH, Laud K, Freund KB, Yannuzzi LA, Spaide RF. Acquired vitelliform lesion
associated with large drusen. Retina 2012;32:647–51
Sensitivity of FAF imaging not
reported, not calculable
Lima LH, Greenberg JP, Greenstein VC, Smith RT, Sallum JM, Thirkill C, et al.
Hyperautofluorescent ring in autoimmune retinopathy. Retina 2012;32:1385–94
Inadequate sample size
(< 10 eyes)
Lima LH, Cella W, Greenstein VC, Wang NK, Busuioc M, Smith RT, et al. Structural
assessment of hyperautofluorescent ring in patients with retinitis pigmentosa.
Retina 2009;29:1025–31
Sensitivity of FAF imaging not
reported, not calculable
Lima LH, Burke T, Greenstein VC, Chou CL, Cella W, Yannuzzi LA, et al. Progressive
constriction of the hyperautofluorescent ring in retinitis pigmentosa. Am J
Ophthalmol 2012;153:718–27
Sensitivity of FAF imaging not
reported, not calculable
Lindner E, Weinberger A, Kirschkamp T, El-Shabrawi Y, Barounig A. Near-infrared
autofluorescence and indocyanine green angiography in central serous
chorioretinopathy. Ophthalmologica 2012;227:34–8
Sensitivity of FAF imaging not
reported, not calculable
Liu DN, Liu Y, Meng XH, Yin ZQ. The characterization of functional disturbances
in Chinese patients with Bietti’s crystalline dystrophy at different fundus stages.
Graefes Arch Clin Exp Ophthalmol 2012;250:191–200
Sensitivity of FAF imaging not
reported, not calculable
Lois N, Owens SL, Coco R, Hopkins J, Fitzke FW, Bird AC. Fundus autofluorescence
in patients with age-related macular degeneration and high risk of visual loss.
Am J Ophthalmol 2002;133:341–9
Sensitivity of FAF imaging not
reported, not calculable
Lois N, McBain V, Abdelkader E, Scott NW, Kumari R. Retinal pigment epithelial atrophy
in patients with exudative age-related macular degeneration undergoing anti-vascular
endothelial growth factor therapy. Retina 2013;33:13–22
Sensitivity of FAF imaging not
reported, not calculable
Lorenz B, Wabbels B, Wegscheider E, Hamel CP, Drexler W, Preising MN. Lack of fundus
autofluorescence to 488 nanometers from childhood on in patients with early-onset
severe retinal dystrophy associated with mutations in RPE65. Ophthalmology
2004;111:1585–94
Sensitivity of FAF imaging not
reported, not calculable
Luttrull JK, Sramek C, Palanker D, Spink CJ, Musch DC. Long-term safety, high-resolution
imaging, and tissue temperature modeling of subvisible diode micropulse
photocoagulation for retinovascular macular edema. Retina 2012;32:375–86
Sensitivity of FAF imaging not
reported, not calculable
MacLaren RE, Uppal GS, Balaggan KS, Tufail A, Munro PMG, Milliken AB, et al.
Autologous transplantation of the retinal pigment epithelium and choroid in the
treatment of neovascular age-related macular degeneration. Ophthalmology
2007;114:561–70
Sensitivity of FAF imaging not
reported, not calculable
Makiyama Y, Ooto S, Hangai M, Takayama K, Uji A, Oishi A, et al. Macular cone
abnormalities in retinitis pigmentosa with preserved central vision using adaptive optics
scanning laser ophthalmoscopy. PLOS ONE 2013;8:e79447
Sensitivity of FAF imaging not
reported, not calculable
Margolis R, Mukkamala SK, Jampol LM, Spaide RF, Ober MD, Sorenson JA, et al. The
expanded spectrum of focal choroidal excavation. Arch Ophthalmol 2011;129:1320–5
Sensitivity of FAF imaging not
reported, not calculable
Marsiglia M, Boddu S, Bearelly S, Xu L, Breaux BE Jr, Freund KB, et al. Association
between geographic atrophy progression and reticular pseudodrusen in eyes with dry
age-related macular degeneration. Invest Ophthalmol Vis Sci 2013;54:7362–9
No appropriate reference
standard
Maruko I, Iida T, Ojima A, Sekiryu T. Subretinal dot-like precipitates and yellow material
in central serous chorioretinopathy. Retina 2011;31:759–65
Sensitivity of FAF imaging not
reported, not calculable
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Study Primary reason for exclusion
Mathew R, Papavasileiou E, Sivaprasad S. Autofluorescence and high-definition optical
coherence tomography of retinal artery occlusions. Clin Ophthalmol 2010;4:1159-63
Inadequate sample size
(< 10 eyes)
Matsumoto H, Kishi S, Sato T, Mukai R. Fundus autofluorescence of elongated
photoreceptor outer segments in central serous chorioretinopathy. Am J Ophthalmol
2011;151:617–23.
Sensitivity of FAF imaging not
reported, not calculable
Maurizio BP, Pierluigi I, Stelios K, Stefano V, Marialucia C, Ilaria Z, et al. Retro-mode
imaging and fundus autofluorescence with scanning laser ophthalmoscope of retinal
dystrophies. BMC Ophthalmol 2012;12:8
No appropriate reference
standard
McBain VA, Townend J, Lois N. Fundus autofluorescence in exudative age-related
macular degeneration. Br J Ophthalmol 2007;91:491–6
Sensitivity of FAF imaging not
reported, not calculable
McBain VA, Kumari R, Townend J, Lois N. Geographic atrophy in retinal angiomatous
proliferation. Retina 2011;31:1043–52
Sensitivity of FAF imaging not
reported, not calculable
Mehta H, Davidson A, Devary S, Egan C, Hykin P, Moore A, et al. Autofluorescence
and spectral-domain OCT findings in an atrophic maculopathy associated with
pseudoxanthoma elasticum. Clin Experiment Ophthalmol 2012;40(Suppl. 1):49–50
(meeting abstract)
Sensitivity of FAF imaging not
reported, not calculable
Meleth AD, Mettu P, Agron E, Chew EY, Sadda SR, Ferris FL, et al. Changes in retinal
sensitivity in geographic atrophy progression as measured by microperimetry.
Invest Ophthalmol Vis Sci 2011;52:1119–26
Sensitivity of FAF imaging not
reported, not calculable
Mendis R, Lois N. Healing of the retinal pigment epithelium (RPE) imaged ‘in vivo’ in
patients. Clin Exp Ophthalmol 2011;39(Suppl. 1):69–70 (meeting abstract)
Sensitivity of FAF imaging not
reported, not calculable
Mesquida M, Llorenc V, Fontenla JR, Navarro MJ, Adan A. Use of ultra-wide-field retinal
imaging in the management of active Behcet retinal vasculitis. Retina 2014;34:2121–7
Sensitivity of FAF imaging not
reported, not calculable




Midena E, Vujosevic S, Convento E, Manfre’ A, Cavarzeran F, Pilotto E. Microperimetry
and fundus autofluorescence in patients with early age-related macular degeneration.
Br J Ophthalmol 2007;91:1499–1503
Sensitivity of FAF imaging not
reported, not calculable
Mones J, Biarnes M, Trindade F. Hyporeflective wedge-shaped band in geographic
atrophy secondary to age-related macular degeneration: an underreported finding.
Ophthalmology 2012;119:1412–19
Sensitivity of FAF imaging not
reported, not calculable
Muqit MM, Gray JC, Marcellino GR, Henson DB, Young LB, Charles SJ, et al. Fundus
autofluorescence and fourier-domain optical coherence tomography imaging of
10 and 20 millisecond Pascal retinal photocoagulation treatment. Br J Ophthalmol
2009;93:518–25
Sensitivity of FAF imaging not
reported, not calculable
Murakami T, Akimoto M, Ooto S, Suzuki T, Ikeda H, Kawagoe N, et al. Association
between abnormal autofluorescence and photoreceptor disorganization in retinitis
pigmentosa. Am J Ophthalmol 2008;145:687–94
Sensitivity of FAF imaging not
reported, not calculable
Oh J, Kim SW, Kwon SS, Oh IK, Huh K. Correlation of fundus autofluorescence gray
values with vision and microperimetry in resolved central serous chorioretinopathy.
Invest Ophthalmol Vis Sci 2012;53:179–84
Sensitivity of FAF imaging not
reported, not calculable
Ojima A, Iida T, Sekiryu T, Maruko I, Sugano Y. Photopigments in central serous
chorioretinopathy. Am J Ophthalmol 2011;151:94–152
Sensitivity of FAF imaging not
reported, not calculable
Olsen TW. The Minnesota Grading System using fundus autofluorescence of eye
bank eyes: a correlation to age-related macular degeneration (an AOS thesis).
Trans Am Ophthalmol Soc 2008;106:383–401
Sensitivity of FAF imaging not
reported, not calculable
Ooto S, Ellabban AA, Ueda-Arakawa N, Oishi A, Tamura H, Yamashiro K, et al.
Reduction of retinal sensitivity in eyes with reticular pseudodrusen. Am J Ophthalmol
2013;156:1184–91
Sensitivity of FAF imaging not
reported, not calculable
Pang CE, Shah VP, Sarraf D, Freund KB. Ultra-widefield imaging with autofluorescence
and indocyanine green angiography in central serous chorioretinopathy.
Am J Ophthalmol 2014;158:362–71
Sensitivity of FAF imaging not
reported, not calculable
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Study Primary reason for exclusion
Pang CE, Freund KB. Ghost maculopathy: an artifact on near-infrared reflectance and
multicolor imaging masquerading as chorioretinal pathology. Am J Ophthalmol
2014;158:171–8
Not a retinal condition
Park B, Kim J, Chung H, Kim HC. Correlation of fundus autofluorescence with foveal
microstructures and vision in branch retinal vein occlusion. Retina 2014;34:531–8
Sensitivity of FAF imaging not
reported, not calculable
Park SP, Siringo FS, Pensec N, Hong IH, Sparrow J, Barile G, et al. Comparison of
fundus autofluorescence between fundus camera and confocal scanning laser
ophthalmoscope-based systems. Ophthalmic Surg Lasers Imaging Retina 2013;44:536–43
Sensitivity of FAF imaging not
reported, not calculable
Parodi MB, Iacono P, Ravalico G. Fundus autofluorescence in subfoveal choroidal
neovascularisation secondary to Pathological Myopia. Br J Ophthalmol 2009;93:771–4
Sensitivity of FAF imaging not
reported, not calculable
Pece A, Isola V, Holz F, Milani P, Brancato R. Autofluorescence imaging of cystoid
macular edema in diabetic retinopathy. Ophthalmologica 2010;224:230–5
Sensitivity of FAF imaging not
reported, not calculable
Peng Q, Dong Y, Zhao PQ. Fundus autofluorescence in exudative age-related macular
degeneration. Genet Mol Res 2013;12:6140–8
Sensitivity of FAF imaging not
reported, not calculable
Peng X-J, Su L-P. Characteristics of fundus autofluorescence in cystoid macular edema.
Chin Med J 2011;124:253–7
Sensitivity of FAF imaging not
reported, not calculable
Pichi F, Morara M, Veronese C, Nucci P, Ciardella AP. Multimodal imaging in hereditary
retinal diseases. J Ophthalmol 2013;2013
Sensitivity of FAF imaging not
reported, not calculable
Pilotto E, Sportiello P, Alemany-Rubio E, Vujosevic S, Segalina S, Fregona I, et al.
Confocal scanning laser ophthalmoscope in the retromode imaging modality in
exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol
2013;251:27–34
Sensitivity of FAF imaging not
reported, not calculable
Pilotto E, Vujosevic S, Grgic VA, Sportiello P, Convento E, Secchi AG, et al. Retinal
function in patients with serpiginous choroiditis: a microperimetry study. Graefes Arch
Clin Exp Ophthalmol 2010;248:1331–7
Inadequate sample size
(< 10 eyes)
Pilotto E, Guidolin F, Convento E, Spedicato L, Vujosevic S, Cavarzeran F, et al. Fundus
autofluorescence and microperimetry in progressing geographic atrophy secondary to
age-related macular degeneration. Br J Ophthalmol 2013;97:62–6
No appropriate reference
standard
Pilotto E, Vujosevic S, Melis R, Convento E, Sportiello P, Alemany-Rubio E, et al. Short
wavelength fundus autofluorescence versus near-infrared fundus autofluorescence, with
microperimetric correspondence, in patients with geographic atrophy due to age-related
macular degeneration. Br J Ophthalmol 2011;95:1140–4
No appropriate reference
standard
Pryds A, Larsen M. Foveal function and thickness after verteporfin photodynamic therapy
in central serous chorioretinopathy with hyperautofluorescent subretinal deposits.
Retina 2013;33:128–35
Sensitivity of FAF imaging not
reported, not calculable
Puche N, Querques G, Blanco-Garavito R, Zerbib J, Gherdaoui F, Tilleul J, et al.
En face enhanced depth imaging optical coherence tomography features in adult
onset foveomacular vitelliform dystrophy. Graefes Arch Clin Exp Ophthalmol
2014;252:555–62
No appropriate index test
Querques G, Zerbib J, Georges A, Massamba N, Forte R, Querques L, et al. Multimodal
analysis of the progression of Best vitelliform macular dystrophy. Mol Vis 2014;20:575–92
Sensitivity of FAF imaging not
reported, not calculable
Querques G, Leveziel N, Benhamou N, Voigt M, Soubrane G, Souied EH. Analysis of
retinal flecks in fundus flavimaculatus using optical coherence tomography.
Br J Ophthalmol 2006;90:1157–62
Sensitivity of FAF imaging not
reported, not calculable
Querques G, Querques L, Forte R, Massamba N, Blanco R, Souied EH. Precursors of
type 3 neovascularization: a multimodal imaging analysis. Retina 2013;33:1241–8
Sensitivity of FAF imaging not
reported, not calculable
Querques L, Querques G, Forte R, Souied E. Microperimetric correlations of
autofluorescence and optical coherence tomography imaging in dry age-related macular
degeneration. Am J Ophthalmol 2012;153:1110–15
Sensitivity of FAF imaging not
reported, not calculable
Querques G, Guigui B, Leveziel N, Querques L, Coscas G, Soubrane G, et al. Insights into
pathology of cuticular drusen from integrated confocal scanning laser ophthalmoscopy
imaging and corresponding spectral domain optical coherence tomography. Graefes
Arch Clin Exp Ophthalmol 2011;249:1617–25
Sensitivity of FAF imaging not
reported, not calculable
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
70
Study Primary reason for exclusion
Querques G, Querques L, Martinelli D, Massamba N, Coscas G, Soubrane G, et al.
Pathologic insights from integrated imaging of reticular pseudodrusen in age-related
macular degeneration. Retina 2011;31:518–26
Sensitivity of FAF imaging not
reported, not calculable
Querques G, Atmani K, Bouzitou-Mfoumou R, Leveziel N, Massamba N, Souied EH.
Preferential hyperacuity perimeter in best vitelliform macular dystrophy. Retina
2011;31:959–66
Sensitivity of FAF imaging not
reported, not calculable
Renner AB, Kellner U, Cropp E, Preising MN, MacDonald IM, van den Hurk JA, et al.
Choroideremia: variability of clinical and electrophysiological characteristics and first
report of a negative electroretinogram. Ophthalmology 2006;113:2066e.1–10
Sensitivity of FAF imaging not
reported, not calculable
Renner AB, Kellner U, Fiebig B, Cropp E, Foerster MH, Weber BH. ERG variability in
X-linked congenital retinoschisis patients with mutations in the RS1 gene and the
diagnostic importance of fundus autofluorescence and OCT. Doc Ophthalmol
2008;116:97–109
Sensitivity of FAF imaging not
reported, not calculable
Reznicek L, Seidensticker F, Stumpf C, Kampik A, Thurau S, Kernt M, et al. Systematic
analysis of wide-field fundus autofluorescence (FAF) imaging in posterior uveitis.
Curr Eye Res 2014;39:164–71
Sensitivity of FAF imaging not
reported, not calculable
Reznicek L, Dabov S, Haritoglou C, Kampik A, Kernt M, Neubauer AS. Green-light
fundus autofluorescence in diabetic macular edema. Int J Ophthalmol 2013;6:75–80
Sensitivity of FAF imaging not
reported, not calculable
Reznicek L, Dabov S, Kayat B, Liegl R, Kampik A, Ulbig M, et al. Scanning laser ‘en face’
retinal imaging of epiretinal membranes. Saudi J Ophthalmol 2014;28:134–8
Sensitivity of FAF imaging not
reported, not calculable
Reznicek L, Wasfy T, Stumpf C, Kampik A, Ulbig M, Neubauer AS, et al. Peripheral
fundus autofluorescence is increased in age-related macular degeneration. Invest
Ophthalmol Vis Sci 2012;53:2193–8
No appropriate reference
standard
Robson AG, Lenassi E, Saihan Z, Luong VA, Fitzke FW, Holder GE, et al. Comparison
of fundus autofluorescence with photopic and scotopic fine matrix mapping in patients
with retinitis pigmentosa: 4- to 8-year follow-up. Invest Ophthalmol Vis Sci
2012;53:6187–95
Sensitivity of FAF imaging not
reported, not calculable
Robson AG, Tufail A, Fitzke F, Bird AC, Moore AT, Holder GE, et al. Serial imaging and
structure-function correlates of high-density rings of fundus autofluorescence in retinitis
pigmentosa. Retina 2011;31:1670–9
Sensitivity of FAF imaging not
reported, not calculable
Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, SEVEN-UP Study Group.
Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON:
a multicenter cohort study (SEVEN-UP). Ophthalmology 2013;120:2292–9
Sensitivity of FAF imaging not
reported, not calculable
Roisman L, Lavinsky D, Magalhaes F, Aggio FB, Moraes N, Cardillo JA, et al. Fundus
autofluorescence and spectral domain OCT in central serous chorioretinopathy.
J Ophthalmol 2011;2011
Sensitivity of FAF imaging not
reported, not calculable
Sallo FB, Rechtman E, Peto T, Stanescu-Segall D, Vogt G, Bird AC, et al. Functional
aspects of drusen regression in age-related macular degeneration. Br J Ophthalmol
2009;93:1345–50
Sensitivity of FAF imaging not
reported, not calculable
Sarks J, Arnold J, Ho I-V, Sarks S, Killingsworth M. Evolution of reticular pseudodrusen.
Br J Ophthalmol 2011;95:979–85
Sensitivity of FAF imaging not
reported, not calculable
Sayegh RG, Simader C, Scheschy U, Montuoro A, Kiss C, Sacu S, et al. A systematic
comparison of spectral-domain optical coherence tomography and fundus
autofluorescence in patients with geographic atrophy. Ophthalmology
2011;118:1844–51
Sensitivity of FAF imaging not
reported, not calculable
Schachar IH, Zahid S, Comer GM, Stem M, Schachar AG, Saxe SJ, et al. Quantification
of fundus autofluorescence to detect disease severity in nonexudative age-related
macular degeneration. JAMA Ophthalmol 2013;131:1009–15
Sensitivity of FAF imaging not
reported, not calculable
Schmitz-Valckenberg S, Fleckenstein M, Gobel AP, Sehmi K, Fitzke FW, Holz FG, et al.
Evaluation of autofluorescence imaging with the scanning laser ophthalmoscope
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Study Primary reason for exclusion
Schmitz-Valckenberg S, Bultmann S, Dreyhaupt J, Bindewald A, Holz FG, Rohrschneider K.
Fundus autofluorescence and fundus perimetry in the junctional zone of geographic atrophy
in patients with age-related macular degeneration.[Erratum published in Invest Ophthalmol
Vis Sci 2005;46:7]. Invest Ophthalmol Vis Sci 2004;45:4470–6
No appropriate reference
standard
Schmitz-Valckenberg S, Fleckenstein M, Gobel AP, Hohman TC, Holz FG. Optical
coherence tomography and autofluorescence findings in areas with geographic atrophy
due to age-related macular degeneration. Invest Ophthalmol Vis Sci 2011;52:1–6
Sensitivity of FAF imaging not
reported, not calculable
Schmitz-Valckenberg S, Jorzik J, Unnebrink K, Holz FG, FAM study group. Analysis of
digital scanning laser ophthalmoscopy fundus autofluorescence images of geographic




Schmitz-Valckenberg S, Bindewald-Wittich A, Dolar-Szczasny J, Dreyhaupt J, Wolf S,
Scholl HP, et al. Correlation between the area of increased autofluorescence surrounding




Schmitz-Valckenberg S, Alten F, Steinberg JS, Jaffe GJ, Fleckenstein M, Mukesh BN, et al.
Reticular drusen associated with geographic atrophy in age-related macular
degeneration. Invest Ophthalmol Vis Sci 2011;52:5009–15
No appropriate reference
standard
Schutze C, Bolz M, Sayegh R, Baumann B, Pircher M, Gotzinger E, et al. Lesion size
detection in geographic atrophy by polarization-sensitive optical coherence tomography
and correlation to conventional imaging techniques. Invest Ophthalmol Vis Sci
2013;54:739–45
Sensitivity of FAF imaging not
reported, not calculable
Sekiryu T, Iida T, Maruko I, Saito K, Kondo T. Infrared fundus autofluorescence and
central serous chorioretinopathy. Invest Ophthalmol Vis Sci 2010;51:4956–62
Sensitivity of FAF imaging not
reported, not calculable
Shah VP, Shah SA, Mrejen S, Freund KB. Subretinal hyperreflective exudation associated
with neovascular age-related macular degeneration. Retina 2014;34:1281–8
Sensitivity of FAF imaging not
reported, not calculable
Shen Y, Xu X, Liu K. Fundus autofluorescence characteristics in patients with diabetic
macular edema. Chin Med J 2014;127:1423–8
Sensitivity of FAF imaging not
reported, not calculable
Silva R, Cachulo ML, Fonseca P, Bernardes R, Nunes S, Vilhena N, et al. Age-related
macular degeneration and risk factors for the development of choroidal
neovascularisation in the fellow eye: a 3-year follow-up study. Ophthalmologica
2011;226:110–18
Sensitivity of FAF imaging not
reported, not calculable
Simader C, Sayegh RG, Montuoro A, Azhary M, Koth AL, Baratsits M, et al. A
longitudinal comparison of spectral-domain optical coherence tomography and fundus
autofluorescence in geographic atrophy. Am J Ophthalmol 2014;158:557–66
Sensitivity of FAF imaging not
reported, not calculable




Spaide RF, Klancnik JM Jr. Fundus autofluorescence and central serous
chorioretinopathy. Ophthalmology 2005;112:825–33
Sensitivity of FAF imaging not
reported, not calculable
Suzuki M, Gomi F, Sawa M, Ueno C, Nishida K. Changes in fundus autofluorescence in
polypoidal choroidal vasculopathy during 3 years of follow-up. Graefes Arch Clin Exp
Ophthalmol 2013;251:2331–7
Sensitivity of FAF imaging not
reported, not calculable
Tan CS, Heussen F, Sadda SR. Peripheral autofluorescence and clinical findings in
neovascular and non-neovascular age-related macular degeneration. Ophthalmology
2013;120:1271–7
Sensitivity of FAF imaging not
reported, not calculable
Teke MY, Elgin U, Nalcacioglu-Yuksekkaya P, Sen E, Ozdal P, Ozturk F. Comparison
of autofluorescence and optical coherence tomography findings in acute and chronic
central serous chorioretinopathy. Int J Ophthalmol 2014;7:350–4
Sensitivity of FAF imaging not
reported, not calculable
Toju R, Iida T, Sekiryu T, Saito M, Maruko I, Kano M. Near-infrared autofluorescence
in patients with idiopathic submacular choroidal neovascularization. Am J Ophthalmol
2012;153:314–19
Sensitivity of FAF imaging not
reported, not calculable
Toy BC, Krishnadev N, Indaram M, Cunningham D, Cukras CA, Chew EY, et al. Drusen
regression is associated with local changes in fundus autofluorescence in intermediate
age-related macular degeneration. Am J Ophthalmol 2013;56:532–42
Sensitivity of FAF imaging not
reported, not calculable
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Study Primary reason for exclusion
Tsakonas GD, Kotsolis AI, Koutsandrea C, Georgalas I, Papaconstantinou D, Ladas ID.
Multiple spots of photodynamic therapy for the treatment of severe chronic central
serous chorioretinopathy. Clin Ophthalmol 2012;6:1639–44
Sensitivity of FAF imaging not
reported, not calculable
Vaclavik V, Vujosevic S, Dandekar SS, Bunce C, Peto T, Bird AC. Autofluorescence
imaging in age-related macular degeneration complicated by choroidal
neovascularization: a prospective study. Ophthalmology 2008;115:342–6
Sensitivity of FAF imaging not
reported, not calculable
Vidinova CN, Gouguchkova PT, Vidinov KN. Fundus autofluorescence in dry AMD –
impact on disease progression. Klin Monatsbl Augenheilkd 2013;230:1135–41
Non-English language
von Ruckmann A, Fitzke FW, Fan J, Halfyard A, Bird AC. Abnormalities of fundus
autofluorescence in central serous retinopathy. Am J Ophthalmol 2002;133:780–6
Sensitivity of FAF imaging not
reported, not calculable
von Ruckmann A, Fitzke FW, Bird AC. In vivo fundus auto fluorescence in macular
dystrophies. Arch Ophthalmol 1997;115:609–15
Sensitivity of FAF imaging not
reported, not calculable
Vujosevic S, Vaclavik V, Bird AC, Leung I, Dandekar S, Peto T. Combined grading for
choroidal neovascularisation: colour, fluorescein angiography and autofluorescence
images. Graefes Arch Clin Exp Ophthalmol 2007;245:1453–60
Sensitivity of FAF imaging not
reported, not calculable
Vujosevic S, Bottega E, Casciano M, Pilotto E, Convento E, Midena E. Microperimetry
and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode
laser versus modified early treatment diabetic retinopathy study laser photocoagulation.
Retina 2010;30:908–16
Sensitivity of FAF imaging not
reported, not calculable
Vujosevic S, Casciano M, Pilotto E, Boccassini B, Varano M, Midena E. Diabetic macular
edema: fundus autofluorescence and functional correlations. Invest Ophthalmol Vis Sci
2011;52:442–8
Sensitivity of FAF imaging not
reported, not calculable
Wakabayashi T, Sawa M, Gomi F, Tsujikawa M. Correlation of fundus autofluorescence
with photoreceptor morphology and functional changes in eyes with retinitis
pigmentosa. Acta Opthalmol 2010;88:e177–83
Sensitivity of FAF imaging not
reported, not calculable
Wang Q, Jiang L. Fundus autofluorescence imaging of acute zonal occult outer
retinopathy. Doc Ophthalmol 2013;127:25 (meeting abstract)
Sensitivity of FAF imaging not
reported, not calculable
Weinberger AW, Lappas A, Kirschkamp T, Mazinani BA, Huth JK, Mohammadi B, et al.
Fundus near infrared fluorescence correlates with fundus near infrared reflectance.
Invest Ophthalmol Vis Sci 2006;47:3098–108
Sensitivity of FAF imaging not
reported, not calculable
Wolf-Schnurrbusch UE, Enzmann V, Brinkmann CK, Wolf S. Morphologic changes in
patients with geographic atrophy assessed with a novel spectral OCT-SLO combination.
Invest Ophthalmol Vis Sci 2008;49:3095–9
Sensitivity of FAF imaging not
reported, not calculable
Wong WT, Forooghian F, Majumdar Z, Bonner RF, Cunningham D, Chew EY. Fundus
autofluorescence in type 2 idiopathic macular telangiectasia: correlation with optical
coherence tomography and microperimetry. Am J Ophthalmol 2009;148:573–83
Sensitivity of FAF imaging not
reported, not calculable
Yoshitake S, Murakami T, Horii T, Uji A, Ogino K, Unoki N, et al. Qualitative and
quantitative characteristics of near-infrared autofluorescence in diabetic macular edema.
Ophthalmology 2014;121:1036–44
Sensitivity of FAF imaging not
reported, not calculable
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Appendix 5 Data extraction tables
Appendix 1  Data extraction tables 
 
Study 1 of 8 – Cachulo and colleagues 
Reference and design Diagnostic tests Participants Outcome 
measures 
Condition being 
diagnosed / detected: 
Choroidal neovascular-
isation (CNV) in exudative 
AMD 
 
First author:  
Cachulo99 
 




Study design:  
Prospective observational 
longitudinal 2 year study 
 






Competing interests:  
Not reported 
1 author appears to be 
employed by Pfizer Inc. 
Index test: 
Fundus autofluorescence 
(FAF): acquired with 
confocal scanning 
laser ophthalmoscopy 
(cSLO) HRA II 
(Heidelberg Retina 
Angiograph)  
Excitation 488nm; barrier 
filter beginning at 
500nm. 
 
Each FAF image was 
compiled from at least 17 
single scans in movie 
mode and automatically 




(FA): acquired using the 










3) Indocyanine green 
angiography 
4) Optical coherence 
tomography 
5) Retinal angiography 
(retinal leakage 
analysis – RLA – 
measuring retinal 
fluorescein leakage 
from the blood 
stream into the 




62 (52 included in 
analysis) 
 






completed the 2 year 
follow-up, dropout 
was due to death (4 
patients), withdrawal 
of informed consent 
(4 patients), 
hospitalisation (1 
patient), loss to 
follow-up (1 patient 






neovascular AMD in 
one eye and early 
AMD in the fellow 
eye (study eye) at 
risk for development 






for study entry: 
1) Older than 50 
years 
2) Any race and 
either sex 
3) Clinical diagnosis 
of wet AMD in one 
eye (non-study eye) 
4) Presence of the 
following 





early AMD to wet 
AMD: sensitivity 





for 2 years or until 
CNV presence was 












from results, but 
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study eye:  
a) 5 or more 
intermediate soft 




drusen within 3,000 
μm of the foveal 
centre 




for study entry: 
1) Current or past 
medical condition 
that would preclude 
scheduled visits or 
completion of the 
study 
2) Current or past 
history of ophthalmic 
disease in the study 
eye (other than 
AMD), that would 
likely compromise 
the visual acuity of 
the study eye 
3) Clinical signs of 
myopic retinopathy 
or refractive power 




4) Past history of 
intraocular surgery 
within 60 days prior 
to enrolling in the 
study 
5) Evidence of past 
or present CNV in 
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Participant characteristics 
Sex, m:f (%male) 26:26 (50) 
Age, years, mean (SD) 76 (6), range 56-92 
 
Results – FAF versus FA 
Calculations are based on 
number of eyes (single eyes 
of 52 subjects) 
Population with disease 
on FA reference 
standard 
Population without 
disease on FA 
reference standard 
Total 
FAF imaging positive 15   a 23  c 38              
FAF imaging negative 2   b 12  d 14             
Total 17 35  52              
 
Diagnosis  95% CI 
Clinical sensitivity a / (a + b) 88.24 %  63.52 to 98.20 
Clinical specificity d / (c + d) 34.29 %  19.15 to 52.21 
PPV a / (a + c)  39.47 %  24.05 to 56.61 
NPV d / (b + d) 85.71 %   57.16 to 97.80 
Positive likelihood ratio [sensitivity/(100-specificity)] 1.34  1.00 to 1.80 
Negative likelihood ratio [(100-sensitivity)/specificity] 0.34  0.09 to 1.36 
Diagnostic odds ratio (a x d)/(b x c) 
 
3.91 0.77 to 20.02 
Comments: Calculations do not agree with values reported in paper. Reported values for FAF are: 
sensitivity 93%, specificity 37%, positive predictive value 57% and negative predictive value 93%. 
This may be because of different ways that the reviewer and authors categorised the 2 eyes in FAF in 
which the pattern of autofluorecence could not be determined because of poor quality images. 
 
Interpretability and acceptability of test  
Numbers excluded from analysis due to poor image quality 2/52 (3.85%) 
Inter-observer agreement Not reported 
Intra-observer agreement Not reported 
Test acceptability (patients / clinicians) Not reported 
Adverse events Not reported 
AMD: age-related macular degeneration; CNV: choroidal neovascularisation; cSLO: confocal 
scanning laser ophthalmoscopy; FA: fluorescein angiography; FAF: fundus autofluorescence; NPV: 
negative predictive value; PPV: positive predictive value.  
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Study 2 of 8 – Dinc and colleagues 
Reference and design Diagnostic tests Participants Outcome 
measures 
Condition being 
diagnosed / detected: 
Cystoid macular oedema 
(CMO) (secondary to 
diabetic retinopathy, 
retinal vein occlusions, 
uveitis, cataract surgery, 




First author: Dinc83 
 
Publication year: 2010 
 
Country: Turkey (not 
stated explicitly) 
 
Study design: Patients 
were selected from a FAF 
database (no further details 
given); informed consent 
was obtained from all 
patients, suggesting the 
study was prospective 
 
Number of centres: Not 
explicitly reported but 
appears to be single centre 
 
Funding: No information 
provided 
 











View mode 30°; pupil 
dilated to a diameter ≥ 6 
mm. Excitation 488nm; 
barrier filter 500nm.  
Stated that a mean of 9 





(FA). Method not 
reported except that in the 
late phase of FA, path-
ognomonic leakage 
of fluorescein at the fovea 
in a petaloid configur-
ation with feathery 




















only that the patients 
diagnosed with 
CMO were selected 





for study entry: 











for study entry: 
Eyes with significant 
media opacity, 
cataract, poor FAF 
images, or having 
subfoveal serous 
retinal detachment 






Detection of CMO 












stated but implied 
to be increased 
autofluorescence in 
a round or oval 
fashion at the 
fovea (example 





Stated that patients 
were selected from 
the FAF database 
between January 
2008 and June 
2009 
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Participant characteristics 
Sex, m:f (%male) 28:27 (51) 
Age, years, mean (SD) 62.1 (14.4) 
Origin of CMO (n= no. of 
eyes) 
Diabetic retinopathy, n=36 
Branch retinal vein occlusion, n=13 
Macular epiretinal membrane, n=5 
Age-related macular degeneration, n=5 
Uveitis, n=4 
Cataract extraction, n=3 
Central retinal vein occlusion, n=1 
 
Results – FAF compared against FA 
Calculations are based on 
the numbers of eyes (both 
eyes of 12 subjects and 
single eyes of 43 subjects) 
Population with CMO 
on FA 
Population without 
CMO on FA 
Total 
FAF imaging positive 64                                 a 2                            c 66 
FAF imaging negative 1                                   b 0                            d    1 
Total 65 2 67 
 
Diagnosis  95% CI 
Clinical sensitivity a / (a + b) 98.46% 91.69 to 99.74 
Clinical specificity d / (c + d) 0.00% 0.00 to 80.71 
PPV a / (a + c)  96.97% 89.46 to 99.54 
NPV d / (b + d) 0.00% 0.00 to 83.45 
Positive likelihood ratio [sensitivity/(100-
specificity)] 
0.98 0.96 to 1.01 
Negative likelihood ratio [(100-
sensitivity)/specificity] 
Not calculable  
Diagnostic odds ratio (a x d)/(b x c) 
 
8.60 0.28 to 268.48 
Comments: Diagnostic outcomes are not reported in paper – calculated by reviewer 
 
Interpretability and acceptability of test  
Numbers excluded from analysis due to poor 
image quality 
None – results are reported for all 67 study eyes 
 
Inter-observer agreement Not reported 
Intra-observer agreement Not reported 
Test acceptability (patients / clinicians) Not reported 
Adverse events Not reported 
CMO: cystoid macular oedema; cSLO: confocal scanning laser ophthalmoscopy; FA: fluorescein 
angiography; FAF: fundus autofluorescence; NPV: negative predictive value; OCT: optical coherence 
tomography; PPV: positive predictive value  
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Dinc and colleagues83 critical appraisal criteria (based on Reitsma et al.81 adaptation of the 
QUADAS Tool93) 
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Study 3 of 8 – Hogg and colleagues 
Reference and design Diagnostic tests Participants Outcome 
measures 
Condition being diagnosed 
/ detected: 
Reticular pseudodrusen 




First author: Hogg96 
 
Publication Year: 2014 
 
Country: Italy, Portugal, 
UK (Northern Ireland) 
 
Study design: 
Prospective cohort study 
 
Number of centres: 3 
 
Funding: Educational grant 
from Pfizer Inc. 
 
Competing interests:  
Authors declared financial 
support or consultancies 
from Pfizer, Heidelberg 
Engineering, Zeiss Meditec, 
Novartis, Allergan, Zeiss, 
Alcon, Bayer, and THEA  
 
Index test: fundus 
autofluorescence (FAF) 






not stated; barrier filter 
not stated. 
 
Settings: Field of view 
30° centred on the 
macula; automatic image 
brightness (also called 
gain); high-speed mode; 
movie duration 30 
seconds; average of 15 
frames (Spectralis mean 
function); and 
tomography settings 




(1) Reference standard 
relevant to the current 
review: Colour fundus 
photography (CFP): 
Stereopair colour images 
acquired using a Topcon 
50X fundus camera. No 
further details given. 
 
(2) Reference standard 
according to the primary 
study: Presence or 
absence of RPD on >1 of 
5 modalities: CFP, red-
free photography (RF), 
Infrared photography 
(IR), fundus auto-




CFP: details as above 
 
IR: acquired using same 
equipment as index test 









Not reported, but 
appears to have 
excluded 12 eyes 
with poor image 






retina clinics at each 
study site who had a 
diagnosis of 
neovascular AMD in 
1 eye were 
approached and 
invited to take part. 
Neovascular AMD 




for study entry: 
Men and women 
older than 50 years 
with a confirmed 
diagnosis of 
neovascular AMD in 
1 eye; study eye 
(fellow eye) free of 
any features of late 
AMD (i.e., no 
neovascularization 
or geographic 
atrophy) with a 
visual acuity of 
20/40 or better; 
sufficiently clear 
ocular media and 
adequate pupillary 
dilatation to permit 
good-quality 
fundus imaging of 
the study eye; and 
Primary outcome 
of study: 




























from 125 to 250 
μm in width or 
lesions that 
















material anterior to 
the RPE often 
occurring as sharp 
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RF: acquired using 
same equipment as index 
test and same settings 
 
OCT acquired using 
same equipment as index 
test.  Centred on the 
macula, using evenly 
spaced lines in the scan 
area: 30° (horizontal) x 
15° (vertical) area; 
number of sections set to 
37; mean function used 




Note: SD-OCT implied 




willing and able to 
comply with 
scheduled visits, 





for study entry: 
Evidence of a 
neovascular lesion 
on FA in the study 
eye; any other 
feature of  
neovascular AMD 
(eg. subretinal or 
intraretinal fibrosis 
within the macular 











of -8 diopters or 
more or axial length 







eg. glaucoma or 
diabetic retinopathy 
in the study eye; 
medical condition 
that would interfere 
with the patient’s 
ability to complete 
the trial; concurrent 




treatment with an 
ocular or systemic 
investigational agent 
in the past 60 days 
for medical 
peaks visible 
within the layers 
corresponding to 
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condition; or known 
serious allergies to 





Sex, m:f (%male) 53:52 (50) 
Age, years, mean (SD) 75.6 (7.5), range 52-93  
Visual acuity in patients with vs. without drusen 
 Distance visual acuity (letters), mean (SD) 
 Near visual acuity (logarithm of the minimum angle of 
resolution), mean (SD) 
 Low luminescence visual acuity (SKILL score), mean (SD) 
 
 83 (6) vs. 81 (6)  
 0.3 (0.1) vs. 0.2 (0.1) 
 
 38 (12) vs. 33 (9) 
 
Results – (1) FAF versus Spectralis OCT 
Calculations are based on 
numbers of eyes (single 
eyes of 93 subjects) 
Population with 
disease on Spectral 
OCT 
Population without 
disease on Spectral 
OCT 
Total 
FAF imaging positive  29                            a     9                       c   38               
FAF imaging negative   4                             b     48                     d   52                 
Total  33                             57                 90           
 
Diagnosis  95% CI 
Clinical sensitivity a / (a + b) 87.88 %  71.78 to 96.52 
Clinical specificity d / (c + d) 84.21 %  72.13 to 92.30 
PPV a / (a + c)  76.32 %   59.75 to 88.53 
NPV d / (b + d) 92.31 %  81.44 to 97.82 
Positive likelihood ratio [sensitivity/(100-
specificity)] 
5.57 3.02 to 10.27 
Negative likelihood ratio [(100-
sensitivity)/specificity] 
0.14 0.06 to 0.36 
Diagnostic odds ratio (a x d)/(b x c)* 
*0.5 added to each number to avoid division by 
zero 
38.67 10.92 to 136.97 
Interpretability and acceptability of test – see table below 
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Results – (2) FAF versus CFP 
Calculations are based on 
numbers of eyes (single 
eyes of 93 subjects) 
Population with 
disease on CFP 
Population without 
disease on CFP 
Total 
FAF imaging positive  15                            a     26                     c   41                 
FAF imaging negative   0                             b     52                     d   52                 
Total  15                               78                 93           
 
Diagnosis  95% CI 
Clinical sensitivity a / (a + b) 100.00 %  78.03 to 100.00 
Clinical specificity d / (c + d) 66.67 %  55.08 to 76.94 
PPV a / (a + c)  36.59 %   22.13 to 53.06 
NPV d / (b + d) 100.00 %  93.08 to 100.00 
Positive likelihood ratio [sensitivity/(100-
specificity)] 
3.00 2.19 to 4.11 
Negative likelihood ratio [(100-
sensitivity)/specificity] 
0.00 Not calculable 
Diagnostic odds ratio (a x d)/(b x c)* 




3.54 to 1066.71 
Comments: CFP is the usual method for diagnosing RPD but was not the reference standard in the 
primary study. Diagnostic outcomes for this comparison were not reported in the paper but have been 
calculated by reviewers from data in Table 4 in the paper.  
 
Interpretability and acceptability of test – see table below 
 
Results – (3) FAF versus >1 imaging modality 
Calculations are based on 
numbers of eyes (single 
eyes of 93 subjects) 
Population with 
disease on >1 
imaging modality 
Population without 
disease on >1 imaging 
modality 
Total 
FAF imaging positive  41                            a     0                      c   41                 
FAF imaging negative   2                             b     50                    d   52                 
Total  43                               50                   93           
 
Diagnosis  95% CI 
Clinical sensitivity a / (a + b) 95.35 %  84.16 to 99.30 
Clinical specificity d / (c + d) 100.00 %  92.82 to 100.00 
PPV a / (a + c)  100.00 %   91.31 to 100.00 
NPV d / (b + d) 96.15 %  86.76 to 99.42 
Positive likelihood ratio [sensitivity/(100-
specificity)] 
Not calculable  
Negative likelihood ratio [(100-
sensitivity)/specificity] 
0.05 0.01 to 0.18 




78.30 to 35903.35 
Comments: The diagnostic odds ratio was not reported in the paper. The calculation of specificity 
differs as the paper reported specificity to be 98%. 
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Interpretability and acceptability of test  
Numbers excluded from analysis due to poor 
image quality 
Not reported.  
Appears to have excluded 12 eyes that were 
ungradable for RPD: Instead of 105 eyes, results 
are presented for 93 eyes comparing FAF 
with >1 imaging modality; 93 eyes comparing 
FAF with fundus photography; and 90 eyes 
comparing FAF with OCT. However, the 
numbers that were ungradable on each imaging 
modality are not specified.  
Inter-observer agreement  
(only for the UK [Belfast] site, n=35), kappa 
statistics 
Colour photography, 0.72 (P<0.001);  
IR, 0.87 (P<0.001);  
RF, 0.53 (P = 0.002);  
FAF, 0.94 (P<0.001);  
OCT, 0.86 (P<0.001);  
ICGA, 0.93 (P<0.001); 
RPD on 1 or more imaging method, 1.0. 
Intra-observer agreement Not reported 
Test acceptability (patients / clinicians) Not reported 
Adverse events Not reported 
AF: autofluorescence; AMD: age-related macular degeneration; CFP: colour fundus photography; 
cSLO: confocal scanning laser ophthalmoscopy; FA: fluorescein angiography; FAF: fundus 
autofluorescence; ICGA: indocyanine green angiography; IR: infrared photography; NPV: negative 
predictive value; OCT: optical coherence tomography; PPV: positive predictive value; RF: red-free 
photography; RPD: reticular pseudodrusen; RPE: retinal pigment epithelium; SD-OCT: spectral-
domain optical coherence tomography 
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Hogg and colleagues96 critical appraisal criteria (based on Reitsma et al.81 adaptation of the 
QUADAS Tool93) 
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Study 4 of 8 – McBain and colleagues 




Cystoid macular oedema 
(CMO) 
 
First author: McBain100 
 






observational case series 
 
Number of centres: 1 
 
Funding: Not stated 
 
Competing interests: Stated 
none 
Index test: 
FAF imaging using 




consisted of a solid-state 
argon blue excitation 
laser (488nm) and 
barrier filter (500nm). 
30 degree field-of-view 
mode was used for the 
images. Sequential 
images were obtained 
and 20 frames were 
selected and averaged to 





(FA) Digital stereo 








Time period between 
tests: within 2 weeks of 
each other; there was a 
minimum gap of 4 days 
washout if FAF was 










clinically suspected  
CMO had FAF 
imaging, of which 
34 patients were 
eligible for inclusion 








were selected from 
FAF imaging 





for study entry: 





disease or idiopathic 
cases, where both 
FAF and FA were 
obtained to confirm 
diagnosis. One eye 
per person included, 
left eye chosen in 
bilateral cases. 
Patients were 
eligible if FAF was 
performed within 2 
weeks of FA 
 
Exclusion criteria 






















were round or oval 
areas of fundus 
autofluorescence at 




ground levels. FAF 
signal is usually 
reduced at the 
fovea compared 
with background, 
due to blockage of 
the signal by the 
luteal pigment. 
 
FA: CMO was 
considered present 
whenever leakage 
of fluorescein dye 
was observed in a 
petaloid pattern 
around the fovea in 








2004 - May 2007* 
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*The numbers do not add up to 106 but 96. There is a discrepancy in reporting the total numbers in 
the abstract (which reports 96) vs the text (reporting 106). There is also a discrepancy in recruitment 
dates in the abstract (reported as between Aug 2004 and June 2006) vs the text (Feb 2004 and May 
2007). It appears that the main text has been updated but the abstract has not, and that 10 exclusions 
have not been accounted for. 
 
Participant characteristics 
Sex, m:f (%male:female) 20:14 (59) 
Age, years, mean (SD) 59 (range 17-89) 
CMO secondary to inflammatory disease, n (%) 17/34 (50) 
CMO following cataract surgery, n (%) 11/34 (32) 
CMO associated with inherited retinal dystrophies, n 
(%) 
3/34 (9) 
CMO idiopathic, n (%) 4/34 (12) 
 
Results – FAF versus FA 
Calculations are based on 
numbers of eyes (= number 
of patients as only one eye 
per patient was included) 
Population with 
disease on FA 
Population without 
disease on FA 
Total 
FAF imaging positive 17  a 4  c 21 
FAF imaging negative 4  b 9  d 13 
Total 21 13 34 
 
Diagnosis  95% CI 
Clinical sensitivity a / (a + b) 80.95 58.08 to 94.44 
Clinical specificity d / (c + d) 69.23 38.61 to 90.72 
PPV a / (a + c)  80.95 58.08 to 94.44 
NPV d / (b + d) 69.23 38.61 to 90.72 
Positive likelihood ratio [sensitivity/(100-
specicifcity)] 
2.63 1.13 to 6.10 
Negative likelihood ratio [(100-
sensitivity)/specificity] 
0.28 0.11 to 0.71 
Diagnostic odds ratio (a x d)/(b x c) 
 
9.56 1.92 to 47.57 
Comments: Calculations agree with values reported in paper except for values for PPV and NPV, 
which are switched in the paper. 
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Interpretability and acceptability of test  
Poor FAF images related to media opacities 
(cataract), n (%) 
9/96 (9.4%) 
Inter-observer agreement Not reported 
Intra-observer agreement Not reported 
Test acceptability (patients / clinicians) Not reported 
Adverse events No side effects were observed related to FAF or 
AF images during the study period. 
The percentage has been calculated by reviewers using the denominator 96 rather than 106, as the 
reasons for 10 exclusions appear to have been omitted from the paper (see above). 
CMO: cystoid macular oedema; FA: fluorescein angiography; FAF: fundus autofluorescence; NPV: 
negative predictive value; PPV: positive predictive value 
 
McBain and colleagues100 critical appraisal criteria (based on Reitsma et al.81 adaptation of the 
QUADAS Tool93) 
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Study 5 of 8 – Smith and colleagues 
Reference and design Diagnostic tests Participants Outcome 
measures 
Condition being diagnosed 
/ detected: Reticular 




First author: Smith101 
 
Publication year: 2006 
 
Country: UK and USA 
 
Study design: 
Retrospective case series (2 
distinct case series 
combined) 
 
Number of centres:  
Not reported 
 
Funding: New York 
Community Trust (lead 
author) and unrestricted 







(FAF) imaging. No 
details of method 
reported; introduction 
suggests probably 







were studied both in 
their original state and as 
highly contrast-enhanced 
versions, to facilitate 
RPD identification. No 











Number of eyes: 
221 (166 eyes of 83 
patients with early 
AMD or GA, 
without evidence of 
choroidal neo-
vascularisation 
(CNV)) and 55 
unaffected eyes of 55 
patients with 









two databases: an 
AMD study database 
at the UK Institute of 
Ophthalmology; and 
a database of patients 
imaged at Columbia 
Eye University, 






for study entry: Not 
explicitly reported. 
Stated only that the 
eyes had either: 
bilateral soft drusen 
± pigment abnor-
malities, but no 
evidence of CNV; or 




for study entry: 
Eyes that did not 
receive both FAF 
imaging and colour 
fundus photography. 
Primary outcome 
of study: The 
fraction and 
relative prob-










the presence or 
absence of 
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Participant characteristics 
Sex, m:f (%male) Not reported 
Age, years, mean (SD) Not reported 
Other key characteristics  None reported 
 
Results – FAF imaging 
Calculations are based on 
numbers of eyes (both eyes 
of 83 subjects and single 
eyes of 55 subjects)  
Population with RPD 
on colour fundus 
photography 
Population without 




FAF imaging positive 28                                  a 4                              c 32                     
FAF imaging negative 2                                    b 187                          d 189                   
Total 30                               191                       221 
 
Diagnosis  95% CI 
Clinical sensitivity a / (a + b) 93.33% 77.89 to 98.99 
Clinical specificity d / (c + d) 97.91% 94.72 to 99.41 
PPV a / (a + c)  87.50% 70.99 to 96.41 
NPV d / (b + d) 98.94% 96.22 to 99.84 
Positive likelihood ratio [sensitivity/(100-
specificity)] 
44.57 16.82 to 118.08 
Negative likelihood ratio [(100-
sensitivity)/specificity] 
0.07 0.02 to 0.26 
Diagnostic odds ratio (a x d)/(b x c) 654.50 114.50 to 3741.07 
Comments: Sensitivity calculation agrees with statement in the paper that “AF imaging was over 90% 
sensitive” (no other diagnostic results were reported in the paper). 
Sensitivity and specificity are also calculable for a sub-group of patients based on unaffected fellow 
eyes of those with unilateral CNV (“CNV-R” group). However, subgroup is defined by auto-
fluorescence pattern (reticular AF and / or RPD) and does not include all patients with unilateral 
CNV. Therefore data have not been extracted here. 
 
Interpretability and acceptability of test     
Numbers excluded from analysis due to poor 
image quality 
None. However, reported that for one patient 
with RPD only this was “perhaps due to 
marginal scan quality” and another patient had 
“bilateral RPD and an AF image in the left eye 
that could not be graded for reticular AF”. 
Unclear whether these were the only poor-
quality images present. 
Inter-observer agreement Not reported 
Intra-observer agreement Not reported 
Test acceptability (patients / clinicians) Not reported 
Adverse events Not reported 
AF: autofluorescence; AMD: age-related macular degeneration; CFP: colour fundus photography; 
CNV: choroidal neovascularisation; cSLO: scanning laser ophthalmoscopy; FAF: fundus 
autofluorescence; GA: geographic atrophy; NPV: negative predictive value; PPV: positive predictive 
value; RPD: reticular pseudodrusen  
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Study 6 of 8 – Ueda-Arakawa and colleagues 
Reference and design Diagnostic tests Participants Outcome 
measures 
Condition being 
diagnosed / detected: 
Reticular pseudodrusen 












Retrospective case series 
 
Number of centres: One 
 













Excitation 488nm; barrier 
filter beginning at 
500nm.  
 
(2) Near-infrared fundus 
autofluorescence (NIR-
FAF): acquired with 
cSLO (same equipment 






Each FAF or NIR-FAF 
image was compiled from 
an average of 15 to 20 




At least 2 of 7 imaging 
modalities (in any 





graphy (CFP): 30°–40° 
field acquired digitally 
using Topcon TRC 
NW6S non-mydriatic 
retinal camera (Topcon, 
Tokyo, Japan). Blue 
channel examined using 
Image J software (Nat-
ional Institutes of Health, 
Bethesda, MD, USA). 
(NB: paper notes that this 
has been the traditional 











8/228 eyes excluded, 
due to phthisis bulbi 
(n=2) or poor image 
quality in ≥3 
imaging modalities 
(n=6). Further 
excluded due to poor 















for study entry: 
Early AMD, 
neovascular AMD or 
geographic atrophy 
in at least one eye. 
Early AMD defined 
as presence of soft 
drusen (≥ 63 μm) or 
areas of hyper- or 
hypopigmentation in 
the RPE. Geographic 
atropy defined on 
colour fundus 
photography as a 
sharply delineated 
area (≥ 175 μm) ie 
hypopigmentation, 
depigmentation or 
apparent absence of 
RPE in which 
choroidal vessels 
were clearly visible. 
Primary outcome 




specificity of each 
imaging modality 





agreement rates for 






RPD diagnosed  
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(2) Infrared reflectance 
(IR): acquired using 
cSLO (same equipment 
as the index test). Light 
stimulus 820nm. 
 
(3) FAF imaging (i.e., an 
index test – see above). 
 
(4) NIR-FAF imaging 
(i.e., an index test – see 
above). 
 
(5) Confocal blue 
reflectance (CBR): 
acquired with cSLO 
(same equipment as the 
index test). Light 
stimulus 488nm; field of 
view 30° x 30°, centred 





acquired with cSLO 
(same equipment as the 
index test). Excitation: 
790nm; detection 800nm. 
 







and vertical line scans 
through the fovea centre 
obtained at a 30° angle, 
followed by serial 
horizontal scans with an 
examination field size 
ranging from 30° x 10° to 
30° x 25. At each 
location of interest on the 
retina, 50 images were 











for study entry: 
People aged < 50 
years, eyes with high 
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Participant characteristics 
Sex, m:f (%male) 79:35 (69) 
Age, years, mean (SD) 73.8 (9.4), range 52-92 
Visual acuity (logarithm of the minimum 
angle of resolution), mean (SD) 




FAF versus ≥2 (of 7) imaging modalities  
Calculations are based on numbers 
of eyes, including both eyes of 
each subject 
Population with 








FAF imaging positive 32                        a 9                            c 41 
FAF imaging negative 5                          b 171                        d 176 
Total 37 180 217 
 
Diagnosis  95% CI 
Clinical sensitivity a / (a + b) 86.49% 71.21 to 95.41 
Clinical specificity d / (c + d) 95.00% 90.72 to 97.68 
PPV a / (a + c)  78.05% 62.38 to 89.42 
NPV d / (b + d) 97.16% 93.49 to 99.06 
Positive likelihood ratio [sensitivity/(100-specificity)] 17.30 9.04 to 33.11 
Negative likelihood ratio [(100-sensitivity)/specificity] 0.14 0.06 to 0.32 
Diagnostic odds ratio (a x d)/(b x c) 121.60 38.25 to 386.57 
Comments: Calculations agree with values reported in paper (except diagnostic odds ratio not 
reported). Paper also reports (in Supplementary Table 2) that the sensitivity of FAF imaging is 86.5% 
when the field size is limited to the same imaging area as SD-OCT, i.e. 30o x 10o – but sample sizes 
(n/N) for this calculation (32/37) are not explained.    
 
Note that CFP is the test usually considered as a reference standard for diagnosing RPD. Although 
diagnostic outcomes for a comparison of FAF versus CFP are given in supplementary Table 1 of the 
paper, these relate only to a subset of 37 eyes that had a reticular pattern on ≥2 imaging modalities, 
therefore these data have not been extracted.  
Interpretability and acceptability of test  
Number of eyes excluded from analysis due to poor 
image quality 
3/220 (1.4%) 
Inter-observer agreement (grading reticular pattern) 89.3%; kappa = 0.700 
Intra-observer agreement Not reported 
Test acceptability (patients / clinicians) Not reported 
Adverse events Not reported 
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NIR-FAF versus ≥2 (of 7) imaging modalities 
Calculations are based on numbers 
of eyes, including both eyes of each 
subject 
Population with 








NIR-FAF imaging positive 9                          a 5                            c 14 
NIR-FAF imaging negative 19                        b   103                        d 122 
Total 28 108 136 
 
Diagnosis  95% CI 
Clinical sensitivity a / (a + b) 32.14% 15.91% to 52.35% 
Clinical specificity d / (c + d) 95.37% 89.52% to 98.46% 
PPV a / (a + c)  64.29% 35.18% to 87.11% 
NPV d / (b + d) 84.43% 76.75% to 90.35% 
Positive likelihood ratio [sensitivity/(100-
specificity)] 
6.94 2.53 to 19.08 
Negative likelihood ratio [(100-
sensitivity)/specificity] 
0.71 0.55 to 0.92 
Diagnostic odds ratio (a x d)/(b x c) 9.76 2.95 to 32.33 
Comments: Calculations agree with values reported in paper (except diagnostic odds ratio not 
reported). Paper also reports (in Supplementary Table 2) that the sensitivity of NIR-FAF imaging is 
28.6% when the field size is limited to the same imaging area as SD-OCT, i.e. 30o x 10o – but sample 
sizes (n/N) for this calculation (8/28) are not explained.        
Interpretability and acceptability of test  
Number of eyes excluded from analysis due to poor 
image quality 
64/220 (29%) 
Inter-observer agreement (grading reticular pattern) 84.2%; kappa = 0.563 
Intra-observer agreement Not reported 
Test acceptability (patients / clinicians) Not reported 
Adverse events Not reported 
 
Number of eyes with good image quality – results for all imaging tests 
FAF 217/220 (99%) 
NIR-FAF 136/220 (62%) 
Blue-channel CFP 220/220 (100%) 
IRR 220/220 (100%) 
ICGA 220/220 (100%) 
SD-OCT 220/220 (100%) 
CBR 204/220 (93%) 
AMD: age-related macular degeneration; CBR: confocal blue reflectance; CFP: colour fundus 
photography; CNV: choroidal neovascularisation; cSLO: confocal scanning laser ophthalmoscopy; 
FAF: fundus autofluorescence; GA: geographic atrophy; ICGA: indocyanine green angiography; IRR: 
infrared reflectance; NIR-FAF: near-infrared fundus autofluorescence; NPV: negative predictive 
value; PPV: positive predictive value; RPD: reticular pseudodrusen; RPE: retinal pigment epithelium; 
SD-OCT: spectral-domain optical coherence tomography 
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Ueda-Arakawa and colleagues97 critical appraisal criteria (based on Reitsma et al.81 adaptation of 
the QUADAS Tool93) 
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Study 7 of 8 – Vujosevic and colleagues 
Reference and design Diagnostic tests Participants Outcome measures 
Condition being diagnosed 
/ detected: diabetic macular 
oedema (DMO) 
 
First author: Vujosevic98 
 





sectional study. Probably 
prospective (not explicitly 
stated but all patients 
provided consent) 
 
Number of centres: Not 
reported (>1 clinic implied) 
 
Funding: None received  
 




(FAF) acquired with 
confocal scanning laser 
ophthalmoscopy (cSLO) 
(Heidelberg Retinal 





emission detected above 
500nm using barrier 
filter. FAF signal 
amplified by calculating 
a mean of 15 aligned 
images after correction 
of eye movements using 






taken with F-10 SLO 
(Nidek Co, Gamagori, 
Japan), which uses 4 
wavelengths: blue, 
green, red and 
infrared. Infrared laser 
was set at 790nm. F-10 
contains 8 apertures (five 
confocal and 3 with a 
central stop) and five 
stops. To obtain a RM-
SLO image, a central 
stop and a laterally 
oriented oval-shaped 
opening was used, from 
both right and left sides. 
 
Comparators: 



























for study entry: 
Type 1 or 2 diabetes 
mellitus; any stage of 
untreated or treated 
DR; and having TD-
OCT, FAF, FA and 
RM-SLO performed 
on the same day 
 
Exclusion criteria 






















FAF: Not reported 
(stated only that 
images were graded 
for different foveal 
patterns [normal, 
single spot increased 
and multiple spots 
increased] and  
presence⁄absence 
of decreased ⁄ 
increased auto-
fluorescence 
in the macula) 
 
TD-OCT: central 
retinal thickness > 
230 μm (measured in 
the central foveal 
zone) 
 
FA: Not reported 
(stated only that late-
phase FA images of 
the macula were 
graded for the 
presence of 
fluorescein leakage 
and pattern of 




reported (stated only 








For all methods, 2 
masked retinal 
specialists trained in 
imaging grading 
independently graded 
all images on a 17-
inch monitor 
dedicated to DR 
screening. In case of 









Sex, m:f (%male) 87:50 (64) 
Age, years, mean (SD) Type I diabetes: 48.8 (11.5), range 28-64 
Type II diabetes: 66.6 (8.1), range 41-85 
Overall : Not reported (numbers with diabetes do not account for all 
patients – see below) 
With Type I or II diabetes, 
N(%) 
Type I: 12 (8.8) [reported as 10.1% in the paper] 
Type II: 107 (78.1) [reported as 89.9% in the paper] 
Not reported: 18 (13.1) 
Duration of diabetes, 
years, mean (SD) 
Type I: 28.8 (11.9), range 5-51 
Type II: 15.4 (8.8), range 1-39 
Central macular thickness, 
mean (SD), μm 
323.4 (125.2), range 154.0-884.0 
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Results - FAF versus RM-SLO 
Calculations based on 
numbers of eyes (both eyes 
of 126 subjects and single 
eyes of 11 subjects) 
Population with DMO 
on RM-SLO 
Population without 
DMO on RM-SLO 
Total 
FAF imaging positive 195                              a     8                           c      203 
FAF imaging negative 16                                b     44                         d      60 
Total 211                           52  263 
 
Diagnosis  95% CI 
Clinical sensitivity a / (a + b) 92.42% 87.98 to 95.60 
Clinical specificity d / (c + d) 84.62% 71.91 to 93.10 
PPV a / (a + c)  96.06% 92.38 to 98.28 
NPV d / (b + d) 73.33% 60.34 to 83.92 
Positive likelihood ratio [sensitivity/(100-
specificity)] 
6.01 3.17 to 11.38 
Negative likelihood ratio [(100-
sensitivity)/specificity] 
0.09  0.06 to 0.15 
Diagnostic odds ratio (a x d)/(b x c) 
 
67.03 26.99 to 166.45 
Comments: Data reported in the paper are for RM-SLO compared against a FAF reference; recalculated 
by reviewers to give sensitivity and specificity of FAF compared against a RM-SLO reference.  
 
Paper states (in the Discussion) that OCT is the ‘new gold standard’ for diagnosing DMO. However, a 
diagnostic accuracy comparison of FAF versus TD-OCT is not possible from the reported data (only the 
diagnostic accuracy of RM-SLO versus TD-OCT, FA and FAF are reported and calculable – not 
extracted here).  
Interpretability and acceptability of test     
Numbers excluded from analysis due to poor image quality Not reported 
Inter-observer agreement Not reported 
Intra-observer agreement Not reported 
Test acceptability (patients / clinicians) Not reported 
Adverse events Not reported 
cSLO: confocal scanning ophthalmoscopy; DMO: diabetic macular oedema; DR: diabetic retinopathy; 
FA: fluorescein angiography; FAF: fundus autofluorescence; NPV: negative predictive value; OCT: 
optical coherence tomography; PPV: positive predictive value; RM-SLO: retromode scanning laser 
ophthalmoscopy; TD-OCT: time domain optical coherence tomography  
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Vujosevic and colleagues98 critical appraisal criteria (based on Reitsma et al.81 adaptation of the 
QUADAS Tool93) 
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Study 8 of 8 – Waldstein and colleagues 
Reference and design Diagnostic tests Participants Outcome 
measures 
Condition being diagnosed 
/ detected: Diabetic macular 
oedema (DMO) 
 
First author: Waldstein84 
 
Publication year: 2012 
 
Country: Not stated, 






Number of centres: One 
 
Funding: 2 authors received 




Fellowship; and funding 






FAF imaging using 
cSLO (modified HRA 
classic, Heidelberg 
Engineering, Heidelberg, 
Germany) with an 
external source of a 
solid-state laser emitting 
at 488nm at a 30˚ field 
of view; and FAF 
imaging using cSLO 
with an argon-ion laser 
emitting at 514nm at a 
30˚ field of view; mean 





version 1.6.4.0). Each B-
scan consisted of 512 A-
scans and was averaged 
nine times using the 
ART mode. A 20˚ x 20˚ 
scan pattern using 25 
sections with an inter-




Macular Pigment Optical 
Density (MPOD) 
imaging (sequential use 
of both 488nm and 
514nm FAF allowed 
calculation of macular 
pigment optical 
density (MPOD) maps 
that topographically 
illustrate the relative 












explicitly; but all 






underwent OCT and 
two-wavelength FAF 
imaging in the 
diabetic retinopathy 







for study entry: 
The presence of 
diabetic retinopathy 
with or without 
DMO; clear ocular 
media that allow 
recording of high-
quality FAF images; 
availability of both 
two-wavelength FAF 
and OCT imaging 




for study entry: 
Presence of any 
ocular comorbidity 
affecting the macula, 








specificity of FAF 
and MPOD for 














Diagnosis of DMO 





using the following 
scoring system: 







bright, single or 
multiple, round or 
oval areas that are 
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Participant characteristics 
Sex, m:f (%male) 46:25 (65%) 
Age, years, mean (SD) 63 (15) 
 
Results: FAF (488nm) versus OCT 
Calculations are based on 
no. of eyes (single eyes 
from 17 subjects and both 
eyes from 54 subjects) 
Eyes with signs of 
DMO on SD-OCT  
Eyes without signs of 
DMO on SD-OCT 
Total 
FAF imaging positive 54                             a 6                                   c 60                          
FAF imaging negative 13                             b 52                                 d 65                          
Total 67 58 125 
 
Diagnosis  95% CI 
Clinical sensitivity a / (a + b) 80.60 69.11 to 89.24 
Clinical specificity d / (c + d) 89.66 78.82 to 96.08 
PPV a / (a + c)  90.00 79.48 to 96.22 
NPV d / (b + d) 80.00 68.23 to 88.89 
Positive likelihood ratio [sensitivity/(100-
specicifcity)] 
7.79 3.62 to 16.77 
Negative likelihood ratio [(100-
sensitivity)/specificity] 
0.22 0.13 to 0.36 
Diagnostic odds ratio (a x d)/(b x c) 36.00 12.73 to 101.81 
Comments: Diagnostic values are calculated by the reviewer from the reported sensitivity and 
specificity. The calculations agree with the results reported in the paper. 
 
Sensitivity and specificity are reported also for MPOD based on combining FAF488 nm and 514nm 
images. MPOD sensitivity and specificity were very similar to those of FAF 488nm alone (data not 
extracted here). 
 
Results: FAF (514nm) versus OCT 
Calculations are based 
on numbers of eyes 
(single eyes from 17 
subjects and both eyes 
from 54 subjects) 
Eyes with signs of 
DMO on SD-OCT  
Eyes without signs of 
DMO on SD-OCT 
Total 
FAF imaging positive 37                                a 3                                      c 40 
FAF imaging negative 30                                b 55                                    d 85 
Total 67 58 125 
 
Diagnosis  95% CI 
Clinical sensitivity a / (a + b) 55.22 42.58 to 67.39 
Clinical specificity d / (c + d) 94.83 85.60 to 98.86 
PPV a / (a + c)  92.50 79.59 to 98.34 
NPV d / (b + d) 64.71 53.59 to 74.77 
Positive likelihood ratio [sensitivity/(100-
specificity)] 
10.68 3.47 to 32.82 
Negative likelihood ratio [(100-
sensitivity)/specificity] 
0.47 0.36 to 0.62 
Diagnostic odds ratio (a x d)/(b x c) 22.61 6.43 to 79.54 
Comments: Diagnostic values are calculated by the reviewer from the reported sensitivity and 
specificity. The calculations agree with the results reported in the paper. 
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Distinct patterns of DMO on OCT (no. of eyes, %):  
              Predominantly foveal intraretinal cysts  51 (76) 
              Predominantly extrafoveal intraretinal cysts 5 (7) 
              Diffuse, small intraretinal cysts 11 (16) 
Sensitivity for detecting Foveal cysts compared to OCT imaging 
              FAF (488nm) 90.0% 
              FAF (514nm) 20.0% 
              MPOD 96.0% 
Sensitivity for detecting Extrafoveal or diffuse cysts compared to OCT imaging 
              FAF (488nm) 60.8% 
              FAF (514nm) 70.0% 
              MPOD 45.5% 
MPOD vs OCT 
              Clinical sensitivity  80.6% 
              Clinical specificity  91.4% 
FAF: Fundus Autofluorescence; NPV: negative predictive value; PPV: positive predictive value; 
MPOD: Macular Pigment Optical Density; SD-OCT: Spectral Domain Optical Coherence 
Tomography; cSLO: Confocal Scanning Laser Ophthalmoscope; DMO: Diabetic Macular Oedema 
 
Interpretability and acceptability of test     
Numbers excluded from analysis due to poor image quality Not reported 
Intra-observer agreement Not reported 
Test acceptability (patients/clinicians) Not reported 
Adverse events Not reported 
Inter-observer agreement (Cohen’s kappa) 
              FAF (488nm) 0.84 
              FAF (514nm) 0.63 
              MPOD 0.79 
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Waldstein and colleagues84 critical appraisal criteria (based on Reitsma et al.81 adaptation of the 
QUADAS Tool93) 
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